Statistical modelling of mitochondrial disease by Grady, John Patrick
 
 
 
 
 
 
Statistical Modelling Of Mitochondrial 
Disease 
 
John Patrick Grady 
BSc (Hons) MSc MRes 
 
This thesis is submitted for the degree of Doctor of Philosophy at 
Newcastle University 
 
Wellcome Trust Centre for Mitochondrial Research 
Institute of Neuroscience/Institute of Ageing and Health 
November 2013
 i 
 
Author’s declaration 
This thesis is submitted for the degree of Doctor of Philosophy at Newcastle University. 
The research was conducted in the Wellcome Trust Centre for Mitochondrial Research 
under the supervision of Professor D.M. Turnbull, Dr Richard McNally, and Dr Claudia 
Racca. Unless otherwise stated all the work is my own, and was conducted between 
October 2010 and November 2013. 
I certify that none of the material offered in this thesis has been previously submitted by 
me for a degree or any other qualification at this or any other university. 
 
 
  
 ii 
 
Abstract 
Mitochondrial DNA mutations are a major cause of disease in the human population. 
Understanding the disease associated with these mutations is complicated by 
heteroplasmy, the mixture of wild-type and mutated mitochondrial DNA. Heteroplasmy 
can vary between cells, tissues, and organs, and the disease associated individual 
mutations is hugely varied on account of this. The mitochondrial genome encodes 
critical proteins of the oxidative phosphorylation system and mutation leads to energy 
deficits in cells and a wide range of secondary effects. The central and peripheral 
nervous system are commonly affected in mitochondrial disease and quality of life for 
patients is severely impaired. 
Although pathogenic mitochondrial genetic mutations were first identified over twenty 
five years ago, little progress has been made in understanding the expected progression 
of disease in patients. The aim of this study was to use statistical modelling to further 
understanding of disease progression in mitochondrial DNA mutations. The Medical 
Research Council Mitochondrial Disease Cohort provided the majority of patient data. 
Patients had been assessed using the Newcastle Mitochondrial Disease Adult Scale, 
which facilitates quantitative research on mitochondrial disease burden.  
This project comprises studies of two of the most common mitochondrial DNA 
mutations. The first study concerns patients with the m.3243A>G mutation, the most 
common pathogenic point mutation, and considers the effect of age and heteroplasmy 
on disease progression. Prediction models of both overall disease burden and specific 
phenotypic features were developed. Important features of the patient cohort were also 
examined, including heteroplasmy in different tissues and differences in disease 
expression between sexes. The second study looks at patients with single large-scale 
mitochondrial DNA mutations. The effect of deletion size, location of the deletion on 
the genome, and heteroplasmy were investigated, and all three predictors were found to 
be significant in understanding disease progression. 
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 Introduction Chapter 1.
1.1. Mitochondria 
Mitochondria are cytoplasmic organelles present in almost all eukaryotic cells which 
house machinery for ATP (adenosine triphosphate) production and perform critical roles 
in apoptosis (Wang and Youle, 2009), calcium homeostasis (Patergnani et al., 2011), 
and iron-sulphur (Fe-S) cluster formation (Rouault and Tong, 2005), as well as 
numerous other functions. In humans, mitochondria are found in all cells other than 
mature red blood cells. Though the vast majority of proteins that make up mitochondria 
are encoded by nuclear DNA (nDNA), mitochondria also contain their own DNA, the 
only extra-nuclear source of DNA in humans, which encodes a small set of proteins 
vital for oxidative phosphorylation (OXPHOS). Mutations in mitochondrial DNA 
(mtDNA) are responsible for a wide range of disease that impact on mitochondrial and 
cellular function as a whole.  
1.1.1. Origins of mitochondria 
Mitochondria have long been believed to have evolved from free Eubacteria that 
became integrated into a primitive eukaryote through endosymbiosis (Margulis, 1971), 
a theory which proposed that the fusion occurred after the emergence of the cell 
nucleus. A competing theory, known as the ‘hydrogen hypothesis’ proposes that the 
mitochondrion and the nucleus formed contemporaneously, after fusion of a hydrogen-
dependent Archaebacterium and a hydrogen-producing Eubacterium (Martin and 
Muller, 1998). In both theories, however, there is a single endosymbiotic event, and a 
subsequent transfer of the majority of the genetic material from the proto-mitochondrion 
to the nucleus. 
1.1.2. Structure 
Traditionally the mitochondria has been viewed as a rod shaped or ovoid organelle 
thought to be approximately 2μm long and 0.5μm in diameter, encapsulated by a double 
membrane (Palade, 1953).  The outer membrane contains an abundance of the voltage 
dependent anion channel (VDAC) otherwise known as porin, which when open allows 
for free movement of molecules and ions of low molecular weight (under 10kDa) 
between the cytoplasm and the inter-membrane space (Alberts et al., 2002).  
The inner mitochondrial membrane (IMM) is essentially impermeable, but contains a 
large number of transport proteins that regulate the flow of material into the 
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mitochondrial matrix contained within the membrane, and is rich in cardiolipin. The 
IMM was traditionally though to be highly folded creating invaginations (known as 
cristae) into the matrix, clearly visible using electron microscopy; however, it is now 
known that the cristae are formed from a distinct membrane connected to the inter-
membrane space through cristae junctions, and thus the IMM can be subdivided into 
two parts, the inner boundary membrane (IBM) and the cristae membrane (CM) (Frey 
and Mannella, 2000). The CM is enriched in proteins involved in oxidative 
phosphorylation, iron-sulphur cluster biogenesis, protein synthesis and mtDNA-encoded 
protein transport, whilst the IBM is rich in proteins responsible for mitochondrial fusion 
and nDNA-encoded protein transport (Vogel et al., 2006). The invaginations of the CM 
create a huge surface area over which OXPHOS can be conducted. 
The mitochondrial matrix contains multiple mtDNA molecules, transcriptional and 
translational machinery, the various proteins responsible for the tricarboxylic acid 
(TCA) cycle, and is the site of Fe-S cluster formation. 
1.1.3. Oxidative phosphorylation 
Mitochondria are often referred to as the powerhouses of the cell, on account of their 
major role in the production of cellular ATP. OXPHOS is a highly efficient process for 
the production of ATP that utilises several intermediate products of the TCA cycle (also 
known as Kreb’s cycle or the citric acid cycle) (Hatefi, 1985). 
Cellular respiration begins with glycolysis in the cytosol, where glucose is broken down 
into pyruvate, producing two molecules of ATP (Equation 1.1). 
                                          
            
Equation 1.1. Glycolysis. 
 
The pyruvate is transported across the double mitochondrial membrane into the matrix, 
where the enzyme pyruvate dehydrogenase converts it into acetyl CoA (Equation 1.2). 
                                          
Equation 1.2. Pyruvarte decarboxylation. 
 
Acetyl CoA is one of the major substrates of the TCA cycle, along with NAD+ and 
FADH, and provides the carbon atoms within the acetyl group to be oxidised whilst the 
other two substrates are reduced, becoming electron carriers. The overall TCA cycle is 
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shown in Equation 1.3,   
                                  
                             
Equation 1.3 Outcome of the TCA cycle. 
 
     and       are essential components of the final stages of respiration, 
OXPHOS,  in that they act as electron carriers, donating electrons to complex I and II 
respectively. These complexes in turn transfer electrons to complexes III and IV, 
releasing energy which is used to pump    into the intermembrane space from the 
matrix. This creates an electro-chemical gradient which is then used by complex V 
(ATP synthase) to generate ATP from ADP. 
 
Figure 1.1 Oxidative phosphorylation. 
The protein complexes are embedded in the cristae membrane of the inner mitochondrial membrane. 
Electrons (in red) enter the electron transport chain (ETC) via complexes I and II and are transported to 
complex III via reduction of ubiquinone (Q), which is soluble in the membrane. Complex III re-oxidises 
the ubiquinol (QH2) back to ubiquinone, and the electrons pass via cytochrome c (C) in a further redox 
reaction to complex IV. During this process complexes I, III, and IV pump electrons from the matrix to 
the inter-membrane space, creating an electro-chemical gradient, which drives the ATP synthase 
(Complex V) to produce ATP. Below each subunit the ratio of nuclear encoded to mitochondrially 
encoded subunits is shown. Complex II is the only complex that is entirely encoded by nuclear DNA. 
Image (adapted) courtesy of Eve Simcox. 
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1.1.3.1. Complex I 
Complex I (NADH dehydrogenase (ubiquionone)) couples transfer of two electrons 
from NADH to ubiquinone with translocation of four protons across the inner 
membrane. It is the largest complex of the OXPHOS system, made up of 46 subunits of 
which 7 are mtDNA encoded (Ugalde et al., 2004). The overall reaction is shown below 
(Equation 1.4). 
               
                
  
Equation 1.4 Complex I reaction. 
 
Complex I dysfunction is the most frequently observed OXPHOS defect in humans, 
caused by mutations of both nuclear and mitochondrial origin, and related both to 
mutations in the structure itself and the assembly of the complex (Mimaki et al., 2012). 
Leber’s hereditary optic neuropathy (LHON), for example, is a disease generally caused 
by mutations in genes encoding complex I subunits (Wallace et al., 1988). 
1.1.3.2. Complex II 
Complex II, also known as succinate dehydrogenase (SDH) or succinate ubiquionone 
oxioreductase, is the only complex of the OXPHOS system that is entirely nuclear 
encoded, and is also the smallest, comprising four subunits. It does not translocate 
protons as the other four complexes do, however it plays the crucial role of catalysing 
the conversion of succinate to fumarate whilst generating      , which is then 
oxidised to FAD and the electrons used to reduce ubiquinone to ubiquinol (Hagerhall, 
1997). The overall reaction is shown in Equation 1.5. 
                         
Equation 1.5 Complex II reaction. 
 
Complex II mutations are associated with tumorigenic phenotypes, thought to be 
through caused by excessive generation of reactive oxygen species (ROS)  or 
stabilization of hypoxia inducible factor 1 (HIF1) during normoxia (Hoekstra and 
Bayley, 2013). 
1.1.3.3. Complex III 
Complex III, or ubiquinol:cytochrome c oxioreductase comprises 11 subunits, only one 
of which is mitochondrially encoded, by the MT-CYB gene (cytochrome b). The 
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complex transfers two electrons to cytochrome c from ubiquinol, and also pumps two 
protons into the inter membrane space. The reaction is shown in Equation 1.6. 
                             
                           
  
Equation 1.6 Complex III reaction, the Q cycle. 
 
Complex III abnormalities are rare in humans (Benit et al., 2009). The phenotype of 
Complex III abnormalities are similar to other OXPHOS defects, in particular LHON is 
also associated with Complex III mutation (Brown et al., 1992). 
1.1.3.4. Cytochrome c 
Cytochrome c is a highly conserved nuclear encoded haem-containing protein found in 
the inter membrane space, and has a critical role in the ETC, apoptosis, and also acts as 
a ROS scavenger (Huttemann et al., 2011). In OXPHOS it carries a single electron from 
complex III to IV. 
1.1.3.5. Complex IV 
Complex IV, or cytochrome c oxidase (COX) is the terminal complex of the ETC, and 
comprises 13 subunits, three of which are mitochondrially encoded. It reduces O2 to 
H2O using electrons provided by cytochrome c, and transfers 4 protons per oxidised 
molecule from the matrix to the inter membrane space, as shown in Equation 1.7. Four 
electrons are required for the reduction of one molecule of O2 to H2O, and this step is 
thought to be rate-limiting in the mammalian ETC (Huttemann et al., 2011). 
                     
                             
  
Equation 1.7 Complex IV reaction. 
 
1.1.3.6. Complex V 
Complex V, the FOF1 ATP synthase, is the final step of OXPHOS, which catalyses the 
conversion of ADP to ATP. The complex is made up of two domains, FO located in the 
membrane, and F1 which extends into the matrix. Each unit comprises multiple copies 
of several subunits, the majority of which (14) are nDNA encoded, with two 
mitochondrially encoded subunits, both in the FO domain. Proton movement through the 
FO domain generates rotary torque, which powers the formation of ATP from ADP and 
phosphate. Each molecule of ATP costs 2.7 protons in production (Ferguson, 2010).  
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Mutations in Complex V often lead to very severe disease, characterised by lesions in 
the brain and particularly the striatum, including NARP (neurogenic muscle weakness, 
ataxia, and retinitis pigmentosa) and Leigh Syndrome, a severe infantile neurological 
disorder resulting in infant death, commonly through respiratory failure (Schon et al., 
2001). 
1.1.3.7. Supercomplexes 
It has been shown that the ETC complexes tend to group together into conglomerates 
called supercomplexes; for instance, almost all mammalian Complex I is found 
aggregated with Complexes III and IV (Schagger and Pfeiffer, 2000). It is thought that 
Complexes III and IV are assembled independently, but that Complex I assembly is 
multi-stage and the final stage, the addition of the NADH dehydrogenase catalytic 
module, occurs after supercomplex formation (Moreno-Lastres et al., 2012; Winge, 
2012). From the perspective of disease and pathology this is of fundamental importance, 
as inter-dependence of the complexes is potentially explanatory of genetic defects in 
one complex affecting functional operation or assembly of other complexes, particularly 
as regards Complex III or IV defects affecting Complex I assembly. 
 
1.1.4. Other functions of mitochondria 
1.1.4.1. Iron homeostasis and iron-sulphur (Fe-S) cluster biogenesis 
The production of Fe-S clusters is the sole conserved function of both mitochondria and 
primitive mitochondria (mitosomes) across all eukaryotes, underlying the importance of 
this process. Fe-S clusters are essential in OXPHOS as they facilitate the electron 
transfer by repeated redox changes from Fe
2+
 to Fe
3+
, and form part of complexes I, II, 
and III (Schultz and Chan, 2001). 
Iron within mitochondria is used for haem or Fe-S cluster synthesis or stored in 
mitochondrial ferritin. Import of iron into mitochondria through the inner membrane is 
regulated by mitoferrins (Paradkar et al., 2009), though the transport mechanism from 
the cytosolic iron pool and across the outer mitochondrial membrane remains to be 
elucidated (Richardson et al., 2010).  
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1.1.4.2. Ca2+ signalling and homeostasis 
Mitochondria have long been recognised for their role in cytosolic Ca
2+ 
buffering 
(Carafoli, 2003) and by extension extracellular Ca
2+ 
regulation (Cohen and Fields, 
2004), and are able to absorb up to 1000nmol Ca
2+
 per mg of mitochondrial protein, 
imported via the outer membrane VDAC pore and the calcium uniporter located in the 
inner mitochondrial membrane (Kirichok et al., 2004). The importance of this role 
cannot be understated; Ca
2+
 signalling is an essential regulator of cellular function 
(Clapham, 2007) and has a fundamental role in intercellular communication (Hofer et 
al., 2000), induction of apoptosis (Orrenius et al., 2003), regulation of ATP production 
(Griffiths and Rutter, 2009), and regulation of pre-synaptic transmission in neurons 
(Kostyuk, 2007). 
1.1.4.3. Apoptosis 
Programmed cell death, or apoptosis, is a vital function of an organism to eliminate 
unwanted or damaged cells, and is vital for proper embryonic development (Danial and 
Korsmeyer, 2004). It is inducible by both an extrinsic cell receptor mediated pathway, 
and an intrinsic cell damage mediated pathway, contingent upon the release of 
cytochrome c from the mitochondria and subsequent activation of caspase-9 (Wang and 
Youle, 2009). 
1.1.4.4. Reactive oxygen species 
Though mitochondrially produced reactive oxygen species (ROS) were historically 
thought to lack a physiological role and were only associated with cell damage, there is 
growing evidence that ROS have a critical physiological role. It is hypothesised that 
ROS levels at a basal level maintains homeostatic function in the cell, but fluctuations 
in ROS alter signalling pathways; ROS is known to have roles in cell differentiation, 
autophagy, immune cell activity, and metabolic adaptation (Sena and Chandel, 2012). 
ROS have been shown to induce reversible posttranslational modifications of several 
proteins within important signalling cascades (Finkel, 1998; Rhee et al., 2000).  
Complex I and III are both major sources of ROS (Turrens and Boveris, 1980; Sugioka 
et al., 1988), though Complex I is thought to be more a more proliferative producer of 
superoxide O2
-
, predominantly when ATP is not being produced and there is a high 
proton motive force (the sum of the membrane potential and pH gradient), or there is a 
high NADH/NAD
+
 ratio in the matrix (Murphy, 2009). However, Complex III produces 
O2
-
 on both sides of the inner membrane, but Complex I produces it only matrix-side. 
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Overall, though mitochondria are a significant source of cellular ROS, it is not by any 
means certain that they are the major source of ROS within cells, as the endoplasmic 
reticulum and peroxisomes are also known sources (Brown and Borutaite, 2012). 
1.1.5. Biogenesis regulation 
Mitochondrial biogenesis is tightly regulated by cells in order to tailor ATP production 
to suit cellular energy requirements. The peroxisome proliferator-activated receptor γ 
(PPARγ) co-activator 1α (PGC-1α) is the primary controller of mitochondrial 
biogenesis, and has a critical role in signalling cascades involving AMP activated 
protein kinase (AMPK) and the Sirtuin class of proteins that sense energy imbalances in 
cells and regulate mitochondrial biogenesis accordingly (Hardie et al., 2012; Andreux et 
al., 2013).  
1.1.6. Dynamics 
Though traditionally thought of as discrete organelles, mitochondria in fact form a 
dynamic network that undergoes constant fission and fusion (Westermann, 2010). The 
importance of this dynamism is illustrated by the fact that mutations in several nDNA 
encoded proteins with critical roles in fission and fusion are associated with disease, 
including mitofusins 1 and 2 (MFN1 and MFN2), optic atrophy 1 (OPA1), and 
dynamin-1-like protein (DNM1L) (Liesa et al., 2009). OXPHOS generates an electro-
chemical gradient across the inner membrane of the mitochondria, which is maintained 
at around -140mV (Gerencser et al., 2012), and a healthy membrane potential is a 
requirement for fusion to occur (Legros et al., 2002; Meeusen et al., 2004).  
As well as fission and fusion, mitochondria undergo autophagic degredation known as 
mitophagy, which has been shown to selectively target impaired mitochondria (Kim et 
al., 2007; Twig et al., 2008). This process is intimately related to human disease, for 
example in the mutations of the PINK1 and PARK2 genes that are linked to inherited 
early-onset Parkinson’s disease and which are involved in the mitophagic pathway 
(Chen and Chan, 2009). 
The umbrella term ‘mitochondrial dynamics’ also includes consideration of the 
migration and movement of mitochondria within the cytoplasm to areas of high energy 
need, for instance neuronal growth cones, and pre- and post- synaptic sites (Morris and 
Hollenbeck, 1993; Li et al., 2004; Miller and Sheetz, 2004; Chang et al., 2006). 
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1.1.7. The mitochondrial genome 
The human mitochondrial genome (mtDNA) is a 16,569bp double-stranded circular 
intron-less genome located in the mitochondrial matrix. It codes 37 genes; 13 
hydrophobic proteins essential for OXPHOS, 22 tRNAs, and 2 rRNAs. The structure is 
shown in Figure 1.2. The majority of the genes (all but one of the protein encoding
 
Figure 1.2 The human mitochondrial genome. 
The genome encodes 37 genes, including 13 polypeptides, 22 tRNAs, and 2 rRNAs. All but one of the 
protein encoding genes are found on the outer heavy strand of the genome; 6 subunits of Complex I (MT-
ND1-5 and ND4L) , one Complex III subunit (Cytochrome B), three subunits of Complex IV (COX1-3), 
and two subunits of Complex V (ATPase 6 & 8). The final protein encoding gene is the ND6 subunit of 
Complex I on the inner light strand.  The tRNA genes are dispersed around both strands. The D-loop is 
the only major non-coding region of the genome. The origins of heavy (OH) and light (OL) strand origin 
are also shown. Image (adapted) courtesy of Dr Casey Wilson.   
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genes, 14 of the tRNAs, and both rRNAs) are transcribed from the outer (heavy) strand. 
The other 8 tRNAs and the protein encoding gene MT-ND6 are transcribed from the 
inner (light) strand. The only substantial non-coding region, the displacement-loop or d-
loop, contains the major control elements for transcription and replication, and extends 
approximately 1kb in human mtDNA. 
Multiple copies of the mtDNA molecule are found within an individual cell; in general 
mammalian cells house tens to hundreds of mitochondria, and each mitochondrion 
contains several copies of the mitochondrial genome (Wiesner et al., 1992), with an 
estimated 5,000 to 10,000 copies of the genome per cell (Lightowlers et al., 1997). 
mtDNA is packaged into discrete nucleoids composed of mtDNA with some of the 
machinery necessary for replication and transcription of the DNA (Brown et al., 2011). 
The number of DNA molecules per nucleoid is debated, but has recently been measured 
as generally a single copy per nucleoid (Kukat et al., 2011). In this study mitochondrial 
transcription factor A (TFAM) was reported as the bulk constituent of the nucleoid, 
though other proteins are also present, including single-stranded DNA binding protein 
(mtSSB). 
1.1.8. Transcription and translation 
There are three sites of transcription initiation within the D-loop, the L-strand promoter 
(LSP) and the two H-strand promoters (HSP1 and 2); transcription generates long 
polycistronic molecules, as depicted in Figure 1.3. The LSP generates a single transcript 
containing the all the genes on the L-strand, as HSP2 does for the H-strand; HSP1, on 
the other hand, generates a transcript containing only the two rRNA genes and two 
tRNA genes (Montoya et al., 1982; Chang and Clayton, 1984; Zollo et al., 2012). 
Transcription is bi-directional and conducted by the mitochondrial RNA polymerase 
(POLMRT) in conjunction with other proteins including TFAM and mitochondrial 
transcription factor B2 (Rebelo et al., 2011). Termination of transcription is 
implemented by mitochondrial termination factors (MTERF), four of which have so far 
been identified. The roles of these factors are still very much under debate however; it 
has been recently shown, contrary to long standing belief, that MTERF1 does not 
couple rRNA gene transcription initiation and termination but instead appears to block 
transcription to avoid transcriptional interference at the L-strand promoter (Terzioglu et 
al., 2013). 
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Figure 1.3 Mitochondrial DNA transcription. 
The D-loop contains one promoter site for the light strand (LSP) and two for the heavy strand (HSP1 and 2). LSP and HSP2 generate polycistronic transcripts of all the genes on each 
strand respectively, whereas HSP1 generates a shorter polycistronic transcript containing only the two rRNA genes and two tRNAs. Image courtesy of Dr Casey Wilson.   
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Post-transcriptional processing of the polycistronic transcripts is proposed to occur by 
the ‘tRNA punctuation’ model, whereby the cloverleaf-like folding of the tRNAs act as 
a substrate for the RNA processing enzymes, (Ojala et al., 1981; Rorbach and Minczuk, 
2012) though some questions remain unanswered by this, for instance the processing of 
mRNAs not separated by tRNAs (Temperley et al., 2010b). 
Translation of mitochondrial mRNA occurs in three phases; initiation, elongation, and 
termination, and occur in the mitochondrial matrix in mitoribosomes, which are 
constructed of an estimated 80-100 nuclear encoded proteins and the two mitochondrial 
rRNA species, one in each ribosome subunit (O'Brien, 2003; Smits et al., 2010). 
Mitochondrial ribosomes differ from both bacterial and eukaryotic cytoplasmic 
ribosomes in their high protein and low rRNA content. Mitochondrial mRNA 
translation utilises and requires only 22 tRNAs, as compared to the 31 required for the 
nuclear genome (Barrell et al., 1980); 8 of the tRNAs can recognise codons with any 
base in the third position, and 14 of them discriminate between pyrimidine and purines 
at the third position, thus recognising 60 codons in total; two of the remaining four 
codons (UAA and UAG) are stop codons recognised by the mitochondrial translational 
release factor 1a (mtRF1a), and the remaining two (AGA and AGG) are proposed to 
cause a -1 frameshift which moves the ribosome to a recognised UAG stop codon 
(Temperley et al., 2010a). 
1.1.9. Replication 
mtDNA is replicated independently of nDNA and replicates throughout the cell cycle 
(Bogenhagen and Clayton, 1977), including post-mitotic cells such as skeletal muscle 
and neurons (Reeve et al., 2009), though the turnover rate in such cells is thought to be 
very slow compared to mitotically active cells (Wang et al., 1997). Replication and 
transcription have been shown to be highly co-ordinated with the cell cycle, at least in 
cells synchronised by serum depletion; mtDNA replication peaks towards the end of the 
G1 phase preceding nDNA replication in the S phase, and has a second peak towards the 
end of the S phase after nDNA replication preceding mitosis (Chatre and Ricchetti, 
2013) The replication process is reported to take 60 (Clayton, 1982) to 75 (Korr et al., 
1998) minutes. Mitochondria are entirely dependent on nuclear encoded proteins for 
DNA replication and maintenance machinery (Shadel, 2008). 
There are several major competing theories regarding the process of mtDNA 
replication.  The first and more entrenched theory is known as the ‘asynchronous’ or 
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‘strand displacement’ model (Clayton, 1982), which suggests that replication initiates at 
the origin of heavy strand replication (OH)  and two-thirds of the H-strand is replicated 
before OL (the L-strand origin of replication) is exposed and light strand replication 
initiates. Once the strands are completed they are circularised, superhelical turns are 
introduced, and finally the D-loop is replicated. More recently, a second method known 
as the ‘synchronous’ model has been proposed (Holt et al., 2000), based on evidence of 
replication intermediates that are resistant to single-strand nucleases. This model was 
refined based on further experiments that demonstrated replication occurs bi-
directionally, initiates from a broad range of the genome incorporating MT-ND5, MT-
ND6 and MT-CYB and terminates at rather than initiates from OH (Bowmaker et al., 
2003). A third mechanism, was proposed that is similar to the asynchronous model but 
involves simultaneous binding of RNA to the lagging strand (the as yet unreplicated L-
strand) as the H-strand is replicated, which is then subsequently converted to DNA; this 
method is known as RITOLS (ribonucleotide incorporation throughout the lagging 
strand), and was evidenced by the activity of RNase H on replication intermediates, 
since this enzyme acts only on RNA hybridised to DNA (Yasukawa et al., 2006). 
The currently known essential machinery for mtDNA replication are the mitochondrial 
DNA polymerase gamma (POLG) comprising a catalytic unit POLG and accessory 
subunit POLG2, the mitochondrial helicase TWINKLE, the mitochondrial single-
stranded DNA binding protein (mtSSB) and the mitochondrial RNA polymerase 
(POLRMT) (McKinney and Oliveira, 2013). 
1.2. Mitochondrial genetics 
1.2.1. Heteroplasmy 
As cells contain multiple copies of the mitochondrial genome, it is possible for cells to 
harbour mtDNA with different polymorphic or pathogenic variations. This mixture of 
different mitochondrial genomes is termed heteroplasmy. The co-existence of wild-type 
and mutant mtDNA species within individual cells is a fundamental aspect of 
mitochondrial genetics and the phenotypic expression of mutation.  
Quantitatively, the word heteroplasmy is generally used to refer to the proportion of 
pathogenic mutant mtDNA molecules within a cell or tissue, expressed as a percentage. 
The proportion of wild-type is therefore 100% minus the heteroplasmy level in the case 
of a single pathogenic variant. 
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1.2.2. Clonal expansion 
Clonal expansion refers to the process of a mutated mtDNA molecule expanding in 
population within a cell, increasing the level of heteroplasmy. Thus a single mutated 
mtDNA molecule may expand in influence until a cell or tissue (generated through 
mitosis) contains a majority of the mutated molecule or even become homoplasmic.  
The mathematics and biology underlying clonal expansion are not well understood. It 
was initially thought that a mutation such as a deletion would lead to a smaller mtDNA 
molecule that would replicate faster and therefore tend to accumulate (Wallace, 1992); 
though one group does find evidence to support this (Diaz et al., 2002; Fukui and 
Moraes, 2009), this is in non-physiological conditions, and other work in trans-
mitochondrial cell lines it has been shown not to be the case (Tang et al., 2000). It is 
argued that the time between replications is far greater than the replication time (the 
half-life of mtDNA is between 8 and 23 days whereas the time for replication is little 
over an hour (Korr et al., 1998)) and thus faster replication would confer no advantage. 
However, it has also been shown that most mtDNA replication occurs in peri-nuclear 
mitochondria (Davis and Clayton, 1996) which could mean only a small population of 
cellular mtDNA undergo replication at a more rapid rate to maintain the overall 
population; yet this finding is also contradicted by a more recent study that 
demonstrated replication throughout the cytoplasm (Magnusson et al., 2003).  
Other theories that also explain expansion for non-deletion mutations proposed that 
mitochondria with mutations would proliferate in order to overcome respiratory chain 
deficiencies, causing clonal expansion (Yoneda et al., 1992), or that mutated mtDNA 
leads to slower OXPHOS and less ROS than wild-type mitochondria which are 
degraded at a higher rate as a result (de Grey, 1997). It has also been shown, however, 
that even without a selective advantage random intracellular drift leads can lead to 
mutations expanding to high levels (Elson et al., 2001).  
Clonal expansion has been shown to occur with ageing in many tissues, though there are 
tissue specific differences in the mutations that accumulate, for instance point mutations 
but not deletions in the colon (Taylor et al., 2003), whereas deletions are frequently 
found in muscle (Fayet et al., 2002; Yu-Wai-Man et al., 2010a) and the brain 
(Kraytsberg et al., 2006). Though the reasons for this tissue specificity are unproven, it 
is postulated that mitotic tissues may exert negative selective pressure on deletions. 
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1.2.3. Threshold effect 
Pathogenic mutations at a low level of heteroplasmy are thought not to exhibit an 
observable phenotype; OXPHOS impairment and other primary or secondary 
phenotypic effects are observed only when heteroplasmy reaches a critical threshold 
(Rossignol et al., 2003). This has been documented in several tissues, for instance 
muscle fibres from MERRF (myoclonic epilepsy with ragged red fibres ) and MELAS 
(mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) patients, 
where a cellular threshold level of around 80% (Taylor and Turnbull, 2005) or 90% 
(Shoffner et al., 1990) have been reported, though it a threshold for a severe defect has 
also been reported at around 60% (Miyabayashi et al., 1992). Large-scale single 
deletions are generally thought to have a lower threshold at around 60% (Hayashi et al., 
1991; Rossignol et al., 2003). Measurements and estimates vary, but it is thought that 
the threshold is likely to vary according to tissue type, dependent on the level of energy 
requirement or tissue specific nuclear gene expression; it has been recently shown that 
for mtDNA deletions the extra-ocular muscles have a significantly lower threshold for 
expression of an OXPHOS defect than skeletal muscle (Greaves et al., 2010), though no 
difference in threshold for point mutations.  
This issue will be discussed in greater detail with regard to m.3243A>G in Chapter 4 
and single-large scale mtDNA deletions in Chapter 5. 
1.2.4. Segregation 
As a result of continuous replication, segregation of mtDNA mutations is possible in 
both mitotic and post-mitotic tissues. Random segregation was proposed to explain the 
observed tissue specific segregation in many mutations (Macmillan et al., 1993), though 
there is evidence that segregation is not random (Raap et al., 2012), and specific tissues 
demonstrate consistent alteration from the average heteroplasmy level of an individual, 
for instance in m.3243A>G mutation tends to be highest in muscle and urine and lower 
in buccal mucosa, hair, and blood (Chinnery et al., 1999). Specific nuclear encoded 
mitochondrial proteins that affect this segregation are beginning to be identified, for 
example the GIMAP3, an outer mitochondrial membrane GTPase (Jokinen et al., 2010). 
This issue will be considered in more depth in Chapter 4 in relation to the m.3243A>G 
mutation, particularly with regard to the dynamic change of heteroplasmy through the 
life of patients in different tissues. 
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1.2.5. Inheritance 
Inheritance of mtDNA is thought to be strictly maternal, though there is one 
documented case of an inherited paternal mtDNA deletion (Schwartz and Vissing, 
2002). Destruction of sperm mitochondria is thought to occur post-fertilisation by 
proteasomal degradation (Sutovsky et al., 2000) though autophagy has also been 
demonstrated (Al Rawi et al., 2011), and more recently pre-fertilisation degradation has 
been proposed (Luo et al., 2013). 
The mtDNA in oocytes arise from primordial germ cells, which have been shown to 
have a very low number of mtDNA molecules, around 200 (Jenuth et al., 1996; Cree et 
al., 2008) . This is thought to cause what is termed a ‘genetic bottleneck’; the restriction 
and then re-amplification of mtDNA leads to random shifts of heteroplasmy from one 
generation to the next, observable in the variability of heteroplasmy in the children of 
mothers with pathogenic mtDNA mutations (Taylor and Turnbull, 2005). 
1.3. Mitochondrial disease 
1.3.1. mtDNA mutations 
mtDNA mutations are prevalent, causing disease in at least 1 in 5000 people and 
estimated to be present asymptomatically in at least 1 in 200 live births, whilst de novo 
mutations are thought to occur in at least 1 in 1000 live births (Elliott et al., 2008). 
Current treatment options are limited (Pfeffer et al., 2012) and clinical care is generally 
focussed on management of complications (Horvath et al., 2008). 
The mitochondrial genome is thought to be significantly more vulnerable to mutation 
than the nuclear genome for a number of reasons, including the proximity to ROS 
produced from the ETC, the lack of protective histones for the DNA, and fewer repair 
mechanisms than for nuclear DNA. It is estimated that the mutation rate of mtDNA is 
ten times that of nuclear DNA (Brown et al., 1979). 
Recent research into mtDNA mutation have shown that levels of mutation are often 
surprisingly low even in aged individuals, indicating that repair or degradation 
mechanisms of damaged mtDNA are more robust than previously thought (Shokolenko 
et al., 2009). These mechanisms are entirely nuclear in origin, and include base excision 
repair, single-strand break repair, and mismatch repair (Kazak et al., 2012), and there is 
also evidence of homologous recombination after double-strand breaks (Bacman et al., 
2009; Fukui and Moraes, 2009) (though the possibility of mtDNA recombination is 
hotly disputed (Stewart et al., 2008a)). In spite of this, however, the human 
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mitochondrial genome still has a high mutation rate, and deleterious mutations 
associated with disease are the focus of this particular work. Other mutations, such as 
somatic mutations accumulated through life and associated with ageing, or those 
encountered as ancient regional variations in the human population, are also frequent 
and important areas of research (Wallace, 2010).  
1.3.1.1. mtDNA point mutations 
Point mutations are single base pair substitutions in mtDNA, and were first identified as 
a cause of clinical disease in 1988 when Wallace et al. associated a mtDNA point 
mutation with Leber’s hereditary optic neuropathy (LHON) (Wallace et al., 1988). The 
m.3243A>G related to MELAS was identified shortly afterwards (Goto et al., 1990b; 
Kobayashi et al., 1990), along with the m.8344A>G mutation associated with MERRF. 
Epidemiological studies have estimated the minimum prevalence of the most common 
point mutation, m.3243A>G, to be 3.65/100,000 (Schaefer et al., 2008) or 16.3 
(Majamaa et al., 1998), though the first of these studies was based on attendance at 
mitochondrial clinic and likely to be a significant underestimate, and the second based 
on identification of patients with moderate to severe neurological symptoms. The most 
recent studies in large groups not a priori identified by symptoms reported prevalence 
of 236/100,000 (Manwaring et al., 2007) and 140/100,000 (Elliott et al., 2008), 
considerably higher than previous estimates. 
Mutations in protein coding genes may be synonymous (resulting in an unchanged 
amino acid coding) or non-synonymous. However, the majority of point mutations are 
identified in tRNA genes, and most inherited mutations are tRNA mutations. Studies on 
inheritance of mtDNA mutations in mice using POLG mutator mice (which cause 
frequent sporadic mutations) followed by backcrossing to wild-type males to remove 
the POLG mutation whilst leaving the existing mtDNA mutations demonstrated that 
most non-synonymous changes in protein coding genes were lost within two 
generations, suggesting strong selection against deleterious mutations (Stewart et al., 
2008b). Other studies have also demonstrated similar findings (Fan et al., 2008). Elson 
et al. speculated that the most pathogenic mutations (with the most pronounced 
biochemical defect) would be sporadic rather than inherited, and found that though the 
mutation threshold for respiratory chain deficiency in muscle was not associated with 
inheritance, there was a clear difference in blood, where sporadic mutations were 
generally undetectable (Elson et al., 2009). 
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The most common point mutation is the m.3243A>G mutation; however this mutation 
is the focus of Chapter 4 and will not be discussed further in this introduction. However, 
several other mutations will be discussed briefly. Figure 1.4 depicts the position of 
several known mutations on the mitochondrial genome. Though rare, multiple 
pathogenic point mutations in patients have been reported (Nakamura et al., 2010). 
The m.8344A>G mutation in tRNA
Lys
 is most commonly associated with MERRF 
syndrome (myoclonic epilepsy with ragged red fibres) and was first identified in 1990 
in association with this syndrome (Shoffner et al., 1990; Yoneda et al., 1990). The 
mutation was demonstrated to cause a severe reduction in protein synthesis (Chomyn et 
al., 1991; Yoneda et al., 1994).The mutation is in the TΨC loop of the tRNA, and has 
been shown to cause a loss of the usual taurine modification of the uridine wobble-
position anticodon; this is thought to weaken the codon-anticodon binding and thereby 
impede protein translation, as it has been shown to lead to the tRNA being unable to 
translate it’s cognate codon and leads to ribosomal stalling (Yasukawa et al., 2000a; 
Yasukawa et al., 2001). It does not appear to cause mistranslation of non-cognate 
codons. MERRF is a multi-systemic disorder, characterised by myoclonus, but patients 
demonstrate a wide range of neurological defects such as ataxia, generalised epilepsy, 
weakness, and dementia. 80% of patients with MERR F syndrome carry the 
m.8344A>G mutation. It has recently been suggested that the m.8344A>G mutation is 
more aptly named myoclonic ataxia than myoclonic epilepsy as this seems to be the 
more common phenotypic presentation (Mancuso et al., 2013a). 
Though tRNA mutations are more commonly observed, there are some relatively 
common mutations in protein encoding genes, for instance in the ATPase subunit 6 
gene (MT-ATP6). Mutations in this gene include the m.8993T>G mutation usually 
associated with NARP (neuropathy, ataxia, and retinitis pigmentosa) (Schon et al., 
2001), though it has also been associated with Leigh’s syndrome, a devastating infant 
onset progressive neurological disorder resulting in childhood mortality, with necrotic 
lesions of the brain stem, basal ganglia and thalamus observed post mortem (Leigh and 
Thompson, 1951). Other mutations in this gene associated with Leigh’s syndrome are 
m.9176T>G (Carrozzo et al., 2001) and m.9176T>C (Thyagarajan et al., 1995). 
Most (> 95%) of mutations that lead to Leber’s hereditary optic neuropathy (LHON) 
occur in Complex I subunit genes, for instance MT-ND1 (m.3460G>A), MT-ND4 
(m.11778G>A) and MT-ND6 (m.14484T>C), which all cause loss of retinal ganglion 
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Figure 1.4 Point mutations associated with disease.  
Point mutations and the associated disease phenotypes are shown, connected by an arrow to their associated gene. Abbreviations: LHON – Leber’s hereditary optic neuropathy. LS - 
Leigh syndrome. MELAS - mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. MERRF – myoclonic epilepsy and ragged red fibres. MIDD – maternally 
inherited diabetes and deafness. MILS – maternally inherited Leigh syndrome. NARP – neurogenic muscle weakness, ataxia, retinitis pigmentosa. PS – Pearson’s syndrome.
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cells in the optic nerve, leading to sudden acute or sub-acute visual loss (Chinnery et al., 
2000b). 
1.3.1.2. mtDNA rearrangements 
There are two major forms of mtDNA rearrangement that have been considered in a 
disease context, mtDNA deletions (molecules with missing sections of genetic 
material), and duplications (molecules with extra repeated genetic information). 
1.3.2. Single large-scale mtDNA deletions 
Single-large scale mtDNA deletions are a common cause of mitochondrial disease, and 
are generally found at heteroplasmic levels in multiple tissues of an affected individual. 
Such deletions are found throughout the mitochondrial genome though predominantly 
within the major arc (between the two origins of replication, as shown in Figure 1.2). 
Deletions vary in size, but the most frequently reported is the so called ‘common 
deletion’ of 4,977bp extending from base 8,470 in MT-ATP8 to base 13,477 in MT-
ND5, flanked by a 13bp direct repeat (Zeviani et al., 1988). 
It was long thought that deletions were most likely to occur through errors in mtDNA 
replication (Shoffner et al., 1989), though the proposed mechanism requires unprotected 
single-stranded DNA and, as discussed in section 1.1.9, this is not thought to occur. 
Additionally, mitotic tissues, where mtDNA replication proceeds at a faster rate than 
post-mitotic, should be expected to demonstrate faster accumulation of deleted species, 
however deletions are rarely found in mitotic tissue such as the colon (Taylor et al., 
2003) but are much more commonly found in post-mitotic tissue such as muscle and the 
brain, and have been shown to accumulate with age (Cortopassi et al., 1992; Melov et 
al., 1995; Kraytsberg et al., 2006). More recently a mechanism based on errors during 
repair of double-stranded breaks has been proposed, caused by direct homologous 
repeats on either side of the break, which is consistent with the pattern of deletions 
found in tissues and ageing (Krishnan et al., 2008) and also with the flanking of most 
deletions by direct repeats (Samuels et al., 2004).  
Though common, deletions are generally thought not to be inherited through the 
germline, though there is an isolated report (Shanske et al., 2002).  
Disease associated with single large-scale mtDNA deletions are discussed in depth in 
Chapter 5. 
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1.3.3. Multiple deletions 
Multiple mtDNA deletions are also found, as a secondary effect of nDNA mutation, and 
are discussed in section 1.3.5. 
1.3.4. Duplications and dimers 
A second major class of rearrangement are mtDNA duplications, which have been 
associated with disease in patients with myopathy and multisystemic features (Poulton 
et al., 1989; Rotig et al., 1992; Poulton and Holt, 1994; Martin Negrier et al., 1998). 
However, it has been shown that the disease state of an individual is generally governed 
by the presence of mtDNA species with deletions and that duplications are most likely 
to not exhibit pathological effects (Manfredi et al., 1997). Duplication dimers, 
consisting of repeated deleted mtDNA species, are also reported (Brockington et al., 
1995; Jacobs et al., 2004), though the pathogenicity of these are thought to be the same 
as duplication monomers. 
1.3.5. Nuclear DNA mutations 
Of the estimated 1500 proteins that functionally make up the mitochondrion, the 
mitochondrion itself encodes merely thirteen; the nuclear genome encodes the 
remainder (Zhu et al., 2009). Mutations in these genes are responsible for a great 
number of disease phenotypes. There are over 80 genes in the OXPHOS complexes 
alone, and many others with a critical role in assembly, catalytic regulation, stability, 
and maintenance of the complexes and supercomplexes (Vartak et al., 2013) with novel 
contributors being recognised at a progressive pace (Ikeda et al., 2013). 
The nuclear encoded mitochondrial replication enzymes are a critical breakpoint in 
mitochondrial function. Mutations in the POLG and PEO1 genes encoding the POLG 
cayaltyic subunit and TWINKLE helicase respectively are associated with a spectrum of 
disease caused by transcriptional defects including multiple deletions and point 
mutations that are found in affected tissues, which commonly present as chronic 
progressive external ophthalmoplegia (CPEO) (Hudson and Chinnery, 2006; Fratter et 
al., 2010; Wallace, 2010). Pathogenically low levels of mtDNA are observed in patients 
with POLG mutations that lead to Alpers-Huttenlocher syndrome (Davidzon et al., 
2005) or mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), caused by 
mutation in the TYMP gene for thymidine phosphorylase (Nishino et al., 2001). This is 
known as mtDNA depletion. TWINKLE mutations are also associated with mtDNA 
depletion (Sarzi et al., 2007), though they are more commonly associated with the 
CPEO phenotype.  
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Mutations in genes related to mitochondrial dynamics are also a known cause of 
disease, for instance OPA1 which encodes a protein with a critical role in mitochondrial 
fusion is named from its association with autosomal dominant optic atrophy (Delettre et 
al., 2000). 
This is a very brief overview of just a small number of known nDNA encoded 
mitochondrial proteins that have known associations with disease; though this thesis is 
focussed on mtDNA mutation, it is important to acknowledge that the nuclear genome 
is a deeper and broader source of mitochondrial disease. 
1.3.6. Phenotype and progression of mtDNA disease 
The phenotypic presentation of mtDNA disease is highly variable; part of this 
variability has long been attributed heteroplasmy (Ciafaloni et al., 1991), though 
specific mtDNA mutations are also associated with certain characteristic clinical 
phenotypes, such as the m.3243A>G mutation with MELAS or MIDD (maternally 
inherited diabetes and deafness), m.8344A>G with MERRF, and single large-scale 
deletions with CPEO, Kearns-Sayre syndrome (KSS) and Pearson’s syndrome (PS). 
However, the links between genotype and phenotype are not exclusive and frequently 
overlap; MELAS is associated with a host of other mutations, as indeed are MERRF, 
MIDD, and CPEO, which in particular is associated with a variety of mutations, both 
deletions, point, mutations, and nuclear defects. 
The variety of clinical symptoms reported in mitochondrial disease is vast; myopathy 
and cardiomyopathy are common, as are neurological features such as cerebellar ataxia 
and epilepsy, but there are few if any organs or systems that are not reported as affected 
by mtDNA disease in some form. This heterogeneity is a problem for clinical diagnosis 
(McFarland and Turnbull, 2009). 
Though universally recognised as clinically progressive (Zwirner and Wilichowski, 
2001; Arpa et al., 2003; Taylor and Turnbull, 2005; Majamaa-Voltti et al., 2006; 
Whittaker et al., 2007; Horvath et al., 2008; Coku et al., 2010; Chen et al., 2012), 
disease progression in patients with mtDNA mutation is little understood, both in terms 
of the likelihood of development of specific system involvement, or the rate of 
progression of the burden of disease on patients.  
Discussion of the phenotypic presentation of the mutations studied in this thesis will be 
considered in detail in chapters devoted to each mutation.   
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1.4. Data sources 
1.4.1. The MRC Mitochondrial Diseases Patient Cohort Study UK 
The Mitochondrial Diseases Patient Cohort Study UK is a large cohort of living patients 
with genetically and/or biochemically confirmed mitochondrial disease. It is the largest 
such cohort globally, and is funded by the Medical Research Council (MRC) Centre for 
Translational Research in Neuromuscular Diseases. Symptomatic adults and children 
comprise the majority of the cohort, but there are additional asymptomatic individuals 
who have requested genotyping (usually due to a family history) and have proved 
positive. All individuals are phenotypically characterised in out-patient clinics, on the 
basis of examination, clinical history, and detailed investigation. 
This patient cohort forms the basis of the studies conducted for this thesis. 
1.4.2. The NHS Specialised Services for Rare Mitochondrial Diseases 
The NHS Specialised Services for Rare Mitochondrial Diseases is situated in Newcastle 
upon Tyne. A large part of the diagnostic tissue, samples, and genetic information used 
in this work have been provided by the service. 
1.5. The NMDAS 
The Newcastle Mitochondrial Disease Adult Scale (NMDAS) was published in 2006 as 
a semi-quantitative rating scale to monitor mitochondrial disease (Schaefer et al., 2006). 
It is a clinically validated tool, that has been extensively used both at our centre 
(Apabhai et al., 2011; Bates et al., 2012b; Lax et al., 2012) and other specialist 
mitochondrial centres (de Laat et al., 2012; Enns et al., 2012; Orsucci et al., 2012; 
Yatsuga et al., 2012; Kornblum et al., 2013; Mancuso et al., 2013b). The NMDAS 
permits quantitative analysis of both general and system-specific disease progression 
and has already been used in assessment of clinical progression in patients with the 
m.3243A>G mtDNA mutation, although this was not a longitudinal study (Whittaker et 
al., 2009).  The Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) is a 
similar scale used to monitor paediatric mitochondrial disease patients (Phoenix et al., 
2006). 
Development of the NMDAS was prompted by success of other similar assessments for 
other mainly neurological conditions, such as those developed for Parkinson’s Disease 
(Ebersbach et al., 2006). It was developed to meet several key objectives; (1) to reflect 
the multi-dimensional nature of mitochondrial disease, (2) to monitor both the progress 
of the underlying dysfunction and the functional impact of the dysfunction (3) to allow 
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input from multiple sources, including the patient, carer, clinician, and clinical records 
(4) to be concise and straightforward to complete. To achieve this aim, the test 
comprises 4 sections, or domains; I, which assesses current function; II, which measures 
system specific involvement; III, which is a current clinical assessment; and IV, a 
quality of life survey. 
Sections I to III are made up of several questions, each scoring from 0 (no involvement) 
to 5 (severe involvement). Section I comprises 10 questions assessing current function, 
and is in the main concerned with the impact of disease on the daily life and functions 
of the patient. Section II comprises 9 questions assessing system specific involvement, 
including neurological, respiratory and the cardiovascular system. Section III comprises 
10 questions to summarise a general and neurological clinical examination, including 
three cognition tests to generate a combined cognition score. The final section of the 
assessment comprises the SF-12v2 quality of life survey (Ware et al., 1996). The 
NMDAS questionnaire can be found in Appendix I. 
1.6. Aims 
From a clinical care perspective, it is vital to improve understanding of the progression 
of disease in patients with mtDNA disorders, in order that management of the disease 
can be tailored to patient needs, and care and monitoring be pre-emptive rather than 
reactive. Thus the overarching aim of this study is to improve understanding of the 
clinical progression of disease associated with mtDNA mutations.  
To achieve this aim, I chose to study the mutations that are most prevalent in the cohort 
of adult patients regularly monitored in the Newcastle National Commissioning Group 
(NCG) Mitochondrial Disease Service. These are the patients carrying the m.3243A>G 
mutation and the patients with single large-scale mtDNA deletions.  
There were two main focal points in the study of each patient group. The first was to 
improve understanding of the progression of total disease burden of patients, as 
measured by the score achieved on the NMDAS assessment. The second was to 
improve understanding of the development and progression of individual phenotypic 
features associated with each of these mutations, using the individual features examined 
in the NMDAS assessment. For both of these foci I aimed to investigate not only the 
predicted progression over time, using age as a predictor of disease burden, but also 
genetic factors which influenced the progression of disease in patients.
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 Statistical methodology Chapter 2.
2.1. Introduction 
The use of statistics in medical and biomedical fields is widely accepted as a powerful 
and necessary tool in the scientific research process. Statistical methods have been 
derived specifically to address the needs of researchers (Altman, 1981; Altman, 1982; 
Altman et al., 1983), along with guidelines developed for reviewers of statistical 
publications to ensure high standards of peer review (Gore et al., 1992; Altman, 1998; 
Goodman et al., 1998; Altman et al., 2002). However, there is a consensus that 
statistical reporting in medical journals is of low standard, with frequent erroneous use 
of statistical methodology and reporting (Gore et al., 1977; Gardner et al., 1983; 
Andersen and Forrest, 1987; Dar et al., 1994; Porter, 1999; Gardenier and Resnik, 2002; 
Nagele, 2003; Marshall, 2004). Misuse of statistics is unethical and has the potential to 
lead to serious clinical consequences (Strasak et al., 2007). 
As this thesis is focussed on using statistical methodology to understand mitochondrial 
disease, this section will give a brief overview of all the statistical methods employed 
throughout this study. The less familiar statistical techniques will be discussed in more 
detail. 
2.2. Basic statistical techniques 
Basic statistical approaches can be classified into two broad categories of approach, 
parametric and non-parametric. The majority of parametric tests are suitable for use 
with data that is normally distributed. The t-test is ubiquitous and is the basic parametric 
test used throughout statistical analysis. Non-parametric approaches to analysis are 
subject to less stringent criteria regarding the shape or form of the data, but are also 
generally less powerful than the equivalent parametric test. The non-parametric 
equivalent of the t-test is the Mann-Whitney U test. Note that there are still assumptions 
associated with the Mann-Whitney U test; the data must be ordinal for instance. 
Additionally, all observations must be independent. 
2.2.1. Linear regression 
Linear regression is at the heart of many parametric statistical analysis techniques. The 
principles of linear regression are taught from an early age in school (the concept of the 
line of best fit, or regression line). Computational methods for deriving the regression 
line and quantifying the variability of data are more advanced. An understanding of 
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linear regression is a vital foundation for understanding the more complex statistical 
techniques used in this study. 
Figure 2.1 illustrates an example of linear regression (or simple linear regression), and 
defines the residual, which is the distance of each data point from the regression line. 
Residuals allows us to calculate R
2
, the coefficient of determination, a measure of how 
well the model (regression line) fits the data; it is defined by summing the squares of the 
residuals in the fitted model, summing the squares of the residuals without fitting the 
model (so the differences from the average y value), and taking the ratio of these 
quantities. It is subtracted from 1 to give a value that is 1 for perfect correlation and 0 
for no correlation. Mathematically, R
2
 is also equal to the square of the Pearson’s 
correlation coefficient. 
 
Figure 2.1 Example of linear regression. 
The regression line (blue) is shown. The residual for each point, the vertical distance from the regression 
line, can be calculated. Computational methods for regression calculate the regression line by Ordinary 
Least Squares (OLS), which positions the regression line such that the sum of the squares of the residuals 
is minimized.  
2.3. Multiple regression 
Linear regression can be extended to encompass more than one predictor. This is 
difficult to visualise, as it requires a dimension for each predictor (or X). However, the 
principles of regression are the same as for simple linear regression; for two predictors 
the line of regression becomes a plane of regression in a total of three dimensions, with 
three predictors we would need to visualise a four dimensional space, and so on. 
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2.4. General linear model (GLM) 
The t-test is the simplest test for comparison of the difference between the means of two 
groups. ANOVA is the extension of the t-test to multiple groups. The general linear 
model (GLM) subsumes the t-test, linear regression, ANOVA, and several other related 
statistical techniques such as ANCOVA, MANOVA, and MANCOVA into a single 
umbrella analysis; this is possible as they are all based on the same basic linear 
modelling principles. The general linear model can be written as shown in Equation 2.1. 
where y is the vector of observations of the dependent variables(s), X is the vector of 
observations of the predictors,   is the design matrix (that we are estimating with our 
model), and   is the vector of random errors. 
       
Equation 2.1 General linear regression (GLM). 
y is the vector of observations of the dependent variables(s), X is the vector of observations of the 
predictors,   is the design matrix (that we are estimating with our model), and   is the vector of random 
errors. 
 
GLM assumes that the errors in   are independent and normally distributed, with a 
mean of zero. Note that   and X are one larger than the number of dependent variables 
in the model as they include the intercept term of the model. 
For many analyses, there is only one dependent variable, in which case y,  , and   are 
vectors. For multivariate analysis (so the extension of MANOVA and MANCOVA) 
these become matrices.  
2.5. General linear mixed model (GLMM) 
General linear mixed models, also known simply as mixed models, are statistical 
models that incorporate both fixed effects and random effects. A major development 
that separates mixed modelling from its predecessors is that it allows for modelling of 
observations that are not independent, by incorporating into the model the correlation 
structure of the errors. They are particularly useful in situations where repeated 
measurements are taken from the same observation subject (Macchiavelli and Moser, 
1997). 
The mathematical description of the mixed model is shown in Equation 2.2. 
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Equation 2.2 General linear mixed model (GLMM).  
  and   are vectors of fixed effect and random effect regression parameters respectively which are to be 
determined,   and   are matrices relating the observations   to   and  , and   is a vector of normally 
distributed errors with zero mean and equal variance. 
This model has two critical qualities; the (potentially) correlated random effects 
described by   , and the fact that the rows of the vector   are not required to be mutally 
independent as for traditional regression, but can be structured to allow covariance 
between errors. This allows repeated measures analysis to be performed.  
In contrast to GLM, mixed models are fitted using a maximum likelihood approach, 
which unlike least squares methodology is robust in the case of missing data where 
multiple recordings are made from subjects (Moser, 2004). Principal assumptions of 
GLMM are the normality of residuals  , which can be checked by residual diagnostics, 
and the homogeneity of variance across between-subject factors (homoscedacity) 
(Chiarotti, 2004). 
Mixed models are extensively used in biostatistical studies and many other fields as 
they permit a flexibility of model that cannot be achieved by GLM or ordinary linear 
regression (Wolfinger, 1997). The approach has been widely used to understand disease 
progression in many neurodegenerative conditions including dementia (den Heijer et 
al., 2010; Galvin Je and et al., 2005; Hassing et al., 2004; Johnson et al., 2009; 
Knopman et al., 2009; Tornatore and Grant, 2002), Parkinson’s disease (Dobkin et al., 
2011; Johnson and Galvin, 2011; Nandhagopal et al., 2009; Vu et al., 2012) and 
Multiple Sclerosis (Meier et al., 2007). 
2.5.1. Repeated measures 
A key characteristic of the cohort data is that it is longitudinal. Repeated measures is 
used to describe data composed of multiple observations of the same sampling unit. 
Usually it is the case that repeated observations are correlated, and this correlation must 
be incorporated into the linear model for appropriate inferences to be made (Littell et 
al., 2000; Moser, 2004). 
2.5.2. Fixed and random effects 
Random effects allow modelling in which experimental data can be considered samples 
from a larger population. As an example, in a drug trial of two drugs A and B, the effect 
of the drug is a fixed effect, whereas variation attributable to individual patients is 
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considered a random effect. This distinction is important in order to correctly estimate 
variation in the model (Laird and Ware, 1982). 
In a model incorporating random effects the observations are no longer independent, 
even if the errors are, since all observations are dependent on a shared set of random 
predictors.  
For fixed effects we are generally concerned with estimating means, whereas for 
random effects we are not generally interested in specific differences in means between 
one factor and another, but how much variance in the dependent variable can be 
explained by the random factor. 
2.5.3. Covariance structure 
Traditional repeated measures analysis is designed to deal with experimental design that 
has an equal number of measurements taken for each subject at equivalent intervals. The 
data used in this study are considerably more complex in form; data for each subject 
have a generally unique temporal layout, depending on when patients are assessed in 
clinic, and the number of data points available varies considerably. 
The most appropriate covariance structure for such data is a spatial power structure 
(Moser, 2004), the simplest of which, denoted in SAS as SP(POW), can be written as 
Equation 2.3. 
   (        )   
       
Equation 2.3 Spatial power covariance structure. 
  indexes the subjects,   indexes the time points,    is the common variance of the error terms,      is the 
temporal distance between two data points (measured in arbitrary units of years), and   is the correlation 
parameter to be determined.  
2.5.4. Model selection 
The prime imperative of model selection is that the model structure is representative of 
the data and appropriate for the objectives of the model (Diggle, 1988; Lindsey, 1993). 
Secondly, modelling assumptions (normality of residuals, indicator variable 
independence) should be verified. Many graphical approaches used in other modelling 
approaches common to ordinary regression are applicable, including influence and 
residual diagnostics (Christensen et al., 1992). 
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2.5.5. Assessing model fit 
There is no simple objective measure of model fitness for GLMM. However, the 
likelihood based approach provides several useful measures for assessing model fitness, 
such as Akaike’s Information Criterion (AIC) (Akaike, 1974) or Bayesian Information 
Criterion (BIC) (Schwarz, 1978). All such measures utilise the log likelihood and 
penalize in some way to promote model parsimony. AIC is generally used where model 
accuracy of prediction is considered more important than how well the model represents 
the true underlying data structure (Macchiavelli and Moser, 1997). In the model 
evaluation in this thesis a pragmatic approach was taken to use both AIC and BIC where 
they agreed on model preference, and AIC where they did not (Kuha, 2004). It should 
be noted that the lower the AIC or BIC the better the model describes the data. The AIC 
can be used for comparing non-nested models as long as the likelihood estimation 
procedure considers both fixed effects and random effects, i.e. it uses ML (maximum 
likelihood) not REML (restricted or residual maximum likelihood) (Kreft and de Leew, 
1998). 
Generation of a mixed effects model is a multi-step process involving iterative changes 
to fixed effects, random effects and covariance structure, with repeated re-testing of 
previously optimised model choices. 
2.5.6. Restrictions 
Multicollinearity occurs where two correlated fixed effects are included in a model 
together. This must be avoided in model specification, as it leads to imprecise 
estimations and inflated variance of parameter estimates (Silvey, 1969; Wißmann et al., 
2007). Independence of model effects must be verified. 
2.6. Key concepts in statistical analysis 
Many critical considerations of statistical modelling apply to a number of modelling 
approaches including linear regression, GLM, or mixed modelling. In all cases, the task 
of the modeller is to ensure that the model fits the data appropriately and that any 
modelling assumptions are not severely violated, so that reliable inferences can be made 
from the outputs of the model. 
2.6.1. Residuals diagnostics 
Analysis of the residuals from a fitted model is vital to assess whether a model is 
appropriate for the data, and they must meet certain requirements. At a basic level, 
residuals should be compared against the predicted value and each of the predictors, to 
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ensure that there are no trends in the data that show the residuals are not independent. If 
residuals are ill formed then the model needs to be revised. A common approach to 
address such issues would be transformation of the dependent or independent variables, 
discussed in 2.7, in order to improve the linearity of the data.  
2.6.2. Influence and leverage 
Leverage is a measure of how much a change in a data point’s y value will change the 
outcome of a regression. Each point has an associated leverage. High leverage points 
are those that are far away from the average x value.  
Influential data points are those that would result in a significantly changed outcome if 
they were omitted from the calculation. Influential data points will tend to have high 
leverage, but high leverage points are not necessarily influential; if the points happen to 
lie on or near the line of regression that fits all the other points in the data set then the 
influence will be small, despite high leverage. Influential points are those that have high 
leverage but also do not fit the pattern of the other data points very well.  
Looking at residuals does not necessarily reveal influential points, since an outlier at a 
position of high leverage will tend to drag the regression line towards it strongly, which 
masks the effect. Thus specific influence and leverage analysis needs to be carried out. 
The Cook’s distance (Cook’s D) statistic (Cook and Weisberg, 1982) is useful in 
influence diagnostics. Cook’s D for each point is calculated by measuring the effect of 
removal of the point on the errors of the other points in a regression. 
Points with high influence need to be carefully considered, as removal from the model 
may be warranted. 
2.7. Data transformation – Box-Cox analysis 
The most powerful modelling techniques currently available generally rely on a linear 
relationship between independent and dependent variables. However, it is rare for actual 
data, biological or otherwise, to exhibit a direct linear relationship. Non-linear 
modelling techniques are possible and frequently employed, but often the simplest and 
most powerful approach is to attempt to transform the data so that a non-linear 
relationship can be analysed using linear techniques.  
Box-Cox analysis is a specific approach of power transform that is commonly used in 
statistical analysis (Box and Cox, 1964). In essence, Box-Cox analysis is used to find 
the transformation of the dependent variable (either a power, e.g. y
2
 or y
3.5
, or the log 
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transformation) that minimizes the variance of the dependent variable when regressed 
against the independent variable(s). A result of this variance minimization is usually a 
reduction in skew or other distributional features that complicate analysis, and thus 
tends to produce data that is more normal in distribution. 
Box-Cox is by no means a panacea, and will fail to find a suitable transformation where 
no simple transformation is optimal. Additionally, it is of limited use in situations where 
the variance in the model is truly heteroscedastic (Sakia, 1992).  
2.8. Logistic regression 
Linear regression, GLM, and mixed modelling are all restricted to dependent variables 
that are continuous; discrete data cannot be analysed with such techniques. Discrete data 
is commonly encountered however, whether in the form of yes/no binary data, or data 
on a discrete and limited scale, such as the responses to individual questions of the 
NMDAS which have a 6 point (0 to 5) scale. 
Logistic regression is useful for analysis of such data. In contrast to linear regression, 
where coefficients are determined for the linear relationship between predictors and the 
outcome variable, in logistic regression parameters are determined that define the 
probability of an event occurring, e.g. for a given set of predictors the probability of the 
response variable being ‘yes’. The link between the predictors and the outcome is no 
longer linear but defined by the logistic function, which can be written as seen in 
Equation 2.4 for a logistic regression with one predictor: 
           
 
            
 
Equation 2.4 Logistic regression. 
 
Though superficially mathematically more complex than the equation         , 
which is solved for linear regression, the mathematical principles for identifying 
parameters are the same, and involve estimating the optimal parameters ( ). 
Similar to mixed modelling, maximum likelihood estimation is generally used to solve 
the equations to find the optimal parameters, which is an iterative procedure that begins 
with a tentative solution and iteratively tests solutions until convergence is achieved 
(any change in the estimated parameters results either in a poorer solution or one that is 
better by a negligible amount).  
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Logistic regression has an intuitive interpretation, in that the parameter for each 
predictor is the log of the odds ratio for a unit change in the predictor variable.  
2.8.1. Assessing model fit 
Similar to mixed modelling, the goodness of fit of a model can be analysed using the 
likelihood function, and the Akaike Information Criteria (AIC) provides a method for 
assessing the effectiveness of model fit whilst controlling for the number of parameters 
in the model (Akaike, 1974). 
Dichotomous models can also be evaluated by using the ROC (receiver operating 
characteristic) curve (Hastie et al., 2009). The area under the ROC curve (AUC) has a 
simple interpretation; the AUC is the probability that the regression result for a 
randomly selected affected individual will be greater than that of a randomly selected 
unaffected individual. Thus a poor regression has an AUC of 0.5, as this is no better 
than chance, and a perfect regression an AUC of 1.  
2.8.2. Coefficient of determination (R2) 
There is general consensus about the use of the coefficient of determination (R
2
) in 
ordinary least squares (OLS) multiple regression to describe the proportion of explained 
variance in a model. However, this is not the case in logistic regression. The problem 
occurs because in OLS there is only one reasonable measure of residual (unexplained) 
variance, the sum of squares of the deviations from predicted values. For logistic 
regression the situation is not so simple, as we have several ways to measure deviation 
(squared difference, entropy,  qualitative difference) which are not mathematically (i.e. 
calculated the same way) or conceptually the same (Efron, 1978). There are also two 
very different ways of looking at the outcome of the model; either consideration of the 
(continuous) predicted probabilities that the model generates, or the accuracy of the 
(discrete) classification of the model. (Menard, 2000). Several pseudo-R
2
 statistics have 
been derived for use in logistic regression, which are discussed by Menard extensively 
(Menard, 2000) and will not be discussed in detail here. However, in agreement with 
several published commentaries on the issue (Menard, 2000; Shtatland et al., 2002) I 
use the pseudo-R
2
 defined by McFadden to compare models (McFadden, 1974) where 
no other comparison was possible.  
2.8.3. Ordered logit and multinomial logistic regression 
Where discrete data has more than two levels there are two approaches to modelling the 
data with logistic regression. Multinomial logistic regression can be used, which 
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requires a set of parameters for each change in level of the dependent variable; for the 
NMDAS data this would require 5 sets of parameters to define the change from each 
level 0 to 4 to the next level. A simpler approach, requiring a much reduced number of 
parameters is to use ordered logit, which makes the assumption of proportional odds 
(McCullagh, 1980); for the NMDAS data, this would mean the odds of scoring 0 vs 1-5 
is the same as scoring 1 vs 2-5, or 2 vs 3-5, etc. This assumption is restrictive and must 
be tested for data conformity, but if the data structure is appropriate it is a statistically 
efficient model for analysing discrete ordinal response data. 
2.9. Generalised linear modelling 
Generalised linear modelling is an extension of mixed modelling that allows non-
identity link functions (linking the predictors to the outcomes) to be used; this opens up 
the possibility of creating models with both fixed and random effects but non-linear 
outcome variables (Nelder and Wedderburn, 1972). For instance, using the logit 
function mixed logistic models can be created, and other link functions extend the 
principles of linear mixed modelling to non-linear modelling. 
2.10. Bootstrapping 
Bootstrapping is a computational method for estimating the accuracy of a sampling 
statistic, first developed by Bradley Efron (Efron and Tibshirani, 1986). It is a simple 
and universally applicable technique for almost any estimation problem and facilitates 
calculation of the accuracy of estimates in situations where the sampling distributions 
are too complex for parametric statistical analysis (Johnson, 2001; Christie, 2004). It is 
one of a set of techniques known more generally as resampling. 
Bootstrapping is particularly useful when we are interested in estimating properties of 
an estimator itself; for example, calculating the accuracy of a measure such as the 
standard error. For illustration, in a particular population we may take a random sample 
of people, measure their heights, and use this to calculate the mean height and the 
standard error. The standard error gives an estimate of the variation of heights in the 
population. However, there is no straightforward statistical way to estimate the accuracy 
of the standard error itself. In this situation, we can use bootstrapping to evaluate how 
accurate the estimate of the population variance is. 
Bootstrapping estimates properties of an estimator by resampling, with replacement, a 
random sample from the original sample. A resample in a bootstrap contains the same 
number of samples as the original sample. For each resample, the relevant estimators 
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(for example sample mean or standard error) are calculated. The set of resampled values 
then gives us an empirical distribution from which we can determine confidence 
intervals for the estimator (or indeed, calculate the standard error of the standard error, 
if the distribution of the estimator is Gaussian). 
Bootstrapping and resampling methodology is used in two contexts in this study. The 
first is in Chapter 3, where bootstrapping is used to estimate the variability in the real-
time assays for measuring mtDNA heteroplasmy and total mtDNA copy number. 
Secondly, it is used several times in Chapter 4, in particular to evaluate which 
measurement of heteroplasmy (blood or urine) best predicts disease progression in the 
m.3243A>G patient cohort. 
The bootstrapping was executed in matlab. The code used can be found in Appendix II. 
  
2.11. General Methodology 
2.11.1. Disease progression modelling 
As several chapters of this thesis use similar statistical methodology, the generic aspects 
of the modelling will be detailed here and referred to in each chapter as appropriate. 
Disease burden analysis utilises the NMDAS assessment scores, as described in section 
1.5. The total NMDAS score is a summary of the disease burden for a patient at a given 
time (assessment date). Though the NMDAS score is actually a discrete scale, in effect 
we can consider it a quasi-continuous scale and thus it can be modelled using 
techniques such as linear regression. The total score of all NMDAS questions was used, 
excepting the score for respiratory function; this was excluded as the scoring system for 
this aspect of the NMDAS is currently under review and the existing scores are not 
considered to reflect the respiratory function of the patients.  
For each analysis, Box-Cox analysis is used to stabilise the variance of the dependent 
variables and to identify optimal transformations of the variables to satisfy assumptions 
of normality,(Box and Cox, 1964) thus enabling the use of parametric testing. Where 
data is already satisfactorily Gaussian in distribution Box-Cox should identify the 
optimal transform as identity. 
For all analyses conducted using the total NMDAS score, Box-Cox analysis has shown 
that the optimal transformation to achieve normality is to take the fourth root of the 
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NMDAS score (NMDAS
0.25
) as the dependent variable. This transformation is used in 
all cases, unless otherwise stated.  
2.11.1.1. Total Disease Burden Basic Statistical Analyses 
For the majority of patients we have several NMDAS assessments recorded. Basic 
analyses assume independence of all data, and thus multiple data for each patient cannot 
be included in basic modelling. Hence, for basic analyses I use a single summary data 
point for each patient, determined by taking the mean NMDAS score and mean age at 
assessment. Basic analyses are conducted using SAS PROC GLM for simple linear 
regression and multiple linear regression.  
2.11.1.2. Total Disease Burden Longitudinal Modelling 
Though basic analyses are useful for a summary understanding of data, longitudinal 
modelling is required for a deeper understanding of disease progression over time. 
PROC MIXED was used for longitudinal mixed modelling using a spatial power 
structure to model covariance of repeated data from the same patient.(Singer, 1998; 
Moser, 2004). Polynomial terms of time up to cubed (time
3
) were included. The Akaike 
Information Criterion (AIC) was used to compare models (Akaike, 1974). Model 
validation included the use of residual, influence, and leverage diagnostics to check 
model assumptions and verify model stability. SAS version 9.2 (Cary, NC) was used 
throughout.  
2.11.2. Statistical reporting conventions 
In all statistical analyses reported in this thesis, the same general conventions are 
adhered to, unless otherwise stated.  
For pre-determined hypothesis testing, significance was determined at P < 0.05, high 
significance at P < 0 .001.  
For multiple regression, I report the standardized coefficient (B) (standardized to have 
unit variance) and significance value (P value) for each parameter estimate, together 
with the number of subjects (N) and the adjusted coefficient of determination (R
2
) for 
the overall regression.  
For simple linear regression I report N, the Pearson’s correlation coefficient (r) and the 
P value.  
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For multiple logistic regression I report N, and the standardized coefficient and P value 
for each parameter estimate. 
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 Methods development Chapter 3.
3.1. Large scale single-mtDNA deletion level measurement assay 
3.1.1. Introduction 
The MT-ND4/MT-ND1 assay was developed for measuring the deletion level, or 
heteroplasmy level, of single large-scale mtDNA deletions (He et al., 2002). For 
diagnostic or prognostic purposes an approximate estimation of the deletion level in 
skeletal muscle homogenate is often sufficient. However, for certain studies a more 
accurate measure of heteroplasmy is required.  Resistance training, for example, has 
been shown to improve muscle oxidative capacity in patients with single large-scale 
mtDNA  deletions (Murphy et al., 2008). This is thought to be the result of activation, 
proliferation, and incorporation of satellite cells; though satellite cells have similar 
deletion levels to the mature muscle cells, the mutations have been shown to be lost 
during the transition from satellite cell to myoblast (Spendiff et al., 2013). It is 
hypothesised that analysis of deletion levels in patients undergoing resistance training 
will reveal lowering of heteroplasmy levels in resistance trained muscles; however, 
sensitive measurement of heteroplasmy in muscle homogenate is a requirement for this 
analysis. 
It has long been known that the MT-ND4/MT-ND1 assay is more accurate at high 
heteroplasmy levels (over 70%) than at lower levels, with an empirically estimated cut-
off of around 30% as a baseline for accurate quantification (Prof Doug Turnbull, 
personal communication). It has also recently been reported that the measurement error 
in real-time PCR (qPCR) is dependent on DNA concentration (Sochivko et al., 2013), 
with empirical error increasing as DNA concentration decreases.  
To date the variation in the MT-ND4/MT-ND1 assay has not been quantified. Accurate 
quantification of this variation is necessary to plan experiments that require subtly 
changes in deletion level to be measured. 
3.1.2. Aim 
The aim of this study is to quantify the variation in the assay with respect to two 
variables, the deletion level (heteroplasmy) of the sample, and the concentration of the 
DNA. 
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3.1.3. Methods 
3.1.3.1.1. Methodological approach 
The methodological approach to the analysis was to repeat each sample the maximum 
number of times possible on a qPCR plate in order to be able to estimate with highest 
accuracy the variability of the assay. Bootstrapping was further used to quantify the 
precision of this variability estimate. 
The accuracy of the assay was then verified with samples of similar deletion level to 
confirm that small changes in deletion level are measurable. 
3.1.3.2. Real-time PCR methodology 
All molecular analyses were performed using total skeletal muscle DNA extracted using 
standard protocols. mtDNA deletion level in muscle homogenate was quantified using a 
validated, multiplex qPCR MT-ND4/MT-ND1 assay (He et al., 2002; Krishnan et al., 
2007).  
Wild-type skeletal muscle DNA from a control subject was used to produce the standard 
curve for each real-time analysis. 
All mtDNA deletion level quantification was performed by Dr Julie Murphy. 
3.1.3.3. Intra-plate variability measurement 
3.1.3.3.1. Study design 
Six patients with a range of previously quantified deletion levels were selected, with 
deletion levels ranging from around 6% up to 80%. All DNA samples were diluted to 
approximately the same concentration on a trial run of qPCR to achieve a target of 
around 20 CTs. These samples were then serially diluted to a range of concentrations to 
achieve final CT values of around 27, 31, and 35 CTs. 
Each plate was made up of 84 replicates; the remaining wells on each 96 well plate were 
used up by no-template controls and serially diluted wild-type total DNA for standard 
curve estimation. 
3.1.3.3.2. Statistical methodology 
Severe outliers, defined as more than 3 times the interquartile range below the lower 
quartile or above the upper quartile, were removed from the data prior to further 
analysis. 
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The standard deviation of the replicates on each plate was calculated. Bootstrapping was 
then used to calculate 95% confidence intervals for the observed standard deviation.   
The standard deviation at high DNA concentration (< 23 CTs) was used to calculate 
minimum detectable differences observable using a two tailed t-test for a range of N 
values at β=0.80 and  α=0.05. 
3.1.3.4. Empirical verification of deletion level 
To confirm the reliability of the assay to measure deletion level changes, 3 different 
samples at a low deletion level (20%-25%) were run on three separate plates. Each 
sample was run with 24 replicates on each plate. This was used to calculate independent 
values for the differences between samples per. The difference between samples 1 and 2 
and the difference between samples 2 and 3 are reported for each plate (samples 1 and 3 
are not compared as this is not an independent comparison, it can be derived from the 
other two differences). 
The same experiment was performed with three samples at high deletion levels (70%-
80%).  
For each pair of samples, the true difference was estimated by taking the mean of all 
replicates on each plate. The deviation for each replicate from this true value was then 
calculated.  
3.1.4. Results 
3.1.4.1. MT-ND4/MT-ND1 assay variability is dependent on DNA concentration 
and heteroplasmy level 
The quantified variation in the assay is depicted in Figure 3.1. As shown in Figure 3.1A, 
for each DNA sample, dilution of the DNA to lower concentration increases the 
variance of the measurement, and heteroplasmy also decreases with increasing 
heteroplasmy. The relationship between heteroplasmy and the assay variation is linear at 
high DNA concentration (below 23 CTs), as seen in Figure 3.1B (r = -0.996, P < 
0.0001). The parameters for the regression equation are found in Table 3.1. 
Whilst Figure 3.1 depicts the data for a selection of the data produced for this study, 
Figure 3.2 depicts all of the data produced, including data at very low DNA 
concentration (> 31 CTs). This illustrates the extreme increase in variation as DNA 
concentration decreases.  
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Figure 3.1 Variation in the MT-ND4/MT-ND1 assay is dependent on heteroplasmy and DNA 
concentration. 
The y axis depicts the standard deviation in absolute percentage points; for example, a 3% standard 
deviation (95% confidence interval approx. ±6%) for a measured 20% heteroplasmy would be 14%-26%. 
(A) Standard deviation of the MT-ND4/MT-ND1 assay as measured for three concentrations of source 
DNA; the average CT of the assay is indicative of the DNA concentration, with the most concentrated 
DNA at lowest average CT. Variance increases with decreasing DNA concentration (increasing CT). At 
each DNA concentration, assay precision increases as heteroplasmy increases. (B) Relationship between 
assay variation and heteroplasmy at low (< 23) CT. Assay precision is linearly related to the heteroplasmy 
level. r = -0.996, P < 0.0001. 
 
Parameter Estimate Std Dev 95% Lower 95% Upper 
Slope -0.03711 0.002468 -0.04234  -0.03188 
Intercept 3.491 0.1225 3.231 3.751 
Table 3.1 Regression coefficients for relationship between assay standard deviation and 
heteroplasmy. 
The estimated value, standard deviation, and 95% confidence intervals are shown for each parameter. 
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Figure 3.2 Relationship between DNA concentration and assay variation at various levels of 
heteroplasmy.  
The y axis is log scaled. At any heteroplasmy level, assay variation increases with increasing CT 
(decreasing DNA concentration). Between 18 and around 28 CTs variation increases slowly at any 
heteroplasmy level. At very low DNA concentrations (above approximately 31 CTs) assay variation is 
extremely high and increases rapidly with average CT. 
3.1.4.2. Verification of intra-plate and quantification of inter-plate variability 
Results for the difference in samples are shown in Figure 3.3. The empirical standard 
deviation for the difference is 3.14% at 20%-25% deletion level and 1.28% at 70%-80% 
deletion level. This can be verified by scrutiny of the figure; the majority of values for 
the deviation at low deletion level are within ±6%, which is an approximate 95% 
confidence interval based on a standard deviation of 2.5%. 
The expected standard deviation for the difference between two deletion levels can also 
be calculated. Using the linear regression coefficients in Table 3.1, at 25% deletion level 
the standard deviation for a single heteroplasmy measure is calculated as 2.56%. Thus 
the standard deviation of the difference of two deletion levels (using the fact that 
variance of the difference of two normally distributed variables is the sum of the 
variances) is calculated as √        3.62%. 
Chapter 3 Methods development 
 45   
 
At 70% deletion level the standard deviation is calculated as 0.89%. The difference of 
two means at this level is, therefore, calculated as √        1.26%. 
The estimate for the inter-plate variation is 0.496% at low deletion level and 0.479% at 
high deletion level, with a pooled estimate of 0.485% using all samples. 
 
 
Figure 3.3 Inter- and intra-plate variability in the measurement of the difference in deletion level 
between samples.  
To confirm the reliability of the assay to measure deletion level changes, 3 samples at a low deletion level 
(20%-25%) were run on three separate plates, 24 replicates of each sample per plate. This was used to 
calculate independent values for the difference between samples. The same experiment was performed 
with three samples at high deletion levels (70%-80%). The graph illustrates the variability in this 
difference; the data is centred by subtracting the best estimate of the actual deletion level difference. The 
mean value for each plate was within 1% of the actual deletion level difference. Variability at high 
deletion level was lower than at low deletion level. 
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Del 
Level 
Standard 
Deviation 
3 5 10 20 
10% 3.12% 9.6% 6.3% 4.1% 2.8% 
20% 2.75% 8.4% 5.6% 3.6% 2.5% 
30% 2.38% 7.3% 4.8% 3.2% 2.2% 
60% 1.26% 3.9% 2.6% 1.7% 1.1% 
80% 0.52% 1.6% 1.1% 0.7% 0.5% 
Table 3.2 Relationship between standard deviation, heteroplasmy levels and sample replicates.  
For the given number of replicates, this table indicates the minimum detectable heteroplasmy difference.  
3.1.5. Discussion 
Severe outliers were removed from the data prior to further analysis. Though this may 
seem questionable considering the assay variability is under investigation, this was 
considered an appropriate pre-filter, in order to eliminate wells which were clearly 
erroneous. A basic interpretation of an outlier taught in many high school textbooks is 
based on points more than 1.5 times the interquartile range below or above the data 
quartiles; using a cut-off of 3 times the interquartile range makes the test much more 
liberal but avoids severely erroneous points being included in the analysis. 
The results in section 3.1.3.4 show that the calculated standard deviation for the 
difference between two samples at high deletion levels (1.26%) is very close to the 
empirical level (1.28%). However, at low deletion level the empirical value (3.14%) is 
somewhat lower than the calculated value of 3.62%. The reason for this unexpected 
precision is unknown, but the value is not sufficiently different from the expected value 
to cause concern. 
The estimate for the inter-plate standard deviation is low, under 0.5%. This implies that 
the advantage to be gained from running repeat plates for a given result is minimal. 
The results from this analysis are important in two respects. Firstly, it has quantified for 
the first time the variability in this assay, and decisions can be made on the number of 
replicates required to precisely estimate deletion level. Many researchers use three 
replicates in any qPCR estimation as a matter of course; it is clear from this analysis 
that this approach is not valid at either low deletion level or low DNA concentration. 
There are limitations to be acknowledged. Though we studied the inter-plate variation, 
this aspect of the study was not comprehensive as only three plates were run for each 
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investigation (six plates in total). It would be desirable to measure this more precisely to 
be confident that a single real-time PCR plate is sufficient to accurately quantify the 
heteroplasmy to a given required precision. Additionally, the linear regression provided 
guidelines for quantification of the variation only for concentrated DNA. The same was 
not done for lower DNA concentrations; however, rough estimates can be obtained by 
interpreting the data from the graphs.  
3.1.5.1. Theoretical basis for the variation in the assay with heteroplasmy level. 
The increasing variability of the assay with decreasing heteroplasmy can be explained 
by the mathematical process used to calculate heteroplasmy.  
The real-time assay measures the relative difference in the expression of the two genes 
MT-ND1 and MT-ND6. At low heteroplasmy levels, the difference between these two 
quantities is small. For instance, at 10% heteroplasmy and a perfectly efficient real-time 
reaction (doubling each time) the CT difference would be 0.152 (log2(0.9), or the log of 
the heteroplasmy subtracted from 100%). The CT difference for a 90% heteroplasmy 
sample in the same circumstance would be 3.32, or log2(0.1). If the errors are constant 
in the CT difference, for example ±0.1 CT, then the CT difference for the 10% sample 
will be measured within (0.052, 0.252), whilst the 90% heteroplasmy sample will be 
measured within (3.22, 3.42). These two ranges then relate to heteroplasmy measures of 
(4%, 19%) and (89.3%, 90.1%) respectively. Thus, the difference in accuracy arises 
most likely because the errors are independent of the CT differences, and thus will be 
proportionately larger for a small difference than a large difference. 
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3.2. Total mtDNA copy number measurement assay 
3.2.1. Introduction 
Low mtDNA copy number has been repeatedly shown to be associated with disease 
(Moraes et al., 1991; Poulton et al., 1995; Barthélémy et al., 2001; DiMauro and 
Hirano, 2005). It has also been shown that exercise improves physical capacity of 
patients mtDNA disease, and that this is associated with an increased mtDNA copy 
number (Taivassalo et al., 1998; Taivassalo et al., 2006). Understanding the 
mitochondrial changes in muscle that lead to improved physical wellbeing is 
imperative, and mtDNA copy number is a potentially significant aspect of this. Copy 
number determination has not been a significant issue within exercise trial studies when 
single muscle fibres are the focus, as mitochondrial DNA levels are normalised per unit 
area. However, to understand overall changes in muscle it is important to look at 
homogenate muscle samples. 
Gel electrophoresis and Southern blotting of nuclear DNA and mtDNA simultaneously 
has been used to measure the relative quantity of mtDNA to nuclear DNA, but this is 
labour intensive and only semi-quantitative (Shanske and Wong, 2004). Most published 
approaches to measuring mtDNA copy number have used real-time PCR (qPCR), using 
regions of the nuclear and mtDNA genomes where  polymorphisms are rare (Venegas 
and Halberg, 2012). The B2M gene has been used in the literature as it is a convenient 
single copy gene in this respect (Malik et al., 2011), and we already use the MT-ND1 
gene to measure heteroplasmy for mtDNA deletions as deletions covering this region 
are very rare, hence we chose to use this as the mtDNA target for quantification. 
Multiplexing mtDNA and nDNA targets together is problematic, since several thousand 
copies of mtDNA are present in muscle cells but nuclear DNA is single copy. This 
presents problems with PCR kinetics and saturation effects in the multiplexed PCR 
reactions. Multi-copy genes can be used that ameliorate this problem to a large extent, 
such as 18S ribosomal DNA which is present around 600 times in the nuclear genome 
(Schmickel, 1973; Stults et al., 2008); this is suitable for normalization for repeated 
samples from the same individual, but unsuitable otherwise due to inter-subject 
variation in the repeat numbers.  Additionally, in a recent study it was found that the 
accuracy of quantitative real time PCR was severely affected by the concentration of 
DNA within the sample (Sochivko et al., 2013) further highlighting the issue of 
comparing high copy number targets to lower copy number targets.  
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To address these issues, it was decided to develop a non-multiplexed assay with an extra 
dilution of the mtDNA target to ensure that both B2M and MT-ND1 are within a 
reasonable range for quantification by real-time PCR (above approximately 17 CTs but 
below 30 CTs, to ensure quantification is in the exponential phase of growth).  
3.2.2. Aims 
As it was expected that the extra dilution step and the lack of multiplexing would 
introduce experimental error into the quantification process, it was decided to quantify 
the experimental variability in order to make recommendations on the number of 
replicates required to ascertain the relative copy number of two samples within a pre-
determined tolerance. As the experimental error is multi-level (intra-plate variability 
nested within inter-plate variability) simulation will be used to determine the number of 
replicates required to determine a given change in copy number. 
3.2.3. Methods 
3.2.3.1. Real-time PCR  methodology 
All molecular analyses were performed using total skeletal muscle DNA extracted using 
standard protocols. mtDNA copy number in muscle homogenate was quantified by 
measuring the relative expression of the mtDNA MT-ND1 gene and the nDNA B2M 
gene.  
MT-ND1 and B2M reactions were run separately, sequentially on the same real time 
machine. Primers and probes used are detailed in Table 3.3, the mastermixes for each 
reaction are found in Table 3.4 and Table 3.5, and standard cycling conditions are 
described in Table 3.6. The same wild-type skeletal muscle DNA from a control subject 
was used to produce the standard curve for each real-time analysis. Sample were run in 
the same well on the paired MT-ND1and B2M  plates to minimize well-to-well error. 
The target DNA concentration for B2M quantification was 100 fold higher than that for 
MT-ND1 quantification, to ensure that the resulting CTs for both samples would be 
within useful range (18-25). Thus the samples for MT-ND1 quantification were diluted 
1 in 100 relative to the samples for B2M quantification, using two serial 1:10 dilutions 
to reduce dilution error. 
All real-time PCR quantification was performed by Dr Helen Tuppen. 
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Primers: Sequence 
MT-ND1 (NC_012920.1)  
L3485-3504  5’- CCCTAAAACCCGCCACATCT -3’ 
H3553-3532  5’- GAGCGATGGTGAGAGCTAAGGT -3’ 
B2M (NG_012920.1)  
B2F (8969-8990) 5’- CCAGCAGAGAATGGAAAGTCAA -3’   
B2R (9064-9037) 5’- TCTCTCTCCATTCTTCAGTAAGTCAACT -3’ 
  
Probes:  
MT-ND1 (L3506-3529) VIC-5’- CCATCACCCTCTACATCACCGCCC -3’-MGB 
B2M (9006-9032) 6-FAM-5’- CCGACATCATTACCGGGTTTTCCTCTTG 
-3’-MGB 
Table 3.3 Primers and probes. 
 
Taqman universal PCR mastermix 10µl 
B2M F (10µM) 0.6µl (final concentration: 300nM) 
B2M R (10µM) 0.6µl 
B2M probe (5µM) 0.4µl (final concentration: 100nM) 
MgCl2 (50mM) 1.2µl (final concentration: 3mM) 
DNA (optimal concentration ~ 10ng/µl) 5µl 
dH2O 2.2µl 
Table 3.4 Mastermix for the B2M reaction. 
 
Taqman universal PCR mastermix 10µl 
MT-ND1 L3485 (10µM) 0.6µl (final concentration: 300nM) 
MT-ND1 H3553 (10µM) 0.6µl 
MT-ND1 probe (5µM) 0.4µl (final concentration: 100nM) 
DNA (optimal concentration ~ 0.1ng/µl) 5µl 
dH2O 3.4µl 
Table 3.5 Mastermix for the MT-ND1 reaction. 
 
2 minutes at 50°C 
10 minutes at 95°C 
40 cycles of 15 seconds at 95°C and 1 minute at 60°C 
Table 3.6 Standard cycling conditions. 
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3.2.3.2. Intra-plate variability measurement 
3.2.3.2.1. Study design 
Test runs of several samples were executed to find two samples with high relative copy 
number difference. These two samples were diluted to approximately equal DNA 
concentration, and then mixed together in three different ratios. This resulted in 5 
samples of different relative copy number, the original two samples plus three 
interpolated DNA copy numbers.  
On each real-time PCR plate 12 replicates of each sample were run, totalling 60 wells. 
The remaining wells were used for standard curve generation and no template controls. 
Six replicates of five standard curve points (30 in total) were run, to ensure highly 
accurate standard curves for optimal quantification. 
3.2.3.2.2. Statistical methodology 
Severe outliers, defined as more than 3 times the interquartile range below the lower 
quartile or above the upper quartile, were removed from the data prior to further 
analysis. 
The MT-ND1/B2M ratio was calculated for each sample well in each plate, yielding 12 
replicate values per MT-ND1/B2M plate pair. These were used to calculate 12 
independent values for the relative copy number of each of samples 2 to 5 compared to 
sample 1, which resulted in 12 replicates of 4 independent sample comparisons per MT-
ND1/B2M plate pair. Four MT-ND1/B2M plate pairs were run, to examine inter-plate 
variability.  
The standard deviation of the replicates on each plate was calculated. Bootstrapping was 
then used to calculate 95% confidence intervals for the observed standard deviation.   
A linear model was used to verify whether the variance of the assay was independent of 
relative copy number. 
Using the calculated inter-plate and intra-plate variability, sample size calculations were 
performed in SAS using PROC POWER, using the formula for the sample standard 
deviation as shown in Equation 3.1, as the intra-plate (replicate) variability is nested 
within the inter-plate (plate-to-plate) variability. 
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Equation 3.1 Calculation of experimental standard deviation. 
The experimental standard deviation       is calculated from the inter-plate (p2p) standard deviation and 
the intra-plate (rep) standard deviation using the formula for the summation of variances. The sample 
variance for the replicates is divided by the number of replicates     , which is then used to calculate the 
number of plates required. 
3.2.4. Results 
 
Figure 3.4 Intra- and inter-plate variability of the copy number assay. 
5 samples of progressively decreasing copy number are analysed on each plate; each sample is replicated 
12 times on each plate, and 4 plates are run in total. This was used to calculate 12 independent samples of 
the relative copy number of sample 1 compared to each of the other 4 samples. The mean relative copy 
numbers for each sample comparison are comparable from plate to plate.  
 
The relative copy number of sample 1 compared to samples 2 to 5 are shown in Figure 
3.4. With 12 replicates of each measure, these are 12 x 4 x 4 = 192 independent samples 
of copy number.  
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The intra-plate (replicate) and inter-plate (plate to plate) variability for the relative copy 
number of each pair of samples is shown in Figure 3.5. These are not all independent 
samples (the first 4 are independent), but are shown to allow comparison of variability 
across the samples. 95% confidence intervals are calculated using bootstrapping 
methodology. 
To calculate a global estimate for the standard deviations a modified bootstrapping was 
employed, using the pool of all sample comparisons (10 comparisons, 12 replicates of 
each comparison on 4 plates, totalling 480 relative copy number measures in total). 
Each copy number estimate was scaled first by dividing by the best estimate of the 
relative copy number of the two samples. This yielded an intra-plate standard deviation 
of 1.066 (95% CI 1.038-1.101) and an inter-plate standard deviation of 1.027 (95% CI 
1.0047-1.069). 
The inter-plate and intra-plate standard deviations were also compared to the relative 
copy number. The results are shown in Figure 3.6. There is no evidence of a 
relationship between the relative copy number and the variability. 
The number of plates/replicates per plate required to detect a given change in copy 
relative number based on the estimated inter- and intra- plate variation is shown in 
Table 3.7. 
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Figure 3.5 Inter-plate and intra-plate variability across samples. 
The relative copy number (ratio) of each pair of samples was calculated, 12 replicates on 4 plates, a total 
of 48 values per ratio. All 48 values were used to calculate the true value, and each sample divided by this 
to normalize the ratios. The intra-plate (replicate) and inter-plate (plate to plate) standard deviation and 
95% confidence intervals were then calculated for each sample comparison using bootstrapping. All 
variability was examined on the log values; the graph shows inverse log standard deviations, which are 
scale factors. The intra-plate variability is consistently higher than the inter-plate variability. The mean 
inter-plate variability is 1.027 and the mean intra-plate variability 1.066.  
 
Figure 3.6 Linear regression of relative copy number against intra-plate assay variation. 
The graph shows no evidence of a linear correlation between relative copy number and the assay intra-
plate variability (P = 0.4614, r = 0.20). Each point is an independent estimate of the standard deviation 
from a single plate. 
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Relative Copy Number 
Change 
5% 10% 15% 20% 50% 
Log10 factor 0.021189 0.041393 0.060698 0.079181 0.176091 
1 replicate 26 / 0.81 
72 / 0.80 
8 / 0.83 
20 / 0.81 
4 / 0.81 
10 / 0.83 
3 / 0.84 
6 / 0.81 
2 / 0.97 
3 / 0.96  
2 replicates 16 / 0.82 
48 / 0.80 
5 / 0.83 
14 / 0.82 
3 / 0.85 
7 / 0.83 
3 / 0.96 
5 / 0.87  
2 / 0.99 
2 / 0.84 
3 replicates 12 / 0.82 
40 / 0.80 
4 / 0.83 
12 / 0.83 
3 / 0.92 
6 / 0.83 
2 / 0.80 
4 / 0.83 
2 / >0.999 
2 / 0.89 
6 replicates 8 / 0.80 
32 / 0.8 
3 / 0.82 
9 / 0/00 
3 / 0.98 
5 / 0.83 
2 / 0.91 
4 / 0.90 
2 / >0.999 
2 / 0.93 
12 replicates 7 / 0.84 
28 / 0.81 
3 / 0.900 
8 / 0.81 
2 / 0.85 
5 / 0.87 
2 / 0.96 
3 / 0.81 
2 / >0.999 
2 / 0.96 
Table 3.7 Number of real-time PCR plates/replicates required to detect a given change in relative 
copy number. 
Each cell shows the number of plates / actual power for a two sample t-test with the given number of 
replicates (per sample) per plate, to detect the given change in relative copy number at minimum power of 
0.80.  In each cell, the top line shows the calculation using the standard deviation estimates; the bottom 
line shows the calculation using the 95% upper bound of the standard deviation estimates.  
 
3.2.5. Discussion 
This investigation has quantified the variability in this novel approach to measurement 
of mtDNA copy number, and provides guidelines on the number of replicates and plates 
of each sample that should be run to achieve a required accuracy.  
The variation in the assay is confirmed as independent of the relative copy number, 
within the range of relative copy number that was investigated (approximately 2 fold 
difference). This is a practically useful finding, as it implies that the number of 
replicates to determine copy number can be made independently of the copy number of 
the samples under investigation. 
It was anticipated that the extra dilutions of the MT-ND1 samples, necessary to ensure 
both targets were within conveniently measurable CT range, may have introduced 
unacceptable experimental error into the procedure. As each plate was run from re-
diluted samples, the inter-plate variability incorporates any variation introduced by this 
extra dilution. The inter-plate variability (1.027 scale factor) is lower than the intra-plate 
variability (1.066), however it is still variability that needs to be accounted for when 
using the assay to accurately determine copy number. 
Chapter 3 Methods development 
 56   
 
Regarding recommendations for the number of replicates/plates to use to detect specific 
minimum changes in copy number, use of the t-test for requires a minimum of two 
plates in order that the sample variance is estimable. This restriction comes from the 
fact that the intra-plate variation is nested within the inter-plate variation. For large 
enough changes of copy number it seems intuitive that a single plate would be sufficient 
to estimate this change, but formal statistical analysis requires a minimum of two plates. 
There are important limitations to be acknowledged.  
Firstly, the number of plates run was small (four), and more plates would allow more 
accurate quantification of the inter-plate variation, a narrower 95% confidence interval 
for the estimates, and one would hope a lower estimate for the number of replicates 
required. The estimates using the 95% upper bound for the standard deviation estimates 
are impractically high for the smaller changes in copy number, and some reduction in 
the confidence interval would be very beneficial in order to have confidence in the 
results of the assay with the minimum experimental effort. The assay is limited by the 
number of samples that can be run on the same PCR plate, which is limited to 96 wells, 
several of which are used to calculate standard curves and for no-template controls.  
Secondly, the inter-plate variability was confounded with the dilution error in this 
experiment; it may have been valuable to run separate repeated dilutions of samples on 
the same plate in order to separate the inter-plate and dilution variation in this assay, 
which may have identified the true inter-plate error to be small enough to ignore for 
practical purposes. However, since the two targets are intended to be run on separate 
plates (to avoid multiple standard curves on the same plate) some level of inter-plate 
variability is inevitable, thus is seems a prudent approach to combine the dilution and 
intra-plate variation and deal with them both concurrently. This is not necessarily a 
trade-off, as reducing the number of replicates per plate allows more samples to be run 
on each plate.  
Though this assay optimisation and variation quantification has been focussed on 
relative copy number (intended for measuring change in copy number in repeated 
samples from the same patient), it can be extended to calculate absolute copy number. 
This would require an absolutely quantified reference sample to be run on each plate 
requiring absolute quantification.  
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3.2.5.1. Muscle specific issues 
Normalisation of the mtDNA copy number by a single copy nuclear gene presents 
difficulties that are specific to muscle homogenate analysis, with two main issues to 
contend with.  
Firstly, muscle fibres are multinucleated, each fibre formed from the fusion of multiple 
mononucleated myogenic cells (Okazaki and Holtzer, 1966). It is thought that each 
nucleus serves a certain volume of cytoplasm, called the myonuclear domain (Hall and 
Ralston, 1989). Historically, it was thought that the size of the domain was relatively 
constant, supported by general biological considerations that nuclear DNA content 
universally appears to be related to cell size (Gregory, 2001) and by specific 
examination of muscle fibres (Landing et al., 1974). However, there are many findings 
from later studies that contradict this; domain size is related to body mass (Liu et al., 
2009), domain size isn’t conserved during hypertrophic growth (Wada et al., 2003), 
domain size varies along the length of muscle fibres and increases with age (Rosser et 
al., 2002), and domain size decreases with muscle wasting and atrophy (Allen et al., 
1995; Ohira et al., 1999; Bruusgaard and Gundersen, 2008). Furthermore, domain size 
has been shown to vary according to fibre type; Type I fibres (slow twitch, and heavily 
dependent on mitochondria for oxidative phosphorylation) have the smallest domain, 
Type IIa fibres (fast twitch, but also oxidative) are intermediate in size, and Type IIx 
(fast twitch glycolytic fibres with few mitochondria) have the largest myonuclear 
domain (Roy et al., 1999; Van Der Meer et al., 2011).  
The second major issue is related to the cell types found in muscle homogenate. Non-
muscle cells, such as adipocytes or cells of the vascular system are present and will 
contribute to both the nuclear and mtDNA assessment. The relative proportion of 
mitochondrial fibre types is also critical, particularly with reference to the proportion of 
Type IIx fibres which have very low mitochondrial content, though Type I fibres also 
have higher mitochondrial density than Type IIa fibres (Sjostrom et al., 1982; Yu-Wai-
Man et al., 2010b) . Thus care must be taken to ensure that muscle samples for 
comparison are comparable. However, it is important to note that for analysis of 
samples to evaluate exercise trail intervention, the relative proportion of fibre types can 
be significantly altered by training; for example, endurance training has been shown to 
significantly increase the proportion of Type IIa fibres at the expense of Type IIx fibres 
(Ingjer, 1979). With this in mind, fibre type changes between biopsies may be genuine 
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changes induced by the intervention rather than sampling errors attributable to 
heterogeneity of muscle tissue.   
Both of these issues must be considered when using normalisation of myDNA copy 
number by nuclear content with this assay. Prior to analysis, biopsies may need to be 
examined histochemically or otherwise to assess the relative proportions of fibre types 
and non-myogenic cells in order to be satisfied that the analysis is correctly determining 
any alterations in mitochondrial content of muscle cells. 
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 Disease associated with the mt.3243A->G mutation Chapter 4.
4.1. Introduction 
The m.3243A>G mutation was one of the first identified causes of inherited 
mitochondrial disease (Goto et al., 1990b). Of the over 250 known pathogenic mtDNA 
mutations (Tuppen et al., 2010), m.3243A>G is the most commonly inherited, at an 
estimated prevalence in the adult population of  236/100,000 (Manwaring et al., 2007), 
though the estimated minimum prevalence of clinically affected people is lower, at 
3.65/100,000 (Schaefer et al., 2008) or 16.5/100,000 (Majamaa et al., 1998). In the 
cohort of 671 patients seen at the Newcastle mitochondrial disease clinic, 199 (29.7%) 
carry the m.3243A>G mutation. 
The mutation is an A to G transition at position 3243 of the mitochondrial genome, in 
the dihydrouridine loop (D-loop) of the mitochondrial tRNA
Leu(UUR)
 (Goto et al., 
1990b). 
4.1.1. Phenotypic presentation 
The earliest patients to be associated with the m.3243A>G mutation were almost 
exclusively MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
episodes) (Goto et al., 1990b), though a single patient with the mutation presented with 
CPEO, an early indication of the heterogeneous phenotypic variability shortly to be 
associated with the mutation (Hirano et al., 1992). MELAS is a severe and progressive 
neurological disorder, and though it is not exclusively associated with the m.3243A>G 
mutation, around 80% of patients with MELAS syndrome are carriers of the 
m.3243A>G (Goto et al., 1991). Clinical diagnostic criteria were published in 1992 and 
defined as (a) stroke-like episodes before the age of forty (b) encephalopathy (denoted 
by seizures and/or dementia), and (c) lactic acidosis and/or ragged-red fibres (RRF) 
(Hirano et al., 1992). 
Other common phenotypic presentations that were soon to be associated with the 
mutation were maternally inherited diabetes and deafness (MIDD) (van den Ouweland 
et al., 1994), further CPEO cases (Goto et al., 1990a; Moraes et al., 1993; Koga et al., 
2000) and Leigh syndrome (Rahman et al., 1996; Koga et al., 2000). In common with 
other mtDNA mutations the clinical spectrum associated with the mutation is very 
broad. All of the constituent phenotypic features of both MELAS and MIDD are 
frequently seen in patients carrying the mutation, but there are a host of other common 
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features, both neurological and otherwise, including myopathy and exercise intolerance, 
cerebellar ataxia, visual impairment, migraine, cardiomyopathy, and gastro-intestinal 
disturbance (Ciafaloni et al., 1992; Majamaa-Voltti et al., 2006; Kaufmann et al., 2011; 
de Laat et al., 2012; Nesbitt et al., 2013). Distinct phenotypic characterisation is 
problematic; a recent study has reported that although MIDD is the most common 
classical phenotype observed in patients, less than half of patients present with a 
classical recognised phenotype (Nesbitt et al., 2013).  
Stroke-like episodes are a hallmark feature of the MELAS syndrome. Also known as 
sudden neurological deficits, these often present with hemiparesis, hemianopsia and/or 
cortical blindness (Iizuka and Sakai, 2005). Magnetic resonance imaging (MRI) of the 
brain after a stroke-like episode usually shows changes in both grey and white matter, 
mainly in the occipital and parietal lobes, which strongly resemble infarctions; however, 
the distribution is unrelated to vasculature and often shows a progressive spread (Ito et 
al., 2011). The pathophysiology is still controversial, with several competing theories as 
to the cause of the neurological dysfunction; proposals include mitochondrial 
dysfunction in the vasculature, known as the mitochondrial angiopathy theory; a 
generalised cytopathic mechanism caused by oxidative phosphorylation deficits in 
neurons and glial cells; and a non-ischemic neurovascular cellular mechanism, in which 
the stroke-like episodes are caused by neuronal hyper-excitability and an ATP deficit 
due to oxidative phosphorylation deficits(Iizuka and Sakai, 2005). Diffusion weighted 
imaging (DWI) has been used to examine brains of patients after stroke-like episodes 
and many early reports showed an elevated apparent diffusion coefficient (ADC), which 
contrasts with the reduction seen in ischaemic stroke, and which was consistent with 
vasogenic oedema and the mitochondrial angiopathy theory (Yoneda et al., 1999; 
Oppenheim et al., 2000; Yonemura et al., 2001; Kolb et al., 2003). However, more 
recently patients have been reported to demonstrate a reduced ADC more consistent 
with cytotoxic oedema and thus one of the other two other competing theories (Wang et 
al., 2003; Karkare et al., 2009; Tzoulis and Bindoff, 2009). Whatever the precise 
pathophysiology, the consequences for patients suffering stroke-like episodes are 
severe. 
Diabetes mellitus is a second prominent characteristic feature of m.3243A>G; while it 
has been found to be associated with a small number of other mtDNA mutations at 
higher penetrance than in m.3243A>G, on the whole mitochondrial diabetes is 
dominated by the m.3243A>G mutation (Whittaker et al., 2007). Diabetes can be 
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divided into two broad classes, type I insulin dependent and type II non-insulin 
dependent. Early studies observed a connection between type II diabetes and maternal 
transmission, which put mitochondrial DNA under the spotlight (Alcolado and 
Alcolado, 1991), and it had also been noted in maternal relatives of MELAS sufferers 
(Obermaier-Kusser et al., 1991). Indeed, in the diabetic population as a whole 
m.3243A>G is thought to account for 1%-3% of all cases (Gerbitz et al., 1995), and an 
even higher proportion of familial diabetes. 
Myopathy is a commonly reported phenotypic presentation (Karppa et al., 2005), in 
common with many mitochondrial disorders. Cardiomyopathy, long recognised in 
advanced cases of MELAS (Hirano and Pavlakis, 1994) is also recognised as prevalent 
(Bates et al., 2012a; Bates et al., 2012b), and the pathology has been shown to correlate 
with skeletal muscle heteroplasmy (Hollingsworth et al., 2012). 
Renal disease is also increasingly recognised as a phenotypic presentation of 
m.3243A>G (Damian et al., 1995; Cheong et al., 1999; Guillausseau et al., 2001; Hotta 
et al., 2001; Iwasaki et al., 2001; Suzuki et al., 2003; Piccoli et al., 2012; Seidowsky et 
al., 2013). Proximal tubular cells have a high mitochondrial content and are frequently 
reported as affected in mitochondrial disease patients with Fanconi syndrome like 
features (Rötig et al., 1997; Emma et al., 2011), though focal segmental glomerular 
sclerosis (FSGS) is reported as specifically related to m.3243A>G (Hotta et al., 2001; 
Emma et al., 2011). 
Regarding mortality, cardiac and neurological problems are reported as the most 
common cause of early death in m.3243A>G, and reports of sudden death are common 
(Majamaa-Voltti et al., 2002; Uusimaa et al., 2007; Vydt et al., 2007; Bates et al., 
2012a). 
4.1.2. Genotype-phenotype linkage 
Understanding the connection between phenotype and genotype is complicated by 
heteroplasmy, as for all mtDNA disease (Wallace, 1992). Section 4.4 will consider in 
detail the issue of heteroplasmy in the m.3243A>G mutation.  
Early studies on the m.3243A>G mutation suggested that patients with a high mutation 
load in muscle present at a young age with a MELAS-like phenotype, whilst those with 
lower mutation load present later in life with CPEO, myopathy, and deafness (Chinnery 
et al., 1997). Though this is superficially paradoxical, it was suggested that this may be 
due to focal accumulation of mutant DNA in myopathic patients as compared to more 
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uniform levels of the mutation in MELAS patients (Petruzzella et al., 1994), though this 
study was on a small number of patients from only two families. Other studies support 
this to an extent, showing that patients with myopathic phenotypes have a high 
prevalence of COX negative fibres in muscle but relatively low levels of the mutation 
compared to MELAS patients (Moraes et al., 1993; Hammans et al., 1995). However, it 
must be considered that in general genotype-phenotype correlation has long been 
considered very weak in patients with the m.3243A>G mutation (Kobayashi et al., 
1992; Martinuzzi et al., 1992; Shiraiwa et al., 1993; Liou et al., 1994; Morgan-Hughes 
et al., 1995; Chinnery et al., 1997).  
4.1.3. Pathogenesis 
Early in-vitro studies demonstrated that cells harbouring the m.3243A>G mutation (as 
well as those with the m.8344A>G mutation) impair oxidative phosphorylation at a 
cellular threshold of around 85% heteroplasmy (Chomyn et al., 1991; Kobayashi et al., 
1991; King et al., 1992a). Cells harbouring even higher levels of mutation, around 95%, 
have been shown to be more acutely impaired (Dunbar et al., 1996). 
Processing of the polycistronic transcript is not affected by the mutation (King et al., 
1992b; Koga et al., 1993; Kaufmann et al., 1996). However the proportion of 
tRNA
Leu(UUR) 
that is aminoacylated is reduced (Janssen et al., 1999; Chomyn et al., 
2000; Park et al., 2003), most likely on account of a dramatic 25 fold  reduction in the 
efficiency of the aminoacylation of the mutant tRNA as compared to wild-type (Park et 
al., 2003). Compounding this is the reduced steady state levels of the tRNA species that 
has been repeatedly reported (Chomyn et al., 1992; Janssen et al., 1999; Chomyn et al., 
2000; Park et al., 2003). Though the precise nature of the pathogenesis is still under 
debate, certain post translational modifications of the tRNA are impaired (Helm et al., 
1999; Yasukawa et al., 2000b), which results in impaired protein translation (Yasukawa 
et al., 2000a; Yasukawa et al., 2001).  
However, somewhat contradictory is the report that mitochondrial protein translation is 
not seriously affected by the mutation even at levels which severely impair cellular 
respiration, despite highly reduced aminoacylation of tRNA
Leu(UUR)  
in these cells; 
accelerated protein degradation instead was suggested as the pathogenic mechanism 
(Janssen et al., 1999). 
Complex I deficiency has been frequently reported in tissue analysis from patients with 
m.3243A>G (Goto et al., 1992; Morgan-Hughes et al., 1995) and also in cybrid cell 
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analysis (Dunbar et al., 1996). Of all the respiratory chain complexes, complex I 
contains the highest proportion of mitochondrial encoded leucine (UUR) residues, 
which may explain the selective vulnerability of this complex. It has recently been 
demonstrated in induced pluripotent cells (iPSCs) generated from m.3423A>G 
fibroblasts that the respiratory chain dysfunction caused by the m.3243A>G mutation is 
very much tissue dependent (Hämäläinen et al., 2013). For instance, a combined 
respiratory chain deficiency in the parent fibroblast cells became a specific complex I 
deficiency in differentiated neurons, which is consistent with the pathology commonly 
reported in m.3243A>G  (Moraes et al., 1992). Indeed, this study clearly demonstrated 
that Complex I is specifically degraded by sequestration into PTEN-induced putative 
kinase 1 (PINK1) and Parkin-positive autophagosomes, suggesting that the observed 
Complex I defect is potentially a cellular auto-protective response to mitochondrial 
dysfunction, perhaps to reduce potentially harmful ROS production. 
4.1.4. Sex differences 
The prospect of a difference between males and female in the burden of mtDNA disease 
(Frank and Hurst, 1996; Frank, 2012) has prompted the study of sex differences in the 
m.3243A>G mutation, which is covered in section 4.6. 
4.1.5. Therapeutic strategies 
There are few therapeutic treatments for patients with m.3243A>G. Studies on the 
efficacy of antioxidants and vitamins have failed to demonstrate clear benefit to patients 
(Marriage et al., 2003). Treatment with Coenzyme Q10 (ubiquinone) and idebenone 
(Ihara et al., 1989), an ATP production modulator and antioxidant, is routine and 
supported by research (Haefeli et al., 2011). However, these approaches are focused on 
amelioration of ROS induced cell damage and do not address the underlying problems 
with oxidative phosphorylation. 
There are several promising avenues of research into future therapeutics. tRNA import 
into mitochondria has been demonstrated to ameliorate respiratory defects in vitro 
(Karicheva et al., 2011). Similarly, overexpression of mitochondrial leucyl-tRNA 
synthetase (LARS2) has been shown to restore wild-type levels of respiration in cells 
harbouring the m.3243A>G mutation (Park et al., 2008). This study showed 
dramatically increased steady-state levels of tRNA leucine and mitochondrial 
translation products. Interestingly, protein synthesis levels did not exceed those of the 
mutant cells without the overexpression, supporting the hypothesis that protein 
stabilization is the critical effect. More recently it has been shown that the C-terminus of 
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the tRNA synthetase molecule is necessary and sufficient for this effect (Perli et al.), 
and that the effect extends to defects from mutations in non-cognate tRNA species 
(Hornig-Do et al.). However, translating successful in-vitro therapies to patients is a 
currently insurmountable obstacle. 
4.2. Methods 
4.2.1. Heteroplasmy quantitation 
Heteroplasmy levels are used in many of the analyses in this chapter. Heteroplasmy was 
quantitated using pyrosequencing (White et al., 2005), though older samples were 
quantitated using last-cycle hot PCR (Moraes et al., 1992). All quantitation was 
performed by the NHS Highly Specialised Service for Rare Mitochondrial Disorders in 
Newcastle upon Tyne. 
4.2.2. Statistical methodology 
The statistical methodology employed in each section will be detailed prior to the 
presentation of the results in each section. 
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4.3. Disease Progression 
4.3.1. Introduction 
Though many aspects of disease associated with the m.3243A>G mutation are 
considered progressive by clinicians, the nature and speed of this progression, and its 
relation to predictive factors such as age and heteroplasmy, are poorly understood. 
Understanding of likely progression of the disease burden in patients is critical for 
clinicians to be able to support and care for patients.  
Longitudinal studies are a necessity in understanding disease progression. However, 
systematic recording of disease progression in m.3243A>G mutation carriers is poor. 
Though there are two recent longitudinal studies of patients with the m.3243A>G 
mutation (Majamaa-Voltti et al., 2006; Kaufmann et al., 2011), the follow-up period for 
each study (three and four years respectively) was limited. Additionally, neither study 
considered predictive factors such as heteroplasmy and age. Several other recent studies 
have either examined in detail the clinical phenotype of patients (Nesbitt et al., 2013) or 
examined the correlation between disease burden and heteroplasmy (Whittaker et al., 
2009; de Laat et al., 2012; Liu et al., 2013) but without looking at progression or 
accounting for age. 
It has long been thought that clinical variability is at least in part due to heteroplasmy 
(Ciafaloni et al., 1991; Damian et al., 1995), though association between heteroplasmy 
and clinical presentation in patients harbouring the m.3243A>G mutation have proved 
to be weak (Kobayashi et al., 1992; Martinuzzi et al., 1992; Shiraiwa et al., 1993; Liou 
et al., 1994; Chinnery et al., 1997).  However, recent studies have found that urine 
heteroplasmy correlates better with the severity of clinical features than other sources 
such as hair follicles, buccal mucosa, blood, and even muscle (Ma et al., 2009; 
Whittaker et al., 2009; de Laat et al., 2012). Additionally, urine heteroplasmy is 
reported as stable over time (Blackwood et al., 2010), and is currently widely accepted 
as the most suitable non-invasive measure of heteroplasmy (Whittaker et al., 2009; de 
Laat et al., 2012). 
4.3.2. Aims 
Improved understanding of the disease progression is critical both for clinicians caring 
for patients and for patients themselves, particularly regarding clinical management and 
planning of health and social care. To this end, I aim to utilise the MRC Mitochondrial 
Disease Patient Cohort, which contains a large sub-cohort of patients with the 
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m.3243A>G mutation, to ascertain the progressiveness of disease associated with this 
mtDNA mutation, and to quantify the correlation between disease burden and predictive 
factors of age, urine heteroplasmy, and familial lineage.  
I will use longitudinal mixed modelling to understand the progression of overall disease 
burden (as measured by total NMDAS score), and multiple logistic regression to 
examine the relationship between specific phenotypic features (measured by individual 
NMDAS questions) and the predictive factors of age and heteroplasmy.  
As intra-familial clustering of symptoms has been reported (Hammans et al., 1995) I 
will also look at the significance of familial lineage on disease progression. 
All modelling in this section uses heteroplasmy measured in the urinary sediment. 
4.3.3. Cohort summary 
4.3.3.1. Age and heteroplasmy 
For modelling disease progression, all patients with both NMDAS data and urine 
heteroplasmy have been included. Of the 152 total patients with NMDAS data and urine 
heteroplasmy, 95 are female. One male patient was excluded due to renal transplant, and 
one further male and four female patients were excluded due to insufficiently complete 
NMDAS assessments (only those with at least 26 of 29 questions completed were used). 
Thus the final cohort consisted of 91 females and 55 males, 146 patients in total. 
The age and heteroplasmy profile of the cohort are shown in Figure 4.1, along with the 
number of assessments per patient. The median age of the cohort is 42 years, the 
youngest patient is 16 years old and the oldest 73 years old. The median heteroplasmy 
level is 57%, and the range extends from only just detectable (0.1%) to 99%. The 
median number of assessments is 3 per patient, with a maximum of 15. The clinical and 
molecular characteristics for the cohort can be found in Appendix III. 
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Figure 4.1 The distribution of urine heteroplasmy, age, and number of assessments in the cohort. 
The cohort comprises 148 patients. (A)  The distribution of urine heteroplasmy in our cohort. The median 
is 57%, with lower and upper quartiles of 38% and 76%. The distribution is skewed, with a long tail in 
the low heteroplasmy range. (B) The distribution of age in our cohort. The median age is 42, range 17-73. 
(C) Number of NMDAS assessments per patient. The median is 3 assessments, 90
th
 percentile is 10 
assessments. 
4.3.3.2. Phenotypic spectrum 
The phenotypic overview of the cohort is depicted in Figure 4.2. The most common 
features at any severity are deafness and exercise intolerance, followed by GI 
dysfunction, psychiatric disturbance and ataxia. For scores of 2 or above (panel B), 
deafness and GI dysfunction and are both prevalent at over 60%. Additionally, from the 
current function section of the NMDAS, exercise tolerance and gait stability stand out 
as prevalent at over 40%. From the symptoms (section II) psychiatric disturbance,  
migraine, and diabetes have a prevalence of at least 40%. Seizures affect around 22% of 
patients, stroke-like episodes 17% and encephalopathic episodes 18%. In section III of 
the NMDAS (clinical signs) myopathy and cerebellar ataxia most prevalent, with 
cognitive impairment also relatively common. Ptosis affects 20% of patients and CPEO 
16%. 
4.3.3.3. Common phenotypic features distribution with age 
Figure 4.3 illustrates the proportion of patients in each age group that have the given 
phenotypic features (defined as scoring 2 or above in the NMDAS). Deafness has 
increasing incidence with age, as does CPEO, which only substantially affects the oldest 
patients in the cohort. Ataxia affects a proportion of the youngest patients, and a steady 
proportion of those aged over 45. Stroke and seizure are rare but do not appear linked 
with age, though both are absent in the patients over 60. 
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Figure 4.2 Phenotypic characterisation of the cohort. 
(A-B). Profile of phenotypic symptoms from the cohort. For each patient, the maximum score in any 
NMDAS assessment for each NMDAS question is calculated. A is a stacked bar chart of the frequencies 
of each score (the proportion of the 146 patients that reach or exceed the given score); B summarises the 
frequencies for patients with moderate or severe symptoms (scoring 2 and above). The most common 
symptoms at moderate to severe level in our cohort are hearing loss and GI disturbance, followed by gait 
instability, exercise intolerance and psychiatric disturbance. Seizures and stroke affect 15%-20% of 
patients. (C) NMDAS score profile for four significant phenotypic characteristics of patients with the 
m.3243A>G mutation. Scores range in each case from no symptoms (0) to severe impairment (5). 
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Figure 4.3 Proportion of patients in each age group with particular phenotypic characteristics. 
For each feature, N indicates the total number of patients scoring 2 or above. Each bar shows the 
proportion of patients in that age group scoring 2 or above (the number of patients in each age group can 
be found in Figure 4.1B). The presentation of most phenotypic features is fairly constant across age 
groups, including stroke and seizures, which may have been expected to peak in frequency in younger 
patients; though stroke and seizure are notable absent in the 60+ age groups. Deafness is generally 
increasing in incidence with age; incidence of diabetes peaks around 55-60 and decline thereafter. CPEO 
is more common in older patients.  
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4.3.4. Total disease burden 
4.3.4.1. Introduction 
My examination of total disease burden is done in two parts. The first uses a single 
summary NMDAS score for each patient to get an understanding of how disease burden 
and predictors are related. I look at the relationship of urine heteroplasmy, age and 
disease burden.  
In the second part I use repeated measures mixed modelling to model disease 
progression over time. I used urine heteroplasmy and age as predictors in this model. As 
inter-family clustering of disease phenotype and severity has been noted (Hammans et 
al., 1995), I also introduce familial lineage as a predictor to evaluate the predictive 
effect. 
4.3.4.2. Methods 
The general methods for basic statistical analyses are described in section 2.11.1.1. 
Longitudinal modelling is conducted as described in section 2.11.1.2. Appendix IV 
contains the SAS code to generate the model. 
Each analysis uses the largest cohort of patients available with the appropriate 
predictors.  
4.3.4.2.1. Familial lineage 
To incorporate the family lineage into the longitudinal modelling, I divided the cohort 
into two groups; those with other family members in the cohort (familial) and those 
without other family members (non-familial). The repeated measures statement used 
this grouping to define the covariance structure of the data. To avoid over-
parameterisation, familial lineage was introduced as a random effect. 
4.3.4.2.2. Early-onset 
To investigate whether patients with early-onset had significantly different disease 
progression from other patients, a flag was introduced to identify these patients. Early-
onset was defined as any NMDAS assessment on record under the age of twenty-five 
that scored above a nominally low value of 3. 
Longitudinal mixed modelling used this as a grouping for defining the covariance 
structure of the data. Models incorporating both family and early-onset used both of 
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these groups to define the covariance structure, i.e. in four groups (early-familial, early-
non-familial, late-familial, late-non-familial). 
4.3.4.3. Results 
4.3.4.3.1. NMDAS score is predicted by age and heteroplasmy 
Multiple linear regression was used to investigate the relationship between total disease 
burden and the predictors of age and urine heteroplasmy. Box-Cox analysis identified 
the fourth root of the NMDAS (NMDAS
0.25
) as the optimal transformation, and this 
transformed variable was used as the dependent variable in all analyses. 
Table 4.1 lists the P-values for each effect and overall R
2
 for the model; standardized 
coefficients are also shown for analyses with multiple continuous predictors. Though 
heteroplasmy (P = 0.0063) and age (P = 0.0030) are both significant predictors of total 
disease burden, R
2
 is extremely low for each predictor (5.1% and 6.0% respectively). 
Using multiple linear regression with both predictors, adjusted R
2
 increases to 17.6%, 
and both predictors are highly significant (P < 0.0001). Diagnostic plots for the 
regression are shown in Figure 4.4. 
Model 
Predictors 
N Heteroplasmy Age R
2
 Adjusted 
R
2
 
Age 146 n/a 0.0030 6.0% 6.0% 
Heteroplasmy 146 P = 0.0063 n/a 5.1% 5.1% 
Age and 
Heteroplasmy 
146 P < 0.0001 
b = 0.37 
P < 0.0001 
b = 0.40 
18.6% 17.6% 
Table 4.1 Proportion of variability in total disease burden (as measured by NMDAS score) 
explained by predictive factors.  
P values are shown for each predictive factor, and standardised parameters where all predictors are 
continuous. Age and heteroplasmy together explain 17.6% of the variance in NMDAS score. 
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Figure 4.4 Model fit diagnostics for the multiple regression of age and hetereoplasmy on scaled 
NMDAS score. 
The residuals are normally distributed and there are no highly influential points. There are no observable 
trends between the residuals and either the predicted value of the model or the two predictors of age and 
heteroplasmy. There is evidence of heteroscedacity in the model; the extreme residuals are only found in 
the youngest part of the cohort. The White test (White, 1980) identifies this as non-significant (P = 
0.0554). 
4.3.4.3.2. Longitudinal model fit and development 
A preliminary longitudinal model using age and urine heteroplasmy as predictors was 
created and the fit of the model examined in detail. The residuals of the model were 
analysed in two ways; the distribution of the total set of studentised residuals (N=606), 
for a general understanding of model fit, and also the average studentised residuals for 
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each patient (N=146), to ensure independence of the data since there is intra-patient 
correlation of the residuals. 
Figure 4.5 (left panel) illustrates that the model is somewhat ill fitting; there is a cluster 
of data points with high residuals that do not adequately fit the model. Though the 
average studentised residuals are independent of heteroplasmy (P = 0.7176, r = 0.02) 
and age (P = 0.3427, r = -.0.08), they residuals did show a significant relationship with 
the predicted value of the model (P = 0.0012, r = -0.26) as seen in Figure 4.11. 
Scrutiny of the data indicated that the patients that were not well described by the model 
were young and with heavy disease burden. To better model these patients, a further 
predictor was added into the model to identify early-onset patients, defined as those 
under twenty five with non-trivial NMDAS scores. This flag dichotomises the cohort 
into two groups, early-onset (N = 28) and late-onset (N = 118). Figure 4.5 (right panel) 
illustrates the residuals of the model with this new parameter included; they are now 
well formed and normally distributed. Analysis of the average studentised residuals 
found they were now uncorrelated with the predicted value (P = 0.3636, r = -0.08), 
heteroplasmy ( P = 0.5565, r = 0.05) and age (P = 0.4469, r = 0.07). Additionally, the 
AIC for the model dropped from 18.5 to -57.2 indicating a significant improvement in 
the model fit. 
All three parameters (time, heteroplasmy, and early-onset) are highly significant (P < 
0.0001). 
Covariance parameters for the model are found in Table 4.2. The model includes 
separate residual variances for the early- and late-onset patients, i.e. residual variance is 
grouped according to this parameter. If the variance is not modelled separately, AIC of 
the model is -34.2, as compared to -57.2, indicating that allowing separate residual 
variances improves the model. 
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Figure 4.5 Residual diagnostics for models with and without early-onset indicator variable. 
(Left) Residuals for the model without early-onset predictor. The residuals are non-Gaussian, indicating 
an underlying non-random error in the model specification. The cluster of points in the top left of the 
diagram have high residual error and low predicted mean; these correspond to early-onset patients with 
severe disease burden. (Right) The same model with early-onset predictor. The residuals are now 
balanced and normally distributed. 
 
Figure 4.6 Average studentised residuals vs. predicted model value for a linear mixed model with 
age and urine heteroplasmy as predictors. 
The graph shows that the residuals are correlated with the predicted value (P = 0.0012, r = -0.26). This 
indicates the model is not a good representation of the underlying data structure. The cluster of points in 
the top left of the graph is particularly problematic, as they are very poorly fitted by the model. 
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Group Spatial Power Residual Variance 
Time  0.000083 
Late-onset 0.9783 0.02352 
Early-onset 0.9998 0.1915 
Table 4.2 Covariance parameters for the longitudinal mixed model. 
The residual variance of the early-onset group is far greater than that of the late-onset group; this is a 
reflection of the more erratic scores from patients in the early-onset group. 
4.3.4.3.3. Longitudinal modelling of disease progression  
Figure 4.7 illustrates the actual NMDAS scores for each patient in the cohort, grouped 
by the heteroplasmy quartiles, which demonstrates the variability in disease burden for 
patients with similar levels of heteroplasmy. 
Figure 4.8 illustrates the longitudinal modelling of total disease burden in patients with 
the m.3243A>G mutation. Both heteroplasmy and age are highly significant predictors 
(P < 0.0001). The graph shows predicted progression for a nominal patient with selected 
heteroplasmy levels, with 95% confidence intervals. 
Figure 4.9 depicts the actual and predicted progression of total disease burden for 
several patients with comparable heteroplasmy levels. The median (60%) and a high 
(90%) level of heteroplasmy have been utilised for illustration purposes. 
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Figure 4.7 Actual NMDAS scores for each patient in the cohort. 
Patients are grouped into 4 
quartiles by heteroplasmy. 
NMDAS scores for each patient 
are joined by solid lines, and 
labelled with urine heteroplasmy 
%. At low heteroplasmy (A, 
<35%), disease progression is 
slow and relatively homogenous. 
In the second quartile of patients 
(B) heterogeneity is seen to 
increase. The two upper quartiles 
(C & D) appear similar in the 
disease burden, though there is a 
shift to the left (earlier 
presentation) in the highest 
quartile (D). There is 
considerable overlap; patients 
with 2% and 7% heteroplasmy 
(A) have similar disease burden 
to patients with 87% and 92% 
heteroplasmy (D) at similar ages. 
Chapter 4 Disease associated with the mt.3243A->G mutation 
78 
 
Figure 4.8 Longitudinal modelling of total disease burden. 
Predicted progression 
depicted as dashed lines, 95% 
confidence intervals also 
shown except panel D. Both 
heteroplasmy and age are 
highly significant predictors 
in all cases (P < 0.0001). (A) 
Predicted progression of total 
disease burden for early-onset 
patients with 60% (blue) and 
90% heteroplasmy (red). (B) 
Predicted progression for late- 
onset patients, with 20% 
(green), 60% (blue) and 90% 
(red) heteroplasmy. (C) 
Comparison of predicted 
progression for early (red) 
and late (blue) onset patients 
at 60% heteroplasmy. (D) 
Predicted progression for 
patients with 10% to 90% 
heteroplasmy in 10% 
intervals.  
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Figure 4.9 Examples of individual patient predicted progression. 
Predicted and actual progression for a selection of patients with approximately 90% (A) and 60% (B) 
heteroplasmy. Actual assessment scores are depicted as crosses joined by solid lines. Dotted lines with 
shaded 95% confidence intervals denote predicted progression for each patient. These patients illustrate 
the huge variability of disease burden progression for patients with similar heteroplasmy levels of the 
m.3243A>G mutation. The only early-onset patients are patient A and B in panel A; the confidence 
intervals for their progression are much wider than the other patients, indicative of the higher variability 
for early-onset patients. 
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4.3.4.3.4. Familial lineage is predictive of disease progression 
With mixed modelling familial lineage can be introduced into the model as a random 
effect, allowing the effect of family to be represented with a single parameter that 
represents the variability of the family lineage. 
A number of models with family as a random effect were investigated. The models 
investigated all included early-onset as a fixed effect, and various forms of the residual 
covariance were investigated to find the optimal representation.  
Table 4.3 illustrates the evaluation of model fit. The fall in the AIC with the inclusion of 
family as a random effect indicates the model is improved; this is shown to be 
significant by the likelihood ratio test (P = 0.0343). 
Figure 4.10 shows an example the intra-familial clustering. The graph shows two 
familial lineages with sharply different total disease burden progression rates. The 
average progression rates for all families with multiple members in the cohort (N = 36) 
are show in Figure 4.11.  
  Repeated measures groups 
  Early-onset * familial Early-onset Familial 
Random 
effects 
Patient -80.5 -57.2 -52.8 
Family NC 78.9 72.5 
Patient & family -89.2 -65.6 -64 
Table 4.3 Investigation of optimal model with family as a random effect. 
AIC is shown for each model. NC indicates non-convergence of the model. The familial grouping for the 
repeated measures allows the variance of familial patients (those with other maternal relatives in the 
cohort) and non-familial (those with no maternal relatives in the cohort) to be modelled separately. The 
early-onset repeated measures group allows the variance of early-onset and late-onset patients to be 
separately estimated. An improvement in the AIC indicates that these extra parameters improve the 
model. The optimal model includes both patient and family as random effects, as this has the lowest AIC. 
The repeated measures grouping is the interaction of early-onset and family.  
. 
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Figure 4.10 Intra-familial clustering of total disease burden progression. 
The predicted progression for members of two different families are shown. Actual assessment scores for 
individual patients are shown as crosses joined by solid lines, patients are labelled with their 
heteroplasmy level. Predicted progression for individual patients are shown as dotted lines. The predicted 
progression for a nominal patient from each family with 60% heteroplasmy is shown as a heavy dashed 
line. The family depicted in red has slower disease progression than the family in blue.  
 
Figure 4.11 Predicted progression for a nominal patient with 60% heteroplasmy for each family in 
the cohort. 
Heteroplasmy (P < 0.0001), age (P < 0.0001), and family (P = 0.0003) are all highly significant 
predictors.  
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4.3.4.4. Total disease burden discussion 
The phenotypic variability associated with the m.3243A>G mutation has been 
frequently remarked upon (Hammans et al., 1995; Chinnery et al., 1997; Kaufmann et 
al., 2011; de Laat et al., 2012; Nesbitt et al., 2013) and is well recognised by clinicians, 
however little attempt has been made to quantify this variability. The NMDAS scale 
allows such quantification to be made. I have shown that age and the urine 
heteroplasmy level together account for only around 18% of the variance in total disease 
burden, which is noticeably low, but resonates with anecdotal evidence from clinicians 
on the variability of disease in patients with the m.3243A>G mutation, as well as 
previous studies that have noted the weak association between heteroplasmy and 
phenotype (Kobayashi et al., 1992; Martinuzzi et al., 1992; Shiraiwa et al., 1993; Liou 
et al., 1994; Chinnery et al., 1997).  It is a clear that there is a vast amount of variation 
in disease burden that is unexplained by the predictors currently available in this 
analysis. 
The detailed diagnostic examination of the model is cumbersome but gives reassurance 
about several key points. Firstly, there are no observable trends between the residuals 
and the predicted value, or the predictors. This is an important validation of the 
transformation used (NMDAS
0.25
) and reassurance that no further transformation of the 
predictors are required. Secondly, the spread of the data is even; there are no highly 
influential points at either high or low heteroplasmy or age. This gives confidence in the 
interpretation of the R
2
, as this can be strongly affected by influential data points. This 
reassurance about the shape and composition of the data set is important, not just for the 
basic modelling using single summary data points, but also for the longitudinal 
modelling.  
The heteroscedacity of the residuals in the basic modelling with respect to age needs to 
be noted, however it is not unexpected. Patients in their early twenties or younger have 
a hugely varied disease burden, including severe burden associated with MELAS 
associated stroke-like episodes, but also much milder presentation, and there are a 
number of more or less asymptomatic children who are known to have inherited 
m.3243A>G from affected mothers who contribute to this variation. It is important to 
note that these basic statistical analyses are conducted to gain an overview of the 
relationship between the predictors and total disease burden; longitudinal mixed 
modelling allows modelling any heteroscedacity inherent in the system, and indeed, the 
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covariance parameters from the longitudinal models indicate that this heteroscedacity is 
incorporated. 
The longitudinal modelling graphically illustrates two key points in this regard. Firstly, 
the unexplained variance is noticeably large; though both m.3243A>G heteroplasmy 
and age are highly significant predictors of total disease burden, the confidence intervals 
for progression of a nominal patient at a given heteroplasmy level are wide. Secondly, 
the predictive power of the family lineage is clearly illustrated, which concurs with 
previously reported observation (Hammans et al., 1995), and suggests that a reasonable 
proportion of this unexplained variance can be explained by a combination of genetic 
factors of either nuclear or mtDNA origin, though environmental or other epi-genetic 
modulatory factors cannot be disregarded. Indeed, the nuclear genetic background has 
previously been shown in vitro to impact on m.3243A>G phenotypic expression 
(Dunbar et al., 1995). 
At an individual patient level, the power of longitudinal mixed modelling is well 
demonstrated by the graphical outputs shown in Figure 4.9; the introduction of random 
effects into the model demonstrates that individual patient progression can be modelled 
in spite of the wide confidence intervals observed using heteroplasmy and age as fixed 
effects. This modelling is critical in understanding the expected disease progression of 
individual patients. 
The development of the longitudinal model demonstrates important points. Firstly, the 
model is ill-specified without accounting for a distinct group of early-onset patients. 
This division must be included in the model as a predictor (the early-onset flag); the 
residuals of the model clearly show that the model misrepresents the underlying data 
structure. There are some limitations in this approach. Firstly, the definition of early-
onset relies on an arbitrary cut-off, which I set at the age of twenty-five. This cut-off 
point was derived on preliminary observation of the dataset that indicated poor model fit 
for a large number of patients under this boundary. However, I investigated models with 
lower and higher cut-offs and twenty five was more or less optimal for this data set. 
Secondly, it is a potential limitation of the methodology that inclusion within the early-
onset group is contingent on having an NMDAS assessment under this age; it is feasible 
that there are patients within the cohort that were symptomatic before the age of twenty-
five but not seen in the Newcastle clinic until over this age. However, despite both of 
these caveats, the inclusion of this predictor in the model comprehensively resolved 
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issues regarding the fit of the model, which is indicative of the success of the 
methodology. It might be argued that dividing the cohort by age is superfluous, since 
age is already included in the model as a predictor. However, it is critical to note that 
both age and the early-onset predictor are simultaneously predictive in the model, and 
thus the predictor has been shown to be empirically valuable. 
An imperative to understanding m.3243A>G disease is to deepen understanding of the 
pathological mechanisms that cause variability in phenotypic expression, and early-
onset of symptoms is a fundamental facet of this variability. It is clear from this 
modelling that heteroplasmy alone is not an adequate descriptor of the underlying 
pathology. There are several potential areas for further exploration of this, which will be 
discussed in the discussion on general disease progression in m.3243A>G in section 
4.3.6. 
4.3.5. Individual phenotypic features 
4.3.5.1. Introduction 
An understanding of the expected development of specific phenotypic features is of 
vital import to clinicians in care and management of patients.  
As a semi-quantitative assessment scale, the NMDAS enables modelling of phenotypic 
features. As discussed in section 2.8, logistic regression is necessary to model discrete 
data such as individual NMDAS question scores. However, longitudinal modelling of 
discrete data is considerably less flexible as compared to continuous or pseudo-
continuous data such as the overall NMDAS score, and thus the approach I take is 
constrained by the tools available to analyse the data. 
There are prior studies that have considered the appearance of specific phenotypic 
features and the correlation with heteroplasmy (Chinnery et al., 1997; Liu et al., 2013). 
However, though both acknowledged age as a potential confounding factor, neither 
study incorporated age into their analysis. Since many features of mitochondrial disease 
are considered progressive this is a significant limitation. 
4.3.5.2. Aims 
My aim in this section is to use multiple logistic regression to study the relationship 
between individual phenotypic features and the predictive factors of age and urine 
heteroplasmy. I aim to distinguish which features are correlated with either one of these 
predictors or both.  
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I also will compare the multiple regression models with the simple logistic regression 
models with a single predictor of either age or heteroplasmy, to better understand the 
relationship between these predictors and each phenotypic feature. 
4.3.5.3. Methods 
The general methodology for logistic regression is explained in section 2.8.  
I used two approaches to logistic regression. Both used the predictors of age and urine 
heteroplasmy. For each NMDAS question, a single summary score was determined for 
each patient by taking the maximum score achieved on each question and the age at 
which that score was first recorded. 
The first approach used binary (dichotomous) logistic regression by identifying the 
optimal cut-off point for each NMDAS question to divide the cohort into two groups. 
To identify the optimal cut-off point the area under the ROC curve (AUC) was 
maximized. This was done separately for each individual predictor and for the model 
with both predictors, to allow a full understanding of the use of each predictor. Only 
cut-off points that partitioned the data into sets containing at least 10 patients in each 
group were considered to avoid small numbers of patients skewing the results. The code 
for this model can be found in Appendix V. 
The second approach used a proportional odds multiple logistic regression. NMDAS 
scores were re-categorised as asymptomatic (NMDAS = 0), moderate (1-3), and severe 
(4-5). This re-categorisation was necessary for a majority of phenotypic features for the 
model to conform to the proportional odds assumption. Pseudo-R
2
 values, as described 
in 2.8.2, were used to compare models. The code for this model can be found in 
Appendix VI. 
In both approaches, standardised parameters for the predictors were calculated. 
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4.3.5.4. Results 
4.3.5.4.1. Binary logistic regression 
Using a model with age and urine heteroplasmy as predictors, the area under the ROC 
(AUC) curve was calculated for each phenotypic feature at each dichotomous cut-off 
point that had at least 10 patients in each group (below the cut-off point, and above or 
including the cut-off point). The AUCs for each cut-off point are shown in Figure 4.12. 
The higher the AUC the better the predictive power of the model. Steep gradients or 
inflections in the graphs indicate instability in the predictability of the features, i.e. 
prediction success is heavily dependent on where the cut-off is drawn. Hearing and 
cerebellar ataxia are the only two features to achieve an AUC over 0.8, however 
diabetes scores very close to 0.8. Hearing and diabetes are consistently good predictors 
at almost any cut-off level, and several other features are consistent across the board, 
albeit with less predictive power, including cognitive impairment, migraine, and 
encephalopathic episodes. GI disturbance is poorly predicted at any cut-off point. 
Using the optimal cut-off for each NMDAS feature, models were generated using each 
predictor in isolation and both predictors together. The results are shown in Figure 4.14. 
As seen in panel C, the model with both predictors is the optimal model in almost all 
cases, other than GI disturbance, where the model with age alone was marginally better. 
Age is a better predictor than heteroplasmy for 17 of the 28 features. Migraine is the 
only features negatively associated with age, though not significantly so. 
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Figure 4.12 Area under the ROC curve (AUC) for each phenotypic feature and various score cut-off points with all three predictors in the model (age, heteroplasmy, and 
deletion size). 
The cut-off score is used to divide the cohort into two groups; those scoring the cut-off or above versus those scoring below. For each feature, the cut-offs tested were those with a 
minimum of 10 patients in each group. Only hearing and cerebellar ataxia achieve an AUC of 0.8 at any cut-off, though diabetes scores close to 0.8 at almost all cut-off points. GI 
disturbance is notably poor at all cut-offs. 
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Figure 4.13 Standardised parameters and area under ROC curves (AUC) for each phenotypic 
feature from the NMDAS using age and urine heteroplasmy as predictors. 
(A) Optimal cut-off point for each NMDAS feature, by maximizing AUC for the model with all three 
predictors. Cohort is dichotomised into those scoring the cut-off or above against those scoring below the 
cut-off. (B) Standardised parameters with 95% confidence intervals for the binary logistic model using 
the optimal cut-off with all three predictors. Parameters are statistically significant if the confidence 
interval does not cross the line at Y = 1. (C) The AUC using the optimal cut-off for each lone predictor 
and both predictors together. Hearing and ataxia score above 0.8, indicating strong predictive power. 
Diabetes achieves close to 0.8. In all cases, the regression with both predictors is optimal. Only migraine 
is (non-significantly) negatively associated with age. Twenty-five of 28 features are significantly 
associated with heteroplasmy, 20 of 28 with age. GI disturbance is very poorly predicted, but several 
other features have AUC values under 0.7, including cutting food, psychiatric disturbance, migraine, and 
seizures. 
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4.3.5.4.2. Phenotypic features predicted by age and heteroplasmy using 
multilevel ordered logistic regression 
For multilevel-ordered logistic regression the odds ratios are presented; odds ratios 
relate to decades, i.e. a 10% change in heteroplasmy or 10 years for age. For example, 
the odds of having unaffected hearing decreases by a factor of 0.63 for each 10% 
change in heteroplasmy or by a factor of 0.42 for each decade of ageing. Calculation of 
the actual risk requires intercepts .The odds ratios for both age and heteroplasmy for the 
features in the NMDAS assessment are shown in Figure 4.14 as well as standardised 
parameters which allow comparison of the relative utility of age and heteroplasmy as 
predictors. Additionally, Appendix VII details all parameters required for risk 
calculation, including intercepts, and Appendix VIII is an explanation of how to 
calculate the risk for a given age and heteroplasmy with these parameters. 
All features excepting gastro-intestinal disturbance, visual acuity, and ptosis were 
predictable by heteroplasmy. Several key features of classical m.3243A>G phenotypic 
presentation, including stroke-like episodes, seizures, and migraine, were not 
predictable by age.  
Logistic models using a single predictor (age or urine heteroplasmy) were also 
generated, and compared with the multiple regression model containing both predictors, 
using the pseudo-R
2
. To interpret the results of this comparison, an R
2
 inflation factor 
was calculated, defined as the multiple regression R
2
 divided by the sum of the 
individual R
2
 values for the two simple regression models. An R
2
 value over 1 indicates 
that the regression with the two predictors in the same model is more explanatory than 
the individual models. This is graphically illustrated in Figure 4.15, which shows both 
the R
2
 inflation factor and the individual pseudo-R
2
 values for each feature from the 
NMDAS. Almost all features are explained better by multiple regression. Most features 
from the current clinical assessment (section I) are substantially better predicted by both 
predictors together. There are no features that are significantly predicted by both age 
and heteroplasmy that have an inflation factor of 1 or below. The models for several 
features that are explained by only one of the predictors, for example migraine or 
seizures, are not improved by the inclusion of the second predictor. Figure 4.16 
illustrates the change in P-value of each predictor when moving from simple logistic 
regression to multiple regression with both age and heteroplasmy as predictors. Several 
features are only significantly predicted by both age and heteroplasmy when both are 
included in the model together; cardiovascular dysfunction, ataxia, diabetes, exercise 
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intolerance, and neuropathy are not predicted by heteroplasmy unless age is included in 
the model; and cognition, dysphonia, pyramidal features, and speech are not predicted 
by age unless heteroplasmy is also in the model. 
 
Figure 4.14 Risk of developing specific symptoms as predicted by age and heteroplasmy. 
Standardised parameters (top) and odds ratios with 95% confidence intervals (bottom). Intervals crossing 
the line with odds ratio of 1 or standardised coefficient of 0 are not statistically significant. See the text 
for model development methodology. Phenotypic features are divided into the three sections of the 
NMDAS assessment. Ataxia, hearing, diabetes, and myopathy are the most predictive by heteroplasmy. 
Most features are predicted by heteroplasmy, other than GI disturbance, visual acuity, and ptosis, though 
both of the latter two are only just beyond statistical significance. Several features are not well predicted 
by age, all in the symptoms section of the NMDAS other than extrapyramidal features, though these are 
very rare in the cohort. GI disturbance is the only feature neither predicted by age nor heteroplasmy. 
Comparison of the standardised coefficients shows that age is a stronger predictor than heteroplasmy for 
17 of the 28 features of the NMDAS. 
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Figure 4.15 Pseudo-R
2
 values for logistic regression with age, heteroplasmy, and both predictive 
factors, and R
2
 inflation factors. 
An R
2
 inflation factor greater than 1 indicates that both predictive factors together are more predictive 
than the predictive factors in isolation. Only migraine, seizures, and GI disturbance are not predicted 
better by multiple regression. Hearing, CPEO, and pyramidal features are most improved by multiple 
regression.  
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Figure 4.16 Improvement in statistical significance of predictors using multiple logistic regression 
rather than simple logistic regression. 
Graph illustrates how the P-value for each predictor is affected when moving from simple logistic 
regression (horizontal bar) to multiple regression (symbol). The solid horizontal line is drawn at P = 0.05, 
indicating statistical significance. Almost all features show improvement in significance with multiple 
regression, most notably hearing, ataxia, diabetes, and myopathy. Heteroplasmy is not a significant 
predictor of several features including ataxia, neuropathy, and diabetes, unless multiple regression is used.  
4.3.5.4.3. Risk profiles of deafness with age and heteroplasmy 
I have chosen hearing to illustrate the outputs of the logistic regression model. The 
changing risk of deafness associated with age and heteroplasmy is depicted in Figure 
4.17. Both age and heteroplasmy are highly significant predictors of deafness (P < 
0.0001). At a given age, the risk of moderate or severe deafness increases as 
heteroplasmy increases; and conversely, at a given heteroplasmy the risk of more severe 
deafness increases with age.  
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Figure 4.17 Risk of deafness and its relationship to age and heteroplasmy. 
Each panel indicates the changing risk profile for one of the predictors (age or heteroplasmy) whilst the 
other is fixed at a determined value. (A-C) Changing risk of deafness with age for patients with 20%, 
60%, or 80% heteroplasmy. (D-F) Impact of heteroplasmy on the risk of deafness for patients aged 20. At 
age 60, with 50% heteroplasmy, there is an approximately equal probability of moderate or severe 
deafness and a small probability of being asymptomatic.  
4.3.5.4.4. Risk profile of principal phenotypic features 
Risk profiles for a selection of other phenotypic features are shown in Figure 4.18. Each 
graph is shown with one predictive factor (heteroplasmy or age) fixed at an arbitrary 
value, for illustrative purposes. Both age and heteroplasmy are highly significant 
predictors for deafness (P < 0.0001). For stroke, heteroplasmy is predictive (P=0.0044) 
but age is not (P = 0.1078). Heteroplasmy is a significant predictor of cerebellar ataxia 
(P = 0.0003) and diabetes (P = 0.0026), and age is a highly significant predictor of both 
(P < 0.0001). 
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Figure 4.18 Risk profiles for four key phenotypic features of the m.3243A>G mutation.  
Predicted probability of being 
moderately affected (score 1-3), 
severely affected (4-5), or 
asymptomatic (0). (A) Risk of 
deafness with increasing age at 60% 
heteroplasmy. (B)  Risk of stroke 
with age at 90% heteroplasmy. The 
probabilities have wide confidence 
intervals and change little with age 
compared to features such as 
deafness, illustrating that risk of 
stroke is not well predicted by age 
(P = 0.1078). (C) Risk of diabetes at 
age 40 by heteroplasmy. The 
majority of patients are either 
asymptomatic or severely affected, 
illustrated by the uniformly low risk 
of moderate disease. Risk increases 
with increasing heteroplasmy (P < 
0.0001). (D) Risk of ataxia with by 
heteroplasmy (P < 0.0001). By the 
age of 60, patients are likely to be 
moderately or severely ataxic. 
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4.3.5.4.5. Interaction of Heteroplasmy and Age 
To examine whether there is an interaction between heteroplasmy and age in the model 
(i.e. the effect of heteroplasmy being different at different ages, or the effect of age 
being different depending on heteroplasmy) the interaction term was introduced into the 
model. The parameters estimates for the interaction term in the model are depicted in 
Figure 4.19. Out of twenty-eight features the interaction was only significant for 
diabetes (P = 0.0025) and cognitive impairment (P = 0.0357). The interaction for 
diabetes showed that the effect of either predictor is stronger at higher levels of the 
other predictor, i.e. a multiplicative effect. For cognition, the effect was reversed, i.e. 
heteroplasmy is a stronger predictor at a young age than at an older age. 
 
Figure 4.19 Age/heteroplasmy interaction in the logistic regression model. 
Parameter estimate and 95% confidence interval are shown for each NMDAS feature. A confidence 
interval crossing zero is not statistically significant. Only diabetes (P = 0.0025) and cognitive impairment 
(P = 0.0357) have the interaction as a significant term. The negative estimate for diabetes indicates that 
the effect of heteroplasmy is increased as age increases, and similarly the effect of age is more profound 
at higher heteroplasmy. The positive estimate for cognitive impairment indicates that the effect of 
heteroplasmy is lessened as age increases. 
4.3.5.5. Individual phenotypic features discussion 
It has previously been suggested that heteroplasmy is a critical determinant of disease 
phenotype and not age (Chinnery et al., 1997). However, comparing standardised 
coefficients of regression age is a better predictor for 17 out of the 28 measures reported 
by the NMDAS. This is an important characterisation of the disease progression in 
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m.3243A>G that has not been comprehensively considered in the literature of 
m.3243A>G disease to date. 
There are several interesting observations to be made from the modelling of specific 
phenotypic features. Firstly, certain critical features associated with m.3243A>G, 
including stroke-like episodes, seizures, and migraine, are not significantly associated 
with age, but are predicted by the urine heteroplasmy level. For the former two 
symptoms the lack of association with age is apparent from the graphs of symptoms by 
age group in Figure 4.3; both phenotypic features are present throughout the age range 
of patients. Migraine, on the other hand, is negatively associated with age, though non-
significantly; however, this concurs with reports in the literature of declining 
susceptibility to migraine with age (Dahlof et al., 2009). Secondly, deafness and ataxia 
are the most highly correlated with age and heteroplasmy, suggesting that these features 
are particularly degenerative in nature. Thirdly, though gastro-intestinal dysfunction is 
prevalent, the severity is predicted neither by age nor heteroplasmy. The reasons for this 
are unclear.  
Two previous studies have reported that some features of m.3243A>G disease are 
negatively correlated with heteroplasmy, namely myopathy, CPEO, and deafness in a 
study by our own group (Chinnery et al., 1997), and deafness and diabetes in another 
(Liu et al., 2013). In this study, I find to the contrary that these features are all directly 
correlated with heteroplasmy. However the prior studies did not incorporate age as a 
predictive factor, which was indeed acknowledged as a concern by both studies and I 
believe to be a critical omission, as demonstrated by the results from multilevel logistic 
regression models with only one predictor (age or urine heteroplasmy). For example, if I 
exclude age as a predictor in the modelling, heteroplasmy is not predictive of many 
common phenotypic features including diabetes, deafness, and cerebellar ataxia. The 
apparently paradoxical findings of these two previous studies clearly indicate the 
necessity of taking into account confounding factors such as age. 
The motivation for examining the interaction between heteroplasmy and age is that it 
might be expected that some features would show a different relationship with 
heteroplasmy for different age groups, or that the progressiveness of the features in time 
would be modulated by heteroplasmy. The results from this section showed that the 
interaction is only significant in two features, diabetes mellitus and cognitive 
impairment. However, the most useful finding of this analysis is that no highly 
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significant interactions were found, which may have undermined the findings of the 
model without interaction terms.  
Deafness is the most prominent symptom in this cohort; although only around 12% of 
patients suffer from complete deafness, 75% of patients have some form of hearing loss. 
It is also the symptom most predictable using heteroplasmy and age. It should be 
observed that prevalence does not go hand in hand with predictability; gastro-intestinal 
disturbance is almost as prevalent yet not predictable by either age or heteroplasmy. 
Deafness is so common in m.3243A>G patients that it has been suggested as a critical 
diagnostic criteria for identifying carriers of the mutation indeed, in a study of 1482 
patients with post-lingual hearing loss, over 1% of patients were found to carry the 
m.3243A>G mutation (Iwanicka-Pronicka et al., 2012). Another study found that the 
proportion was even higher (7.8%) in those with known sensorineural hearing loss 
(Majamaa et al., 1998). The progression of deafness in m.3243A>G patients has been 
characterised as abrupt and stepwise usually occurring with encephalopathic or stroke-
like episodes (Sue et al., 1998a; Chinnery et al., 2000a). However, the prevalence of 
deafness in this cohort far exceeds that of encephalopathic or stroke-like episodes, and 
thus most of the hearing loss, though it may be stepwise, cannot be so associated. The 
correlation between hearing loss and muscle heteroplasmy has previously been reported 
(Chinnery et al., 2000a), and this study has augmented that finding by incorporating age 
as a co-predictor. Deafness was amongst the symptoms with high R
2
 inflation factors 
and demonstrated a dramatic reduction in P-value with multiple regression, indicating 
that the population level inter-correlation of age and heteroplasmy masks the strong 
association of both of these predictors with symptom severity. 
Sixty-three percent of patients are ataxic to some degree, and 39% are at least 
moderately affected. The prevalence of ataxia in mitochondrial disease has been noted 
in the literature (Lax et al., 2012), and though it is generally acknowledged as a 
progressive symptom, this has not been fully characterised. The modelling documented 
here demonstrates that ataxia is both predictable by heteroplasmy and age. Indeed, the 
pseudo-R
2
 value indicates that it is the most clearly progressive symptom of all in this 
cohort.  
Though gastro-intestinal disturbance stands with deafness as one of the two most 
common phenotypic features seen in patients with m.3243A>G, it is the only feature not 
predicted by either age or heteroplasmy. The reasons for this are unclear. Whilst gastro-
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intestinal disturbance is common within the general population, the incidence in our 
patients is striking. Previous studies have demonstrated respiratory chain deficiency of 
the bowel smooth muscle which could explain the symptoms (Betts et al., 2008), and a 
recent study also found a previously unreported high incidence of coeliac disease in 
children with mtDNA mutations (Mazzaccara et al., 2012). However, it remains unclear 
why the dysfunction would not correlate better with age and heteroplasmy. It is clear 
from the phenotypic characterisation of the cohort seen in Figure 4.2 that NMDAS 
scores of 5 for GI disturbance are very rare indeed, and scores of 4 are also rare. Thus 
either high levels of GI disturbance are rare in the cohort, or this analysis has 
highlighted an issue with the NMDAS data collection which needs to be addressed; 
patients with severe disease who have been hospitalised may not be being accurately 
assessed for criteria such as GI disturbance due to difficulty in performing the NMDAS 
assessment fully (Dr Andy Schaefer, personal communication).  
The methodology employed in this section requires some discussion. To avoid the need 
to deal with repeated measures and the implicit correlation between repeated scores for 
individual patients, I have taken a single summary score for each patient as described in 
section 4.3.5.3. However, a necessary shortcoming of this approach is that the full 
potential of the dataset is not being exploited; nor is it longitudinal analysis. 
Longitudinal analysis using techniques analogous to repeated measures mixed 
modelling would support inferences about individual patients and their expected 
progression by the incorporation of random effects into the model; repeated measures 
multiple logistic regression with random effects would be a desirable approach to 
modelling this data in order to provide prognostic information for individual patients 
based on their phenotypic progression to date. However, current analytical tools for 
conducting such analysis are limited. Though SAS does support incorporation of 
random effects into logistic regression using PROC GLIMMIX, and modelling of the 
covariance structure in repeated measures from the same patient, this analysis is limited 
to dichotomous data. Thus progression from asymptomatic to moderate to severe 
disease cannot be conducted. An additional and more serious issue currently is that for 
most patients there is no noticeable progression in many of the clinical symptoms over 
the period of assessment. As more NMDAS data is collected this form of modelling will 
become more feasible. 
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4.3.6. Disease progression discussion  
This section has used a variety of approaches to examine disease progression in a large 
cohort of patients with m.3243A>G, both examining the progression in total disease 
burden, and the risk of developing specific phenotypic features according to age and 
heteroplasmy. 
Taken together, these analyses have shown that heteroplasmy has some utility as 
predictor of both overall disease burden and most individual phenotypic features, and 
that multiple regression with age is vitally important in order to fully recognise the 
prognostic potential. However, there is a strong imperative to research a more clinically 
relevant and easily measurable predictor of disease progression. 
The basic challenge facing understanding of disease associated with the m.3243A>G 
mutation is identifying further predictors that will transform unexplained variance in 
phenotype and disease progression into explained variance. Understanding the links 
between genetics (both nuclear and mitochondrial), epigenetic modifiers and the 
resulting clinical phenotype is critical future work.  
There are several interesting lines of enquiry in this regard. Firstly, a recent study has 
indicated that wild-type mtDNA copy number, rather than heteroplasmy, may be a more 
useful prognostic indicator than heteroplasmy (Liu et al., 2013). Investigation of 
mtDNA copy number is therefore a priority in furthering this modelling work. 
Secondly, it has been demonstrated in a homoplasmic point mutation in the 
mitochondrial tRNA isoleucine gene (MT-TI) that levels of the cognate tRNA 
synthetase modulate the penetrance of the mutation and the resulting clinical phenotype, 
in this case hypertrophic cardiomyopathy (Perli et al., 2012). To my knowledge, there 
has been no study of patients carrying the m.3243A>G mutation to identify if tRNA 
synthetase levels correlate with clinical phenotype. Indeed, the leucyl tRNA synthetase 
is particularly interesting as it has been shown to act as an amino acid sensor 
modulating the mTORC1 pathway that regulates protein translation, cell size, and 
autophagy (Han et al., 2012), and overexpression of the synthetase corrects the 
m.3243A>G phenotype in cybrid cells (Li and Guan, 2010). Thus there are several 
motivations for understanding how tRNA synthetases modulate disease burden and 
phenotypic expression in m.3243A>G patients. 
Thirdly, it has been reported that a critical difference between MELAS and other 
phenotypic presentations, such as CPEO, is that MELAS patients have a relatively 
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homogeneous distribution of mutant mtDNA in muscle fibres, whereas patients with a 
CPEO-like phenotype appear to have focal accumulation of mutant mtDNA in selected 
fibres (Moraes et al., 1993; Petruzzella et al., 1994). It is speculated that this distinction 
may also be apparent in clinically affected tissues of the CNS though this is yet to be 
reported on. However, it should be noted that in these studies patient age is a 
fundamental confound, since the accumulation of defective mtDNA in fibres is likely to 
be a time-dependent process, and both studies had a significantly younger MELAS 
cohort than the comparator cohort.  
The statistical modelling I have employed is novel in two regards; firstly, in 
comprehensive longitudinal modelling of total disease burden; and secondly, the 
predictive modelling of individual phenotypic features, using both age and 
heteroplasmy as predictors. Though previous studies have used heteroplasmy as a 
predictor of phenotype (Chinnery et al., 1997; de Laat et al., 2012; Liu et al., 2013) this 
approach is limited and risks confounding any findings by not accounting for age. 
Indeed, multiple regression using both factors simultaneously is critical, since at the 
population level urine heteroplasmy and age are negatively correlated, as previously 
reported (de Laat et al., 2012) and confirmed in this cohort. This significant Pearson’s 
correlation is the cause of the increased explanatory power of heteroplasmy and age 
together as compared to either factor as singular predictors. 
There are some limitations in this study which need to be acknowledged. Firstly, I have 
used urine heteroplasmy throughout; though it has been shown to correlate well with 
clinically affected tissues (Blackwood et al., 2010), a more invasive measure of 
heteroplasmy, for example skeletal muscle, may reduce the unexplained variance and 
improve the modelling. This will be discussed further in the next section on 
m.3243A>G heteroplasmy. 
Secondly, I have not considered in the model the baseline level of disease found in the 
normal ageing population, which would be necessary in order to ascertain the degree of 
disease progression attributable to the mtDNA mutation alone. However, from a clinical 
care perspective the overall disease burden for patients is the more relevant quantity. 
Thirdly, as previously discussed in the section on individual phenotypic features, 
longitudinal modelling of specific features has not been conducted, and it is anticipated 
this would be valuable information for clinicians and patients alike.  
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In conclusion, I have produced two model systems for understanding disease burden 
and progression in patients with the m.3243A>G mutation, both utilising age and 
heteroplasmy as predictive factors; a longitudinal model of overall disease burden 
progression, and models to predict the severity of specific phenotypic features. Both 
these models provide critical information to clinicians for the care and management of 
patients with the m.3243A>G mutation. 
  
Chapter 4 Disease associated with the mt.3243A->G mutation 
 102   
 
4.4. Heteroplasmy in m.3243A>G 
4.4.1. Introduction 
Heteroplasmy levels in m.3243A>G remain a rich area for research, and though much 
has been studied and reported there are still large gaps in knowledge.  
Since the earliest reports of blood heteroplasmy decline in the m.3243A>G mutation 
(Poulton and Morten, 1993; Hammans et al., 1995), the decline has been repeatedly 
studied. An earlier study of 18 patients reported an average linear decline of 0.69 
percentage points per year (t Hart et al., 1996); Rahman et al., in a study of six patients, 
compared blood from Guthrie cards taken at birth to blood taken at MELAS disease 
diagnosis and found a linear decline of an average 1.4 percentage points per year 
(Rahman et al., 2001); Pyle et al. reported a linear decrease of 0.6 percentage points per 
year in a longitudinal study of 11 patients (Pyle et al., 2007); Mehrazin et al. quantified 
the loss as 0.53 percentage points per year in MELAS patients and 0.22 percentage 
points per year in carrier relatives in a study of 34 patients (Mehrazin et al., 2009). 
Rajasimha et al., in a departure from the other studies, proposed that the decline in 
blood was exponential rather than linear, provided a coherent model based on 
progressive loss of haematopoietic stem cells which had accumulated high levels of 
mutant mtDNA by random genetic drift, and validated their model by comparison with 
experimental data (Rajasimha et al., 2008). They quantified the decline as an 
approximate compound 2% loss per year. However, it should be noted that some studies 
that have examined longitudinal changes in blood heteroplasmy did not find the change 
significant (Kaufmann et al., 2011), though this is generally attributed to small sample 
size or insufficient time between measures. 
Heteroplasmy changes in other tissues are less well understood. It was shown early on 
that intra-patient heteroplasmy levels in many post-mitotic tissues are similar, for 
instance skeletal muscle heteroplasmy is thought to be broadly representative of the 
level in the neurons within the CNS (Ciafaloni et al., 1991; Macmillan et al., 1993). 
Several studies have reported a negative correlation between heteroplasmy and age in 
diverse samples including urine, skeletal muscle, and buccal mucosa  (Frederiksen et 
al., 2006; Kaufmann et al., 2011; de Laat et al., 2012), though as none of the studies 
were longitudinal it was not possible to draw firm conclusions about decline with age.  
However, there are wide variations in heteroplasmy levels in different tissues. Shiraiwa 
et al., for instance, found the lowest mutation level in the spleen (Shiraiwa et al., 1993). 
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Interestingly, there are reported consistent differences in the average heteroplasmy 
levels between certain tissues. Chinnery et al. reported that the distribution of mutant 
mtDNA was non-random, and that the mutation load in tissues correlated with the cell 
turnover rate in each tissue; levels in muscle were highest, followed by hair follicles, 
buccal mucosa, and lowest in blood (Chinnery et al., 1999). This hierarchy is supported 
by data from several other research groups, many of whom also added heteroplasmy 
measured in urine, which is generally found at a level similar to that found in muscle 
(Shanske et al., 2004; Frederiksen et al., 2006; de Laat et al., 2012). De Laat, for 
instance, quantified that heteroplasmy levels in urine were 11 percentage points higher 
than in buccal mucosa and 23 percentage points higher than blood. 
Non-random segregation of mutant mtDNA was consistent with the finding that foetal 
heteroplasmy levels are strikingly homogeneous (Matthews et al., 1994), and strong 
evidence against the hypothesis that heterogeneous heteroplasmy levels in tissues were 
caused by random mitotic segregation in early embryogenesis (Huang et al., 1996). It 
was also reported that though heteroplasmy levels vary from tissue to tissue there are no 
differences observable between the average levels of tissues originating from the three 
germ layers (Frederiksen et al., 2006), further evidence against early embryonic random 
mitotic segregation, and evidence that variations in heteroplasmy are mainly due to 
selection pressures on either wild-type or mutant DNA during life.  
The significant loss of the mutation in blood contrasts with other rapidly dividing 
tissues which do not exhibit such decline, such as hair follicles (Sue et al., 1998b) and 
the urinary epithelium (Blackwood et al., 2010), though has been speculated as due to 
the low energy requirement of such cells, and it is suggested that in rapidly dividing 
tissues random genetic drift accounts for alterations in heteroplasmy unless a severe 
respiratory deficiency exerts pressure and results in active selection of wild-type 
mtDNA (Rahman et al., 2001). 
Interestingly, variation between hair follicles from the same individual has been shown 
to be very large (Shanske et al., 2004); this was attributed to the fact that individual hair 
follicles develop from one or a small number of stem cells in each follicle bulb 
(Ghazizadeh and Taichman, 2001) and thus random segregation will result in such 
mosaicism whilst maintaining a uniform average heteroplasmy level. 
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4.4.2. Aims 
In this section, I examine the Newcastle cohort data to probe the inter-relationships 
between the various measures of heteroplasmy available for this cohort (urine, blood, 
and skeletal muscle), and also age.  
I have two major aims. The first is to examine urine and muscle heteroplasmy for 
evidence of longitudinal change and to characterise any dynamic shift. The second is to 
examine the decline of blood heteroplasmy in the Newcastle cohort and to validate and 
characterise the proposed exponential decline model (Rajasimha et al., 2008). 
4.4.3. Methods 
4.4.3.1. Exponential decline of blood heteroplasmy (longitudinal) 
This analysis was restricted to those patients with multiple measurements of 
heteroplasmy more than two years apart. 
Exponential decline, defined by a rate parameter here called Rate, can be expressed as 
shown in Equation 4.1. 
                                                          
Equation 4.1 Exponential decline. 
 
For convenience I define the decline factor to be 100% - rate. Thus a decline factor of 
5% indicates a compound decline of 5% (the result of multiplication by 0.95) each year. 
A negative decline factor indicates an increase in heteroplasmy. 
The decline factor is hence calculated as shown in Equation 4.2; e.g. for a patient with a 
decline factor of 5%, if the starting heteroplasmy was 50%, after one year the 
heteroplasmy would decline to                 , after two years        
             , and so on for each year of decline.  
                          
                          
                          
Equation 4.2 Decline factor calculation. 
 
4.4.3.2. Exponential decline of blood heteroplasmy (using urine heteroplasmy) 
A second method I chose to investigate the decline of blood heteroplasmy was to use 
muscle, urine heteroplasmy, or another putatively static heteroplasmy measure as a 
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Urine 
Blood Muscle 
14 
4 
123 
0 
35 
14 
2 1 
  
nominative starting heteroplasmy level at birth. As I have only a limited number of 
muscle heteroplasmy levels recorded, I used urine heteroplasmy as the nominative level. 
Where multiple urine heteroplasmy records are available, I take the mean value.  
Similarly to section 4.4.3.1, I define an exponential decline factor, but this time, I use 
age plus 9 months as the time period, as I am assuming that the urine heteroplasmy level 
is indicative of blood heteroplasmy at conception and that any selective pressure is 
exerted from that point. 
4.4.4. Results 
4.4.4.1. Cohort 
There are 192 patients with m.3243A>G in the Newcastle cohort in total, excluding two 
patients who have had renal transplants and are excluded from heteroplasmy 
investigations for this reason. Figure 4.20 illustrates the number of patients available 
with the respective heteroplasmy levels. The full data can be found in Appendix III. 
Figure 4.20 Number of patients with 
heteroplasmy data available. 
Venn diagram illustrating the number of 
patients with urine, blood, and skeletal muscle 
heteroplasmy. Fourteen patients have no 
measure of heteroplasmy; 35 have all three 
measures. For each analysis. I use the maximum 
number of patients available with the required 
data. 
 
 
4.4.4.2. Relationship between heteroplasmy and age 
4.4.4.2.1. Urine  
The regression of urine heteroplasmy and age is shown in Figure 4.21A. Although there 
is a clear correlation, and the relationship is reasonably linear, the distribution is 
asymmetric. However, Box-Cox identifies the identity function (no transformation) as 
optimal. 
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Figure 4.21 Heteroplasmy and age. Linear regression with 95% confidence and prediction 
intervals. 
(A) Though there is a clear correlation between urine heteroplasmy and age, the relationship is not quite 
linear; the line is reasonably well fitting, but the residuals are asymmetric and do not follow a Gaussian 
distribution (P = 0.0004 Shapiro-Wilk). N = 175, R = -0.41, P < 0.0001. (B) Non-linear relationship 
between blood heteroplasmy and age. Box-Cox identifies the square root as the optimal transform. (C) 
Once transformed the relationship between blood and age is more clearly linear (R = -0.49, P < 0.0001). 
However the residuals are non-Gaussian and do not pass normality tests (P < 0.0001, Shapiro-Wilk). N = 
159 (D) The relationship between SKM heteroplasmy and age is not significant though there is a negative 
trend (P = 0.0664, R = -0.30, N=39). 
4.4.4.2.2. Blood 
The relationship of blood heteroplasmy and age is shown in Figure 4.21B. Age and 
blood are clearly correlated (P < 0.0001); Box-Cox identifies the square root transform 
as optimal, and the linear regression of this is shown in Figure 4.21C. Though this 
improves the fit, the residuals still remain non-normal.  
4.4.4.2.3. Muscle 
Figure 4.21D shows the regression of SKM heteroplasmy against age. Though there is a 
declining trend with age, it is not statistically significant in this cohort (N = 39, P = 
0.0664). 
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4.4.4.3. Urine and blood heteroplasmy levels are linearly related 
On inspection, the relationship between urine and blood heteroplasmy levels is clearly 
non-linear (data not shown). Box-Cox identifies the appropriate transformation of the 
blood heteroplasmy as the square root. Figure 4.22 illustrates the relationship between 
urine heteroplasmy and the square root of the blood heteroplasmy level. The two 
quantities are highly significantly correlated (P < 0.0001, R
2
 = 66.4%, N = 158). 
Residual diagnostics confirm that the errors in this relationship are clearly Gaussian in 
distribution, indicating that the relationship is well formed.  
 
Figure 4.22 Urine heteroplasmy is linearly correlated with the square root of blood heteroplasmy. 
The regression line and both 95% confidence and prediction intervals for the linear correlation are shown. 
The square root relationship is identified by Box-Cox as the appropriate transformation. Residuals are 
Gaussian in distribution, indicating that the relationship is well formed. N = 158, R
2
 = 66.1%, P < 0.0001. 
4.4.4.4. Age at biopsy improves the linear relationship between urine and blood 
heteroplasmy 
As blood heteroplasmy is thought to decline with age, I also examined the relationship 
between urine heteroplasmy, blood heteroplasmy, and age. This analysis also uses the 
square root transformation of blood heteroplasmy. 
Figure 4.23 illustrates the outcome of the multiple linear regression. Both urine 
heteroplasmy (B = 0.69, P < 0.0001) and age (B = -0.30, P < 0.0001) are highly 
significant predictors of blood heteroplasmy (R
2
 = 74.0%). The interaction of age and 
urine heteroplasmy is also highly significant (P < 0.0001) yielding standardised 
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parameters for urine heteroplasmy (B = 0.69, P < 0.0001), age (B = -0.33, P < 0.0001) 
and the interaction (B = -0.15, P < 0.0001) (R
2
 = 76.2%). 
 
Figure 4.23 Multiple regression with age at biopsy improves the correlation between urine and 
blood heteroplasmy. 
The linear regression lines for three age groups are depicted. Adjusted R
2
 increases to 76.2%, from 66.4% 
for the model without age (Figure 4.22). Both age and urine heteroplasmy are highly significant 
predictors (P < 0.0001). The gradient of the line relating urine and blood heteroplasmy is age dependent 
(P < 0.0001). N = 158. P-values are for age as a continuous predictor; graphs show age as a categorical 
variable for illustrative purposes only. 
4.4.4.5.  Urine and SKM heteroplasmy levels are linearly related 
Figure 4.24 illustrates the relationship between urine and muscle heteroplasmy. Where 
repeated measures of urine heteroplasmy are available the mean of the two values is 
used. The two measures are highly significantly linearly correlated (P = 0.0006, r = 
0.53). The regression line defines the relationship between the two measures of 
heteroplasmy shown in Equation 4.3. 
                                                          
Equation 4.3 Relationship between muscle and urine heteroplasmy. 
Age is not a significant factor in this relationship (P = 0.8535). The 95% confidence 
interval for the gradient in this equation is (0.24, 0.81). 
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Figure 4.24 Urine and muscle heteroplasmy levels are linearly correlated. 
Regression line with 95% confidence and prediction intervals are shown. r = 0.53, P = 0.0006, N = 39. 
The gradient (0.53) is significantly non-zero (95% CI 0.24, 0.81). The line y = x is also drawn on for 
comparison, as this would be the regression line describing equality of urine and muscle heteroplasmy 
values. 
4.4.4.6. Longitudinal urine heteroplasmy analysis 
For the patients with at least two sequential urine heteroplasmy measurements (N = 79) 
the percentage point change in heteroplasmy was calculated for the points furthest apart 
in time. As shown in Figure 4.25A, the changes in heteroplasmy were not significantly 
different from zero (P = 0.8487). The mean change is 0.26% (95% CI -2.4% - 2.9%). 
The sample standard deviation is quantified as 11.8%.  
The changes in heteroplasmy were also regressed against several other quantities to 
investigate any trends, as depicted in Figure 4.25B-D. Heteroplasmy change was not 
significantly correlated with age at sampling (P = 0.1791, r = 0.15), though there was a 
non-significant trend towards increasing heteroplasmy with age. Nor was it correlated 
with the years between measurements (P = 0.6126, r = -0.06). Only the initial 
heteroplasmy level showed a significant correlation with the change over time with a 
trend towards falling heteroplasmy at high initial levels (P = 0.0035, r = -0.33).  
The White test for heteroscedacity indicated that the variance in the heteroplasmy 
change was not correlated with years between measurement (P = 0.3652) or age (P = 
0.6569). 
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Multiple regression with age and initial heteroplasmy finds that the significance of age 
as a predictor of heteroplasmy changes from P = 0.01791 to 0.9830, whilst initial 
heteroplasmy remains significant (P = 0.01) (R
2
 = 0.11). 
The standard deviation (11.8%) of the urine heteroplasmy was analysed using 
bootstrapping to establish a confidence interval for the estimate. This generated a 95% 
confidence interval for the standard deviation of (9.62%, 14.01%). 
4.4.4.7. Longitudinal blood heteroplasmy decline is exponential 
The decline factor is calculated as explained in section 4.4.3.1. Twenty-seven patients in 
the cohort had serial blood heteroplasmy records at least two years apart. The results are 
shown in Figure 4.26. Panel A shows that the decline factor is independent of age; panel 
B shows that the factor is not independent of the initial heteroplasmy level. 
As the distribution of the decline factor is non-Gaussian I use non-parametric testing to 
assess whether the decline factor is significantly non-zero. The median decline factor is 
1.30% (95% CI 0.00% to 2.53%). The result is not significantly non-zero (P = 0.0773). 
4.4.4.8. Urine as a nominative initial blood heteroplasmy level provides a 
consistent blood heteroplasmy decline level 
The concept of using urine as a nominative initial starting heteroplasmy to investigate 
blood heteroplasmy decline is considered in Figure 4.27. There are weak and 
insignificant trends with both the decline period and initial heteroplasmy level. Mean 
decline is 2.99% per year. 
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Figure 4.25 Longitudinal changes in urine heteroplasmy over time. 
For each patient with sequential urine measurements (N = 79), the change in heteroplasmy was calculated 
and compared to various potential correlates. Regression graphs depict regression lines with 95% 
confidence and prediction intervals. (A) Change in heteroplasmy is not significantly different from zero 
(P = 0.8487). (B) Change in heteroplasmy over time is not correlated with time between measurements (P 
= 0.6126, r = - 0.06). (C) Change in heteroplasmy is correlated with the initial level of heteroplasmy (P = 
0.0035, r = -0.33) (D) Change in heteroplasmy over time in not significantly correlated with age (P = 
0.1791, r = 0.15).  
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Figure 4.26 Examining the exponential decline of blood heteroplasmy. 
The annual rate of exponential decline of blood heteroplasmy is computed for those patients with serial 
blood measurements more than two years apart (N=27). Linear regression with 95% confidence and 
prediction intervals. A positive factor indicates decline in heteroplasmy over time, a negative  factor 
indicates increasing heteroplasmy (A) The decline factor is independent of age (P = 0.8661, r = - 0.034). 
(B) The decline factor is directly correlated with the initial heteroplasmy level (P = 0.0460, r = 0.387).  
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Figure 4.27 Exponential decline of blood heteroplasmy using urine heteroplasmy as nominative initial level. 
The urine heteroplasmy level is taken as a nominative initial heteroplasmy level at birth, and is used to calculate an exponential decline factor for blood heteroplasmy (N = 155). 
Regression line with 95% confidence and prediction intervals is shown. (A) The relationship between the period of decline and the decline factor. There is a downward trend but it is 
not statistically significant (P = 0.0923, r = -0.14). (B) The relationship between the initial heteroplasmy level and decline factor. There is a non-significant downward trend (P = 
0.3848, r = -0.07), the mean decline is 2.99% per year. 
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4.4.5. Discussion 
4.4.5.1. Heteroplasmy and age 
Several studies have reported a negative correlation of heteroplasmy with age, using 
samples from a variety of sources including buccal mucosa, urine, and skeletal muscle 
(Frederiksen et al., 2006; Kaufmann et al., 2011; de Laat et al., 2012), and these 
observations are confirmed in my analysis of urine and skeletal muscle, though the 
correlation with skeletal muscle in the cohort is not significant. It needs to be considered 
that the sample size of the muscle heteroplasmy data is much lower than that of urine 
and blood. Though some researchers extended these observations to speculation about 
longitudinal changes in patients (de Laat et al., 2012), this has not been studied in a 
large cohort to date in any sample source other than blood. However, it should be noted 
from the outset that a negative correlation in heteroplasmy in all tissues with age is 
potentially explained by the fact that older patients in the cohort are likely to have 
presented with disease later in life and thus be expected to have lower heteroplasmy. 
Thus a negative correlation may be simply a result of sampling bias. 
4.4.5.2. Is urine heteroplasmy static or dynamic? 
The data in section 4.4.4.6 shows that there is no trend in urine heteroplasmy levels 
either upwards or downwards in general. Nor were there any significant trends with the 
age of the patients or the period of measurement. These findings in a large sample are 
strongly supportive of a conclusion that urine heteroplasmy levels do not systematically 
increase or decrease over time. Although this has previously been speculated to be the 
case based on a small cohort of 11 patients (Blackwood et al., 2010), this is the first 
comprehensive report of longitudinal change in heteroplasmy recorded from any source 
other than blood. 
There is, however, a significant correlation with the initial heteroplasmy level; those 
with high heteroplasmy levels are more likely to show a decrease over time, and those 
with low heteroplasmy levels are more likely to show an increase. The association, 
though significant (P = 0.0035), is weak (r = 0.33), and drawing conclusions from this 
association is difficult, as such trend could easily be accounted for by floor and ceiling 
effects when interpreting changes in extreme (low or high) heteroplasmy levels. 
Multiple serial measurements in a large cohort would be needed to better understand if 
there are true longitudinal changes.  
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This observation should be considered in tandem with the relationship observed 
between urine and muscle heteroplasmy levels. It is interesting to note that the linear 
regression implies that for low heteroplasmy levels muscle heteroplasmy exceeds urine, 
but at high levels, muscle is lower than urine. This is a curious observation; though 
urine heteroplasmy levels are not systematically moving either up or down observing 
the cohort as a whole, there is systematic divergence of urine and muscle heteroplasmy 
levels at low and high heteroplasmy levels. These two observations are superficially in 
direct conflict; for example, a urine heteroplasmy level of 80% would tend to show 
decrease over time, but relative to muscle heteroplasmy it appears to be inflated. How 
can these observations be reconciled? 
One explanation is that one or both of these observations is a statistical anomaly, 
perhaps derived from ascribing a linear relationship where there is non-linear 
relationship, which in this case is likely on account of the finite limits (0% to 100%) of 
heteroplasmy measurements. This can only be correctly ascertained by collecting 
further data, as the sample size is not large enough to draw firm conclusions. However, 
it should be considered that divergence of heteroplasmy levels between tissues suggests 
that at some point during development or later life heteroplasmy levels have 
dynamically shifted, though it is unclear here whether the shift has occurred in muscle, 
the cells found in the urinary sediment, or both. Heteroplasmy levels in muscle, as post-
mitotic tissue, are expected to be relatively static, and thus the cells that are found in 
urinary sediment are put into the spotlight. Indeed, in section 4.6, I show that urine 
heteroplasmy in males is significantly higher than females despite similar blood 
heteroplasmy levels, which is further evidence of a potential dynamic shift in 
heteroplasmy in the tissues from which cells in urinary sediment originate.  
A major question is the origin of mtDNA in urinary sediment. Though the cells are 
generally expected to be urothelial cells from the bladder lining and urinary tract 
(Blackwood et al., 2010), this has not been specifically investigated in mitochondrial 
disease and m.3243A>G in particular. Renal dysfunction is common in patients with 
m.3243A>G (Cheong et al., 1999; Guillausseau et al., 2001; Hotta et al., 2001; Iwasaki 
et al., 2001; Suzuki et al., 2003; Piccoli et al., 2012; Seidowsky et al., 2013) and renal 
dysfunction may lead to the presence of renal cells in urine (Simerville et al., 2005). 
Thus it may be that the elevated levels of heteroplasmy in urinary sediment in 
comparison to other measures of heteroplasmy may be indicative of renal dysfunction 
and denote a genuine accumulation of the mutation in such tissue. It may therefore be 
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useful to investigate the relationship between measures of kidney function, such as the 
urine/creatinine ratio, with heteroplasmy or disease burden in this cohort. 
In conclusion, this section does satisfy the question of whether urine heteroplasmy 
levels in general move upwards or downwards; they appear to remain static. The 
question of whether individual patients can or do show systematically changing 
heteroplasmy over time cannot be answered by this dataset however; for this we require 
patients with three or more longitudinal measurements of heteroplasmy.  
4.4.5.3. Variability in urine heteroplasmy measurement 
I have quantified the variation in urine heteroplasmy measurement in this cohort as 
11.8% (the standard deviation of the sequential measurements) and used bootstrapping 
to estimate the confidence interval for this estimate (9.62%, 14.01%). The White test for 
heteroscedacity illustrates that this variance is not dependent on the time between 
measurements. This supports the conclusion that this variation originates either in 
random fluctuations within the biological systems that contribute to the cells found in 
urinary sediment or the heteroplasmy measurement assay itself; however, the same 
assay is used for measuring heteroplasmy from other sources without such extreme 
variation and thus the heteroplasmy of the cells in urine themselves are the most likely 
source.  
Though previous studies have commented on the variation in urine heteroplasmy 
(Blackwood et al., 2010), to my knowledge, this is the first formal quantification of the 
variation. The standard deviation of urine heteroplasmy is troublingly large. Urine 
heteroplasmy has been recommended as the best correlate for disease burden (Whittaker 
et al., 2009), but a confidence interval of ±23% (calculated from the mean standard 
deviation of 11.8%) seriously impacts on the ability of clinicians to understand the 
expected level of heteroplasmy in other tissues when using urine heteroplasmy as a 
guide. The source of this variation is currently unknown. A prior study investigated 
urine heteroplasmy levels, and found that the time of day that urine was collected was 
not a significant factor in the variation (Blackwood et al., 2010). Interestingly, they 
found that even measuring heteroplasmy on the same day sometimes recorded 
differences of up to 20% from the median measurement, which is consistent with the 
standard deviation reported here.  
If urine levels are to be used, it would appear that a single value alone is not sufficient. 
Multiple repeated testing will reduce the variation, for instance 4 samples will halve the 
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standard error. Such an approach is laborious however; though it may be preferable to 
an invasive technique such as a muscle biopsy.  
4.4.5.4. Blood heteroplasmy decline 
The results in section 4.4.4.6 expand current understanding of blood heteroplasmy 
decline whilst raising new questions.  
The exponential decline rate is shown to be independent of age in this cohort. This is 
supportive of the hypothesis that the blood decline is indeed exponential. Additionally, 
though the exponential rate is not statistically significantly non-zero in this cohort, this 
may be due to insufficient power, as I had a limited number of serial measurements in 
blood, and the data is suggestive of blood heteroplasmy decline over time, with a 
median decline factor of 1.3%.  
The significant relationship between the decline factor and the initial heteroplasmy level 
is of concern, as it would indicate that the rate of decline is dependent on the 
heteroplasmy level (note that since we have calculated an exponential decline factor, the 
relationship we are looking at is multiplicative, and should be independent of the actual 
heteroplasmy levels). Scrutiny of Figure 4.26B reveals that this trend is perhaps due to 
the existence of patients with apparently increasing heteroplasmy in the low (0-20%) 
heteroplasmy range. A potential contributor to this is that small errors in measurement 
at low heteroplasmy levels translate into large errors in the multiplicative factor; a 
change from 4% to 5% heteroplasmy in a year translates as a decline factor of -25%, but 
a change from 30 to 31% is a mere -3.3%. To minimise such errors, N must be 
increased or heteroplasmy measured over as long a time period as possible, so that the 
effect of measurement error and random fluctuations are diluted. However, even if we 
restrict the data to measurements taken 5 or more years apart, this relationship still 
exists, albeit not statistically significant (P = 0.1233), though the sample is much 
reduced (N = 14). The cluster of points that show negative decline (and thus increasing 
heteroplasmy) suggest that at heteroplasmy levels below around 20%, decline is no 
longer occurring in general. Furthermore, several patients above this level also show no 
decline over prolonged periods; for instance, a patient with 48% blood heteroplasmy 
demonstrated no decline over a period of 7 years, and several others have similar 
periods of static and relatively high blood heteroplasmy (the full dataset can be found in 
Appendix III). This suggests that some patients may have an asymptotic level of blood 
heteroplasmy far above zero. To my knowledge, there is no discussion in the literature 
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of the asymptotic level to which heteroplasmy is declining, nor a consideration of the 
intra-patient variability in this decline. Indeed, all the discussion appears to implicitly or 
explicitly assume that heteroplasmy levels decline to zero or negligible levels, most 
apparent in the published exponential decline model (Rajasimha et al., 2008). This 
belief is strongly reinforced by the fact that older patients tend to have very low levels 
of heteroplasmy. However, interpreting these very low levels at older age in this way 
misses the point that patients presenting at older age generally have milder disease 
phenotype and are thus likely to have had lower heteroplasmy levels initially. The only 
way to correctly analyse intra-patient variation in heteroplasmy decline is a thorough 
longitudinal analysis, but further investigation of this will require a larger cohort of 
patients studied for a longer period. However, we can conclude that non-zero 
asymptotic levels of blood heteroplasmy is a possible explanation of the shape of the 
data seen here, and this is a potentially significant observation. It will be considered 
further later in this discussion, and in the discussion of disease progression in 
m.3243A>G in section 4.5.5. 
A second approach to studying blood heteroplasmy decline is seen in section 4.4.4.8, 
which uses urine heteroplasmy as a nominative initial level at conception. This 
approach is justifiable on account of the stability over time of urine heteroplasmy, and 
the close correlation of urine heteroplasmy and levels in other tissues, both of which 
have been previously discussed. In section 4.4.4.8, I have demonstrated that there is a 
noticeable, albeit non-significant, relationship between the decline rate and the period of 
decline. It is also important to note that the mean decline factor of around 3% is 
considerably higher than that calculated using the repeated blood heteroplasmy data. 
There are several potential explanations of this.  
The first is that urine heteroplasmy could systematically overestimating the embryonic 
haematopoietic heteroplasmy level and thereby inflate the decline factor estimate. 
However, the relationship with skeletal muscle heteroplasmy suggests this is not the 
case, though it may be overstated at high heteroplasmy levels. 
Secondly, though the mechanism of haematopoietic heteroplasmy decline is not fully 
understood, it has been proposed to occur due to loss of stem cells through a mitosis-
dependent mechanism (Rajasimha et al., 2008). With this in mind, comparative stem 
cell cycling rates in embryogenesis and later life may be critically important. It has been 
shown in mice that during embryogenesis almost the entire population of 
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haematopoietic stem cells (HSCs) cycle every twenty four hours, from around 
embryonic day 7 (E7) until around 3 weeks post natal; after this point 95% become 
dormant and cycle every 145 days, whilst the remaining 5% cycle every 36 days 
(Pietras et al., 2011). If the cell cycling rates are similarly rapid during human 
embryonic development it would be expected that blood heteroplasmy decline would be 
greatly accelerated during this period. This would be expected to significantly inflate 
the decline factor.  
However, it must also be considered that embryonic stem cells are not heavily reliant on 
oxidative phosphorylation for their energy requirements and are more reliant on 
glycolysis in the hypoxic embryonic environment (Shyh-Chang et al., 2013); thus 
oxidative phosphorylation defects are not expected to express a strong phenotype in 
stem cells. However, it is also true that adult stem cells are also glycolytic in general, 
and in particular HSCs (Suda et al., 2011) (Simsek et al., 2010), speculated as a 
necessity in the hypoxic environment of the bone marrow niche. Thus any argument 
against a stem cell driven mechanism applies equally to adult and embryonic HSCs. 
Importantly, however, any long term changes in heteroplasmy in the haematopoietic 
system are almost certain to originate in the HSCs. Though the problem of lack of an 
oxidative phosphorylation driver for selection has been long problematic, recently it has 
been  shown that mitochondrial transcription is heavily regulated in HSCs, despite 
exhibiting relative low mitochondrial membrane potential and thus low oxidative 
phosphorylation activity (Norddahl et al., 2011). It has also been shown that even early 
embryonic changes in HSCs are observable in mutagenic mtDNA mice, which are 
hypothesised to be caused by subtle ROS or redox environment changes (Ahlqvist et al., 
2012). Thus even in the absence of active oxidative phosphorylation, mtDNA 
dysfunction has been shown to affect HSC activity and differentiation. Rajasimha et al. 
proposed a mechanism whereby stem cells with high levels of mutation are 
progressively lost (Rajasimha et al., 2008); a feasible hypothesis is that oxidative 
phosphorylation defects may alter the differentiation products of stem cells, as 
suggested by the aforementioned studies (Norddahl et al., 2011; Ahlqvist et al., 2012). 
Stem cells can divide in three fundamental ways; symmetrically into two further stem 
cells, symmetrically into two progenitors, or asymmetrically into one of each kind. A 
subtle shift towards either of the latter two mechanisms would result in a declining 
heteroplasmy level in the stem cell population. Alternatively, the shift in heteroplasmy 
may result from the ROS-induced senescence of HSCs with high levels of mutant 
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mtDNA (Shao et al., 2011). Whatever the mechanism, a study on the relationship 
between blood heteroplasmy at birth (measured from Guthrie cards) and sources of 
relatively stable heteroplasmy measured in adults (such as urine or muscle) may give 
useful insight into embryonic blood heteroplasmy decline. 
4.4.5.5. Relationship between urine and blood heteroplasmy 
The linear relationship between urine heteroplasmy and the square root of blood 
heteroplasmy has not been previously reported and is intriguing. Firstly, it is further 
evidence against blood heteroplasmy decline to a nominally low level and in support of 
an asymptotic level of blood heteroplasmy related to the initial level of heteroplasmy in 
the embryo. This does need to be verified, by long-term longitudinal observation of 
blood heteroplasmy in m.3243A>G patients. However, this study does suggest that in 
the majority of older patients blood heteroplasmy levels have neared a plateau level. 
This offers an insight into the mechanism of blood heteroplasmy decline, and 
contradicts the mechanism suggested by Rajasimha et al. that assumed an asymptotic 
level of zero irrespective of the starting point (Rajasimha et al., 2008).  The significance 
of age in this relationship suggests that heteroplasmy does continue to decline 
throughout life, though as said the asymptotic level is related to the initial heteroplasmy 
level.  
4.4.5.6. Conclusion 
The variability in urine heteroplasmy has been quantified (s.d. 11.9%), which 
demonstrates that a single measurement of urine heteroplasmy is imprecise and 
undermines confidence in this measurement for prognostic purposes. It has also been 
confirmed that urine heteroplasmy does not appear to change systematically over time 
in patients at a population level. 
Blood heteroplasmy has been shown to decline as previously reported, however 
evidence against the previously proposed model of exponential decline to a negligible 
level has been presented; the asymptotic level of blood heteroplasmy appears to be 
linearly related to levels in other tissues, as demonstrated by the relationship to urine 
heteroplasmy.  
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4.5. Comparative value of blood, urine, and SKM heteroplasmy in prediction of 
disease progression 
4.5.1. Introduction 
Though skeletal muscle was long been considered the gold standard for measuring 
heteroplasmy levels, urine, as discussed, is generally accepted as the most suitable non-
invasive measure of heteroplasmy, and indeed has been shown to be more correlated to 
disease phenotype (Whittaker et al., 2009; de Laat et al., 2012).  
Blood heteroplasmy has repeatedly been shown to be unrelated to disease phenotype 
(Mehrazin et al., 2009), in contrast to studies that report the utility of skeletal muscle 
(Macmillan et al., 1993; Chinnery et al., 1997; Jeppesen et al., 2006). When blood 
heteroplasmy has been found useful, it is not in comparison with other measures of 
heteroplasmy (Laloi-Michelin et al., 2009). However, though blood heteroplasmy has 
historically been disregarded as suitable for analysis of disease phenotype, the results 
from section 4.4 suggest that it may in fact be of utility, since, when suitably 
transformed, blood heteroplasmy is highly linearly correlated with urine heteroplasmy 
and thus should be expected to exhibit reasonably similar predictive properties, and 
indeed improved, if the variability in blood heteroplasmy measurement is lower.  
4.5.2. Aims 
I aim in this section to compare the comparative value of the three measures of 
heteroplasmy that are available in the cohort (blood, urine, and skeletal muscle) to 
assess which is the best predictor for disease burden and progression, particularly in the 
light of observations made in the previous section regarding the variability of urine 
heteroplasmy. Though I also consider muscle heteroplasmy, this is more limited in 
scope for drawing conclusions as the number of patients with samples available is 
considerably smaller. 
4.5.3. Methods 
I look at a variety of the analyses from the previous section on disease progression and 
compare the merit of blood and urine heteroplasmy as predictive factors. 
For the section comparing blood and urine, I use only the cohort of patients that have 
both urine and blood heteroplasmy measured, hence N values are smaller than for 
previous sections. For other comparisons, e.g. with muscle heteroplasmy, I use the 
largest cohort available with all appropriate measures of heteroplasmy. 
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To facilitate the ability to draw firm conclusions regarding superiority of one predictor 
over another I implemented a bootstrapping (resampling) methodology, as described in 
section 2.10. This extends the modelling technique and allows me to calculate a 
confidence interval for the comparative success of predictors, rather than a simple point 
estimate using the entire cohort. 
4.5.3.1. Bootstrapping 
For each comparison, bootstrapping was used to resample the dataset. Bootstrapping for 
the basic statistical comparisons using a single estimate is a straightforward resampling 
of the data. For longitudinal modelling, bootstrapping was done at the patient level, not 
the individual observations, i.e. patients were chosen with replacement from the pool of 
patients, and all observations for each patient were included in the analysis each time. 
This was to ensure that the resampling was concerned with statistically independent 
units. The longitudinal modelling utilised for comparison did not contain random 
effects, as the intention was to evaluate the effectiveness of the fixed effects. 
Each bootstrapping used 1000 resamples to evaluate the distribution of the statistic 
under investigation and 95% confidence intervals were calculated.  
A variety of statistical measures were suitable for bootstrapping. For multiple regression 
I used the difference in R
2
 as the statistic for comparison. For longitudinal modelling the 
difference in log likelihood is utilised. The methodology is in accordance with 
published guidelines (Lewis et al., 2011). 
For each bootstrapping the distribution of the chosen statistic was examined to ensure 
the distribution was reasonable and the statistical approach appropriate. 
4.5.4. Results 
4.5.4.1. Cohort 
134 patients with NMDAS data have both urine and blood heteroplasmy recorded. 34 
patients have both urine and SKM heteroplasmy data, 31 have both blood and SKM 
heteroplasmy. 
4.5.4.2. Blood heteroplasmy is a better predictor of NMDAS score than urine 
using multiple regression 
I use multiple logistic regression with age and heteroplasmy as independent variables, 
and the summary NMDAS score as the dependent variable. Parameters and data from 
Chapter 4 Disease associated with the mt.3243A->G mutation 
 123   
 
the model are found in Table 4.4. Blood heteroplasmy increases R
2
 to 27.8% from 
19.7% with urine heteroplasmy.  
Bootstrapping was used to compare blood and urine heteroplasmy as predictors. Figure 
4.28A depicts the distribution of the percentage point ratio increase observed when 
using blood rather than urine heteroplasmy. The mean increase in R
2
 is 7.7%, and the 
change is significantly above zero (P = 0.042). 
Model N Age Heteroplasmy R
2
 
urine 134 P < 0.0001 
B = 0.416 
P < 0.0001 
B = 0.401 
19.7% 
blood 134 P < 0.0001 
B = 0.608 
P < 0.0001 
B = 0.585 
27.8% 
     
urine 134 n/a P = 0.0070 5.3% 
blood 134 n/a P = 0.0125 4.6% 
Table 4.4 Comparison of the correlation between NMDAS score and blood or urine heteroplasmy.  
Using the same cohort of patients, multiple regression with age and either urine and blood heteroplasmy 
is used to compare model fit. P values and standardised coefficients for each predictor are shown, with the 
R2 for the overall model. Blood heteroplasmy increases R2 to 27.8% from 19.7%, and standardised 
coefficients for age and heteroplasmy both improve. Simple linear regression without age was also 
conducted with each predictor; urine is shown to be marginally more predictive. 
 
Figure 4.28 Resampling comparison of blood and urine heteroplasmy for the total disease burden 
multiple regression model. 
N = 134 1000 resamples with replacement of the patient pool are used to generate the above distributions. 
The percentage point increase of R
2
 when using blood instead of urine heteroplasmy is shown, using 
multiple regression with age and heteroplasmy as predictors. Mean increase is 7.7%, and the change is 
significantly greater than zero (P=0.042).  
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4.5.4.3. Blood heteroplasmy is better than urine heteroplasmy in longitudinal 
modelling of total disease burden; SKM heteroplasmy is not significantly better than 
either urine or blood heteroplasmy. 
The longitudinal model is the same as that described in section 4.3.4, however, the 
cohort is slightly smaller as it is restricted to those patients with both urine and blood 
heteroplasmy (N = 134). The model includes the early-onset flag as a predictor, as this 
is necessary for correctly formed residuals (N = 27 early-onset, 107 late-onset).  
Both urine and blood heteroplasmy are highly significant predictors of total disease 
burden in this slightly smaller cohort (P < 0.0001), as are age and early-onset (both P < 
0.0001 in each model). 
The models were initially compared using the AIC, as shown in Table 4.5. The blood 
model is superior to urine by comparing the AIC values in each case. Note that the AIC 
value for urine differs from that previously described as the cohort is smaller. In 
addition, bootstrapping was performed to investigate the stability of the improvement in 
model fit by using blood heteroplasmy; the results are shown in Figure 4.29. 
To further validate the model using blood heteroplasmy, the average (per patient) 
studentised residuals were examined against the predictors of heteroplasmy and age. 
The results are shown in Figure 4.30. The residuals in the model are not significantly 
correlated with either predictor, demonstrating that the model is well formed. 
Muscle heteroplasmy was also compared to both urine and blood. The results are also 
found in Table 4.6. The cohort in both cases is small, and no statistical significance is 
reported in either comparison, however, both blood and urine explain more variance in 
these smaller cohorts than muscle heteroplasmy. 
Model AIC P value R
2
 
Urine -45.0 0.1285 1.74% 
Blood -57.3 0.3636 0.62% 
Table 4.5 Comparison of blood and urine heteroplasmy models using AIC.  
The table shows the AIC value for the overall model. The P value and R
2
 relate to the regression of the 
predicted value of the model versus the average studentised residuals; significance in this relationship 
would indicate poor model fit. Both urine and blood have residuals that are uncorrelated with the 
predicted values of the model.  
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Figure 4.29 Resampling comparison of urine and blood heteroplasmy using the longitudinal mixed 
effects model. 
The AIC difference for 1000 bootstrapped resamples is shown; a positive AIC difference indicates blood 
is a better predictor than urine. The AIC difference is significantly above 0 (P = 0.046) indicating that 
blood is a consistently better predictor than urine. 
 
  
Figure 4.30 Average studentised residuals of the longitudinal mixed model compared to the model 
predictors of age and blood heteroplasmy. 
(Left) Residuals are not significantly correlated with age (P = 0.4302, r = -0.05). (Right) Residuals are 
not significantly correlated with blood heteroplasmy (P = 0.5565, r = 0.03). 
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  AIC difference    
Comparison N Mean 95%L 95% U P(diff>0  Conclusion 
Urine minus 
Blood 
134 17.5 -2.8 41.9 0.0460 blood significantly 
better than urine 
Muscle minus  
Blood 
31 5.7 -12.9 23.2 0.1840 blood better than 
muscle, not significant 
Muscle minus 
Urine 
34 12.9 -3.7 32.6 0.0600 urine better than 
muscle, not significant 
Table 4.6 Comparison of urine, blood, and muscle heteroplasmy for longitudinal modelling of total 
disease burden.  
The mean AIC difference and 95% confidence limits calculated using bootstrapping are shown. The 
significance value (P) is the proportion of resampled values with a difference greater than 0. Blood is 
significantly better than urine heteroplasmy. The cohort of patients with muscle is small and no 
significant difference can be found between muscle and either blood or urine, though both blood and 
urine are in general more predictive than muscle heteroplasmy. 
4.5.4.4. Comparison of blood and urine heteroplasmy in predicting individual 
features from the NMDAS. 
Bootstrapping was used to probe the logistic regression model incorporating age and 
heteroplasmy as predictors. For each simulation the blood and urinary heteroplasmy 
models were compared to identify the best fitting model. Figure 4.31 illustrates the 
proportion of resamples in which urine heteroplasmy is the better predictor; the line at 
50% separates those features better predicted by urinary heteroplasmy (upper half) and 
those better predicted by blood heteroplasmy (lower half). Cut-off lines at 20% and 
80% are also drawn to identify those with a strong bias in favour of either heteroplasmy 
measure. The features that are better predicted by urinary heteroplasmy are ptosis, 
pyramidal and extra-pyramidal features, and migraine. The first three of these are rare in 
the cohort; migraine is common but not strongly correlated with either age or urinary 
heteroplasmy. Several common features are predicted better by blood heteroplasmy, 
including cerebellar ataxia, diabetes mellitus, cognition, exercise intolerance, and visual 
impairment. 
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Figure 4.31 Blood and urine heteroplasmy model comparison for individual phenotypic features. 
For each feature, the patient pool was resampled 1000 times and the models compared to see which of the 
two models (blood or urine heteroplasmy) was the better predictor. Cerebellar ataxia, cognitive 
impairment, diabetes mellitus, exercise tolerance, gait stability, myopathy, and visual acuity are better 
predicted by blood heteroplasmy; extra-pyramidal, migraine, ptosis and pyramidal by urinary 
heteroplasmy.   
4.5.5. Discussion 
I have used urine heteroplasmy throughout the modelling of disease burden and 
progression. This is on account of various studies that have identified urine 
heteroplasmy as the preferred non-invasive heteroplasmy measure in m.3243A>G 
(Whittaker et al., 2009; de Laat et al., 2012). However, the results in this section show 
that blood heteroplasmy is more predictive of both total disease burden and also several 
individual phenotypic features of m.3243A>G disease. 
Blood heteroplasmy has been repeatedly discredited as being of prognostic value 
(Mehrazin et al., 2009; Whittaker et al., 2009); this was intuitively consistent with the 
finding that blood heteroplasmy levels are not static and decline over time. However, 
the results presented in section 4.4 provide substantial evidence in support of the merit 
of blood heteroplasmy as a more useful predictor than urine heteroplasmy. It is 
significantly better in predicting total disease burden, both using basic statistical 
analysis of the average NMDAS score for each patient, and also using longitudinal 
modelling of disease progression. With regard to individual phenotypic features the 
picture is not so clear; there are several features that are better predicted in our cohort by 
urine rather than blood. However, the features with a strong bias towards urine 
heteroplasmy are generally rare in the m.3243A>G cohort, such as extra-pyramidal and 
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pyramidal features. Migraine is the only feature in this group that is common, however 
it has already been shown in section 4.3.5 that migraine is poorly predicted by either age 
or urine heteroplasmy. Conversely, the features that are strongly biased towards blood 
heteroplasmy are both common and also strongly predictable by urine heteroplasmy, 
including cerebellar ataxia, diabetes mellitus, exercise tolerance, myopathy, and 
cognitive impairment. The notable exception to this is deafness; 67% of resamples 
found urine a better predictor than blood.  
Muscle is not significantly better than urine or blood heteroplasmy in this cohort, and 
indeed the trend is in the opposite direction. However, the sample size (31/34 patients) 
is relatively small, and statistical significance would be difficult to achieve with this 
size of cohort, particularly considering that I have shown heteroplasmy predicts little of 
the overall variation in total disease burden. However, if urine is indeed more predictive 
than muscle, despite being highly variable as reported in section 4.4, the reason for this 
is unknown. I will return to this discussion in section 4.6.4.4 with regard to sex 
differences in the m.3243A>G mutation. 
I speculate that blood heteroplasmy may be a useful prognostic indicator for two 
reasons. The first is that the level of heteroplasmy in blood, though in decline, are more 
consistent than measures of urine or muscle heteroplasmy. I have already been shown 
that urine heteroplasmy measurements vary considerably for single patients; if blood is 
also superior to muscle heteroplasmy it may indicate that a single muscle biopsy 
heteroplasmy level is also a poor estimate of average heteroplasmy. 
The discussion on the utility of heteroplasmy must be put into the context of how useful 
heteroplasmy as a measure of the underlying pathology. It is clear from the basic 
modelling using GLM that heteroplasmy is a poor predictor of disease burden. This 
begs the question of whether another easily measurable quantity may be more useful, 
for example wild-type mtDNA copy number. It has been shown in a recent study that 
wild-type mtDNA copy number is a more useful predictor of disease phenotype than 
heteroplasmy (Liu et al., 2013). As for previous studies (Whittaker et al., 2009) urine 
was noted as superior to blood, however both of these studies fail to incorporate age 
into their modelling.  
Liu et al. convincingly shows that wild-type mtDNA copy number is a better indicator 
than heteroplasmy; however, their results are potentially confounded by the lack of age 
as a predictor. They found that younger subjects had lower mtDNA copy number. Total 
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mtDNA copy number was significantly higher in the m.3243A>G patients than in 
controls. The data shown for total copy number by age group was interesting. For both 
blood and urine total mtDNA copy number, the highest copy number was found in the 
10-20 age group; the lowest was found in the < 10 age group, and above 20 years of age 
the copy number was in between the two. The control data is perhaps the more 
informative of the two data sets here, since it is not biased by more severe disease 
phenotype found in younger patients in the m.3243A>G patients. It would appear that 
copy number is significantly higher in the 10-20 group than the other groups, in both 
blood and urine. This would suggest a non-linear trend of total mtDNA copy number 
with age, which would potentially confound any use of this measure for prediction, 
unless age adjusted correctly. 
There are some caveats to add to this analysis, and all analyses using heteroplasmy 
measures. The methodology for assessment of heteroplasmy has changed and improved 
over the years, and heteroplasmy levels used in this analysis span over 13 years. Though 
this is not expected to materially affect the analysis in general, it may affect the 
variability in the heteroplasmy measurements.  
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4.6. Sex differences in m.3243A>G mutation 
4.6.1. Introduction 
There are diseases associated with mtDNA mutations that have a clear difference in 
expression between sexes, for instance Leber’s hereditary optic neuropathy (LHON), to 
which males are four to five times more susceptible (Yu-Wai-Man et al., 2009). 
However, it is less clear whether there are sex differences in other mitochondrial 
mutations. The prospect of more severe male disease was raised in 1996 by Frank and 
Hurst, who hypothesised that maternal inheritance would open up the prospect of more 
severe phenotypic disease for males, particularly relating to infertility, but also other 
systems exhibiting male-female dimorphism as mutations deleterious only to males 
would not be selectively filtered from the germline (Frank and Hurst, 1996). 
From the phenotypic perspective, there is recent work that highlights the potentially 
critical importance of male-female dimorphism, particularly as regards ageing. Camus 
and colleagues showed that ageing is accelerated in Drosophila melanogaster by 
deleterious mitochondrial mutations, but only in males, not females (Camus et al., 
2012). 
4.6.2. Aims 
The aim of this chapter is to explore sex differences in the m.3243A>G cohort. I chose 
to focus on m.3243A>G, as it is the largest set of patients in the MRC cohort. 
The principal question for exploration in this chapter is whether there any differences in 
the phenotypic expression of the m.3243A>G mutation between sexes. This will 
encompass examining differences in heteroplasmy levels, disease burden, and specific 
phenotypic features. 
Several large studies in m.3243A>G have been conducted, and in each case females 
outnumber males in a ratio of approximately 2:1. To explore the cause of this 
imbalance, I chose to investigate maternal family inheritance to establish whether there 
is any difference in the ratio of males and female children born to mothers carrying the 
m.3243A>G mutation. 
4.6.3. Methods 
4.6.3.1. Cohort 
I utilise the same cohort of patients as described in section 4.3. All families with 
recorded pedigrees were used in the pedigree analysis. For other analyses all patients in 
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the cohort with the appropriate factors (blood, urine, and muscle heteroplasmy) were 
included. 
4.6.3.2. Meta-analysis 
For analysis of the sex ratio at birth, I also collated data on family trees from published 
literature to compare with the data from our own cohort.  
A search was done in PubMed for any of 3243, MELAS or MIDD, together with 
PEDIGREE, and any publications with defined pedigrees were included. In addition, 
any pedigrees from publications that were reviewed in the wider investigation into 
m.3243A>G were included. 
4.6.3.3. Sex ratio methodology 
Each maternal family lineage was considered separately, and a female/male birth ratio 
was calculated for each family.  
All generations of descendants through the maternal line below the earliest known 
m.3243A>G mutation carrier were included; the total number of females and total 
number of males were summed and the ratio calculated. The top level mother was not 
included in the ratio. It was not always necessary for the top-level mother to be a 
confirmed carrier by genetic testing. For instance, if two or more siblings (non-identical 
twins excepted) at any level were confirmed by genetic diagnosis to be carriers of the 
mutation then their mother is assumed to be a carrier, since the chance of separate 
sporadic mutation events in two siblings is negligible.  
4.6.3.4. Statistical analyses 
For sex differences in disease burden I used multiple regression to look at heteroplasmy, 
age, and NMDAS score. 
All tests on sex ratio differences were non-parametric. 
4.6.4. Results 
4.6.4.1. Cohort 
The cohort is the same as used in section 4.3, consisting of 146 patients in total. 
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4.6.4.2. Gender balance in large cohort studies of m.3243A>G 
Table 4.7 shows the balance of male and female participants in several recent large 
cohort studies on m.3243A>G, including our own. Each study comprises an 
independent and non-overlapping cohort. 
Source Male Female Female 
Proportion 
Newcastle cohort 72 124 63.3% 
(Majamaa-Voltti et al., 2006) 33 67 67.0% 
(Kaufmann et al., 2011) 30 56 65.1% 
(de Laat et al., 2012) 42 85 66.9% 
(Suzuki et al., 2003) 36 77 68.1% 
Table 4.7 Male female balance in large cohort studies on m.3243A>G. 
All studies show a consistent proportion of around two thirds female to one third male participants. 
4.6.4.3. Sex ratio at birth 
4.6.4.3.1. General population 
Table 4.8 shows the females proportion in live-births in the in the general population. 
Population Proportion at birth 
(Estimated) 
Proportion in population 
over 65 
World 48.3% 56.2% 
UK 48.8% 55.6% 
Table 4.8 Proportion of females in the population.  
At birth the proportion of females in the population is slightly less than half, at similar proportions both 
worldwide and in the UK. Above the age of 65 the balance shifts to a female dominated population. 
(Central Intelligence Agency, 2013). 
4.6.4.3.2. Analysis of m.3243A>G carriers 
Nineteen separate publications were found for the meta-analysis, detailing 39 separate 
pedigrees. Twenty-two separate pedigrees were identified from the patients in the 
Newcastle cohort. Source data for the analyses can be found in Appendix IX and 
Appendix X. 
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The proportion of female live-births was calculated for each pedigree. The distribution 
for each data set is depicted in Figure 4.32. In the Newcastle cohort the median female 
proportion (58.8%) is significantly higher than that of the general population (P = 0.045, 
N = 44). The median proportion in the meta-analysis (61.5%) is also significantly higher 
than the general population (P = 0.0005, N = 39). 
 
Figure 4.32 Proportion of live-births that are female in the meta-analysis and this cohort. 
The proportion of female live births is significantly different from the proportion of the general 
population. In the meta-analysis the estimated median is 61.5% (P = 0.0005, N = 39), in the Newcastle 
cohort the estimated median is 58.5% (P = 0.045, N = 44). The proportion for the general population is 
taken as 48.8%, as seen in Table 4.8. 
4.6.4.4. Sex differences in heteroplasmy 
For each of the three heteroplasmy measures (urine, blood, and muscle) I used multiple 
regression to examine the effect of age (at biopsy) and sex as predictors. 
As shown in Figure 4.33, urine heteroplasmy is significantly higher in men than in 
women (P < 0.0001, R
2
 = 26.5%, N=145). It is not for significantly different in blood (P 
= 0.8770, R
2
 = 37.0%, N=134) nor in muscle (P = 0.1784, R
2
 = 10.6%, N = 36). 
The relationship between blood and urine heteroplasmy is also modulated by sex. In 
multiple regression with urine heteroplasmy, age at biopsy, and sex as predictors, and 
the square root of blood heteroplasmy as the dependent variable, sex is a highly 
significant predictor (P < 0.0001) as well the other two predictors. (N = 159, R
2
 
=78.0%). 
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Figure 4.33 Sex differences in heteroplasmy levels.  
(A) Urine heteroplasmy levels are significantly lower in females than in males (P < 0.0001, R
2
 = 26.5). 
(B) Blood heteroplasmy levels are not significantly different between males and females (P = 0.8770, R
2
 
= 37.0%). (C) Muscle heteroplasmy is not significantly different between males and females (P = 0.1784, 
R
2
 = 10.6%). 
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4.6.4.5. Sex differences and NMDAS progression  
To investigate whether sex has a significant impact on NMDAS score and progression, I 
first conducted multiple regression with age and sex as predictors, using the scaled 
NMDAS score (NMDAS
0.25
) as the dependent variable. I first examined two models; 
one without an interaction term (allowing different intercepts but not gradients for sex), 
and the second with the interaction term (allowing both intercept and gradient to differ). 
The first model finds that the gradients are not significantly different (P = 0.6552, N = 
146, R
2
 = 6.1%). The second model is illustrated in Figure 4.34. The gradients are not 
significantly different (P = 0.2403, R
2
 = 7.0%).  
I also investigated whether sex differences in NMDAS progression are observable when 
urine heteroplasmy is included in the model. In this model, sex is also not found to have 
a significant effect on NMDAS score (P = 0.3392, R
2
 = 18.3%, N = 146). 
With blood heteroplasmy, sex is also not a significant effect (P = 0.6005, R
2
 = 27.3%, N 
= 135). 
 
Figure 4.34 Scaled NMDAS score, age and sex.  
Linear regression with 95% confidence intervals are shown for males and females. Sex is not a significant 
effect in NMDAS score (P = 0.6552) and the gradients are not significantly different (P = 0.2403). N = 
146. There are no significant sex differences observable in NMDAS score. 
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4.6.4.6. Specific phenotypic features 
As in section 4.3.5, I used logistic regression to model the effect of age and 
heteroplasmy (both urine and blood) on the severity of phenotypic features as identified 
by the NMDAS. I use the same modelling approach here, but introduce sex as a third 
predictor. The results are shown in Figure 4.35. Using urine heteroplasmy, only the 
severity of ptosis is significantly more severe in males than females; however, exercise 
intolerance and myopathy are more severe in females. Using blood heteroplasmy, males 
are significantly more severely affected in several features, namely ptosis, vision, 
cutting food, hearing, cardiovascular dysfunction, and encephalopathic episodes. There 
are no features where females are significantly more severely affected than males. The 
odds ratios for almost all other features show that the (non-statistically significant) trend 
is for females to be less affected than males; the exceptions to this are diabetes, GI 
disturbance, exercise tolerance, and myopathy. 
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Figure 4.35 P-values and odds ratios for the predictive effect of sex on the risk of developing 
specific phenotypic features. 
For each feature, I look at the effect of sex on the logistic model incorporating also age and heteroplasmy 
(either urine or blood). Both graphs use log scales. Solid line on the P-value graph indicates P = 0.05; 
blow this line indicates statistical significance. An odds ratio significantly above 1 implies that males are 
more affected than females at the same age and heteroplasmy; an odds ratio below 1 that males are less 
affected than males. Using urine heteroplasmy, only ptosis is significantly more severe in males, whereas 
exercise intolerance and myopathy are more severe in females. Using blood heteroplasmy, males are 
more severely affected in several features, namely ptosis, vision, cutting food, hearing, and 
encephalopathic episodes. There are no features where females are significantly more severely affected 
than males. 
4.6.5. Sex differences discussion 
As shown in Table 4.7, cohort studies on m.3243A>G are almost invariably female 
heavy in their makeup, with females outnumbering males in a ratio of approximately 
2:1. This is not necessarily an indication that there are more female carriers of the 
m.3243A>G mutation than male, for several reasons. The first is that females are more 
frequent users of health services than men in general (ONS, 2010), for which reason one 
might expect more women to be identified as potential carriers of the mutation than 
men. The second is related to a peculiarity of maternal inheritance of mitochondrial 
mutations; when a patient is identified as a carrier of a potentially inherited mtDNA 
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mutation such as m.3243A>G, it would be normal clinical practice to assess the mother 
of the patient to identify whether the mutation is sporadic or inherited, which would 
swell the number of females assessed (Dr Andrew Schaefer, personal communication). 
The third is a confound that derives from the asymmetrical ageing profile of the sexes; 
due to various factors, and in spite of a slightly higher male birth rate, the population 
above the age of 65 is female dominated (Central Intelligence Agency, 2013). 
To avoid population dynamics confounding my investigation, I chose to look at the 
female/male ratio in live births to females known to carry the m.3243A>G mutation. 
Conventionally the ratio is expressed as the ratio of male births to female births (1.07 
for the worldwide ratio in 2013 (Central Intelligence Agency, 2013)), but when looking 
at small populations such as individual maternal lineages proportions are preferred to 
ratios, to avoid division by zero when a family has only female children. Hence I 
consider the proportion of female births, with extreme values of 0 (all male offspring) 
and 1 (all female offspring). 
The data shows that both in the Newcastle cohort and the meta-analysis there is a 
significant deviation from the normal birth ratio in favour of female offspring. This is a 
novel observation, and has not been reported previously in literature to my knowledge. 
There are two potential causes of this imbalance; an influence on the sex determination 
of the embryo pre-fertilization, or a pathogenic effect specific to males. 
The concept of an adaptive sex ratio has long been of interest to researchers, since the 
seminal theory of Trivers and Willard that first proposed a link between maternal 
characteristics and the sex ratio of offspring (Trivers and Willard, 1973). A second 
theory by Myers agreed with the outcome, but not the reasoning; he theorised that 
mothers under nutritional stress are more likely to give birth to daughters as daughters 
are nutritionally less expensive than sons (Myers, 1978). Factors which modulate the 
sex ratio in mammals have been studied in a variety of species. Diet, for example, has 
been shown to affect the sex ratio (Rosenfeld and Roberts, 2004). Indeed, it has been 
shown in a large number of studies that mothers in good physical condition produce 
more male offspring (Rosenfeld and Roberts, 2004). In humans, a study of the changing 
sex ratio during and after the 1959-1961 famine in China concluded that mothers in 
poor condition are more likely to give birth to daughters (Song, 2012). Pregravid 
diabetes has been shown to bias the sex ratio in favour of female offspring (Ehrlich et 
al., 2012); this is particularly relevant to the discussion regarding m.3243A>G 
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considering the prevalence of diabetes in the cohort. The physiological mechanism 
underlying this adaptive response remains unknown (Helle et al., 2008), but in line with 
the prior research it seems reasonable to infer that mitochondrial dysfunction could lead 
to energy stress in mothers and thus a trend towards female progeny. 
The second possible explanation of the altered sex ratio is that the mutations are more 
pathogenic for male offspring. Sex differences in mitochondrial disease have been 
discussed recently in the scientific literature, prompted by the prospect of mitochondrial 
replacement (MR) therapy (Reinhardt et al., 2013). The argument made by Reinhardt  et 
al. applies to any of the proposed mechanisms of MR, both pro-nuclear transfer (Craven 
et al., 2010) and mitotic spindle transfer (Tachibana et al., 2009). The argument rests on 
the co-ordination between nuclear and mitochondrial gene expression, which is highly 
integrated and tightly co-regulated (Woodson and Chory, 2008). From the perspective 
of mitochondrial evolution males are an evolutionary dead end, since the effects of 
mitochondrial genetic mutations on males are irrelevant as they are not passed on down 
the male line (Parsch, 2011). This leads to the curious situation that mutations that are 
deleterious to males but not females can potentially be successfully passed on without 
fear of genetic selection (Frank and Hurst, 1996). Indeed, mitochondrial replacement in 
fruit flies has been shown to lead to a major change in nuclear gene expression in males 
but not females (Innocenti et al., 2011), which is suggestive of potential major 
differences between mitochondrial gene expression between males and females.  
If the m.3243A>G mutation were indeed more pathogenic for males than females, it 
could be expected that males would exhibit faster disease progression and more severe 
disease phenotype. However, the most appropriate way to assess this is not 
straightforward. I have already shown in 4.6.4.4 that urine heteroplasmy is higher in 
males, but that blood heteroplasmy is not significantly different between sexes. I chose 
to retain heteroplasmy (either blood or urine) and age in the model when looking at both 
overall disease burden progression and also the severity of specific phenotypic features, 
so as to control for the correlations observed between sex and heteroplasmy. However, I 
also investigated the relationship between sex and disease burden and severity with 
heteroplasmy absent from the model altogether. 
Regarding overall disease burden progression (section 4.6.4.5), sex is not a significant 
predictor. This is true whether heteroplasmy of any source is included as a predictor or 
not. This lack of an effect with or without heteroplasmy is slightly puzzling, since I 
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have also shown that urine heteroplasmy is significantly higher in the male patients of 
the cohort (section 4.6.4.4). It was therefore expected that one of the two models, either 
blood heteroplasmy or urine heteroplasmy, would exhibit sex differences.  
The modelling of individual phenotypic features is more illustrative, particularly 
comparing the effect of sex as a predictor when using the different heteroplasmy 
measures as predictors. Here there are several phenotypic features in which males are 
more severely affected when using blood heteroplasmy. Several of these features are not 
observably different between the sexes using urine heteroplasmy as a predictor. This 
suggests that the sex difference in the heteroplasmy level observed in urine is 
potentially explanatory of some of the variation in phenotypic severity; however, it 
should be noted that blood heteroplasmy is in general a better predictor for almost all 
phenotypic features. Of the features that have more severe disease burden for females 
(albeit non-significantly for blood heteroplasmy), it is notable that both myopathy and 
exercise intolerance are features that are more severe in females than in males; both of 
these are related to muscle, in which there are known sex differences (Staron et al., 
2000). 
The discussion of sex differences in m.3243A>G must be examined in the context of 
fundamental physiological differences between males and females. It is not disputed 
that females live longer than males (Austad, 2006; Frank, 2012). There are numerous 
reported differences in males and females reported that are related to ageing however, 
and no consensus on the root causes of the difference in longevity and whether a slower 
ageing process is the root cause of this. However, it has been shown that females 
demonstrate slower immune system ageing (Hirokawa et al., 2013), suffer less 
oxidative DNA damage (Proteggente et al., 2002), and, most relevant to a discussion 
about mitochondrial disease, it has been shown that females have higher mitochondrial 
antioxidant levels and lower mitochondrial oxidative damage than males, directly 
attributable to oestrogen levels (Borras et al., 2003),which is highly supportive of the 
oxidative stress hypothesis of ageing. Thus there may be a natural asymmetry in disease 
progression that is not attributable to mitochondrial disease per se and more related to 
general differences also observed in the general non-diseased population. 
To truly understand whether the mechanism underlying the altered sex ratio is a 
pathogenic mechanism post-conception or selection pre-conception would require a 
study of pregnancies that fail to carry to term and an examination of the sex ratio in 
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unviable foetuses. However, on balance it seems more reasonable to assume that the 
changes in the live birth sex ratio in m.3243A>G are caused by the same mechanism as 
other changes discussed previously, such as seen in nutritional deprivation or diabetes. 
It is important to acknowledge potential limitations of this study. Firstly, any potential 
source of bias in the reporting of family pedigrees must be considered. Secondly, 
caution must be expressed with regard to conclusions of statistical significance; the 
analysis we are carrying out does involve multiple testing, and caution should be 
observed in interpreting the p-values of the effects. However, whilst acknowledging the 
limitation of determining statistical significance in analyses such as this, I believe that 
the analysis has merit regardless and is informative as to the effect of sex on disease 
progression and severity. 
4.7. m.3423A>G discussion 
There are several novel aspects to the work presented here on disease progression 
associated with the m.3243A>G mutation.  
Regarding disease progression, to my knowledge this is the first study to investigate 
disease burden and progression using multiple regression techniques, which has been 
shown as invaluable in understanding the relationship between disease burden, 
heteroplasmy, and age. Without multiple regression techniques the correlation between 
heteroplasmy and age at a population level severely hampers any attempt using a single 
predictor at a time. 
Secondly, longitudinal mixed modelling has been used to provide predictive models of 
total disease burden progression. Again, this is novel, and is important for clinicians in 
understanding the likely course of progression of disease burden.  
Thirdly, the risk profiles for individual phenotypic features using age and heteroplasmy 
as predictive factors are novel and are fundamentally important for understanding the 
link between age, heteroplasmy, and specific features of disease in patients with 
m.3243A>G. 
The investigation into heteroplasmy also demonstrates several novel findings. Firstly, I 
have quantified the variability of urine heteroplasmy.  This is vitally important, as this is 
routinely used by clinicians to understand the likely disease burden of patients and this 
high variability is a serious limitation of urine heteroplasmy as a prognostic measure. 
The characterisation of the relationship between urine and blood heteroplasmy is also 
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novel, as is the observation that blood heteroplasmy levels are likely to be 
asymptotically non-zero in many patients.  
The report of the altered sex ratio in favour of female progeny is novel, and opens up 
further questions about the mechanism behind this alteration. The investigation into sex 
differences in disease associated with m.3243A>G has demonstrated clear differences 
between males and females as regards urine heteroplasmy, which is of concern. 
However, the examination of disease burden and specific phenotypic features indicate 
that the higher urine heteroplasmy level in males may potentially reflect a genuinely 
higher disease burden. 
In conclusion, though much has progress has been made in understanding disease 
progression in patients with the m.3243A>G mutation, the limitations of heteroplasmy 
as a prognostic measure have been clearly demonstrated, and the case for improved 
metrics more useful than heteroplasmy in predicting disease progression has been 
clearly made. 
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 Disease progression in single large-scale mtDNA deletions Chapter 5.
5.1. Introduction 
Single large-scale mtDNA deletions are amongst the more commonly reported 
mutations in mitochondrial disease. Population prevalence in adults is estimated at 
between 1.2/100,000 (Chinnery et al., 2000b) and 2.9/100,000 (Remes et al., 2005). In 
the cohort of 671 patients seen at the Newcastle mitochondrial disease clinic, 86 
(12.8%) have single large-scale mtDNA deletions. 
Single large-scale mtDNA deletions were the first identified genetic cause of mtDNA 
disease (Holt et al., 1988). The clinical phenotypic associated with single large-scale 
mtDNA deletions is traditionally divided into three main presentations (Schon et al., 
2012). The mildest phenotypic presentation is chronic progressive external 
ophthalmoplegia (CPEO) (Moraes et al., 1989), which principally involves weakness of 
the extra ocular muscles and ptosis, but is often associated with more widespread 
muscular weakness. A second major presentation is Kearns-Sayre syndrome (KSS) 
(Kearns and Sayre, 1958), a multi-system childhood or teenage onset syndrome. KSS 
was first characterised with ophthalmoplegia, retinal pigmentary degradation, and 
cardiomyopathy as principal features; the criteria for diagnosis have since been adjusted 
to onset under twenty years of age, PEO, and pigmentary retinopathy. However, other 
features such as cerebellar ataxia, broader myopathy, and other organ involvement are 
also common. Pearson Syndrome (Pearson et al., 1979) is an infantile onset syndrome 
that is often fatal, characterised by sideroblastic anaemia and exocrine pancreatic 
dysfunction. In those who survive infancy it often develops into KSS (Simonsz et al., 
1992).  
As many studies attempting to analyse phenotypic presentation have noted, these 
divisions are somewhat imprecise and misrepresent the true spectrum of single mtDNA 
deletion-related disease; patients denoted CPEO are often sub-divided into groups such 
as ‘classic CPEO’ at the mild end of the spectrum, ‘severe CPEO’ or ‘CPEO+’, and 
‘partial KSS’ or ‘CPEO + Multisystem’ (Auré et al., 2007). Discrete phenotypic 
classification is severely problematic. 
The earliest investigations of disease associated with single large-scale mtDNA found 
little connection between mitochondrial genetics, biochemical defects and clinical 
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phenotype (Zeviani et al., 1988; Holt et al., 1989a; Moraes et al., 1989; Rotig et al., 
1995). More recent studies are rather contradictory. For example, SKM heteroplasmy is 
has been reported as non-predictive of either phenotype or age at onset (Yamashita et 
al., 2008), predictive of onset but not phenotype (López-Gallardo et al., 2009), or 
predictive of both to an extent (Sadikovic et al., 2010).  Similarly, mtDNA deletion size 
is variously reported as either predictive of phenotype and disease severity (Yamashita 
et al., 2008) or not predictive (López-Gallardo et al., 2009). Two recent studies found 
that the location on the genome of the mtDNA deletion was predictive of phenotype or 
age at onset, though with contrary findings. One study found that mtDNA deletions 
including one of the three mtDNA-encoded structural components of cytochrome c 
oxidase (COX) (MT-CO1, MT-CO2 or MT-CO3 genes) or complex V (MTATP6 or 
MTATP8 genes) had significantly earlier-onset (Yamashita et al., 2008). However, 
another study found that deletion of the mitochondrial cytochrome b (MT-CYB) gene 
was significantly associated with the more severe KSS phenotype as compared to CPEO 
(López-Gallardo et al., 2009). 
To improve analysis of disease burden and phenotype, researchers have attempted to 
better segregate patients into groups that are more appropriate for analysis. Auré et al 
segregated patients by the presence of a neurological phenotype, distinguished by the 
presence of cerebellar involvement (Auré et al., 2007); a second group looked at 
whether the phenotype was purely myopathic in nature (López-Gallardo et al., 2009).  
However, as is true for many mitochondrial genetic disorders, the disease spectrum is 
multidimensional, with a wide range of potential systems involved, each to varying 
degrees of severity. This severely hampers any attempt to discretely classify the disease. 
In this context, the NMDAS is a significant aid in understanding disease severity, 
progression, and the correlation with predictive factors, and offers a route to 
understanding disease progression that sidesteps the issue of discrete phenotypic 
classification.  
5.2. Aims 
In this study, I chose to use repeated measures mixed modelling with the collated 
NMDAS data to test the hypothesis that mtDNA heteroplasmy levels and mtDNA 
deletion size and location are predictive of single, large-scale mtDNA deletion disease 
progression.  
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I also aimed to apply multiple linear regression analyses to examine the relationship 
between these predictors and outcome measures such as age at onset, clinical 
phenotype,  the level of biochemical defect (as determined by COX-deficient fibre 
density) in both our cohort and a meta-analysis of previously published data.  
Finally, I aimed to use logistic regression to examine the relationship between 
individual phenotypic features and predictive factors. 
5.3. Methods 
5.3.1. Newcastle patient cohort 
All the patients in this cohort were investigated by the NHS Highly Specialised Service 
for Rare Mitochondrial Disorders in Newcastle upon Tyne. The majority (55 out of 87) 
were recruited to the MRC Mitochondrial Disease Patient Cohort UK  and followed in 
our clinic at regular 6 or 12 monthly intervals, and assessed using the NMDAS at each 
visit (Schaefer et al., 2006). The remaining 32 patients comprise individuals not seen in 
our clinic and for whom we have limited clinical information, and those for whom we 
do not have NMDAS data available. For some of these patients we have been able to 
ascertain disease onset from medical records. A full listing of the clinical and molecular 
characteristics of the patient cohort can be found in Appendix XI. 
For phenotypic analysis the patients were divided into two groups, those classified 
either as CPEO or as CPEO with myopathy (combined together, N = 54) and those 
classified as KSS (N = 9). 
5.3.2. Meta-analysis 
The meta-analysis is based on a previous meta-analysis by López-Gallardo et al. 
(López-Gallardo et al., 2009) which includes data on patient age at disease onset, age at 
biopsy, clinical phenotype, SKM heteroplasmy, mtDNA deletion size, and in many 
cases specific mtDNA deletion breakpoints. I used the data as published by López-
Gallardo et al. except where review of the literature identified differences between the 
published data and that used by this group (three cases) or where there was 
inconsistency between the reported mtDNA deletion size and location of the 
breakpoints (one case). I also eliminated those cases where the reported mtDNA 
deletion was characterised by restriction endonuclease digests and there was uncertainty 
as to whether specific genes under scrutiny (MT-CO or MT-CYB genes) were deleted 
(seven cases) or other mutations were reported concurrently for the same patient (nine 
cases). One patient with a highly unusual mtDNA deletion in the minor arc of the 
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mitochondrial genome was also excluded. Also excluded are any patients that have been 
reported in studies from this centre. 
The data was augmented with other cases from subsequent studies or those not included 
by López-Gallardo et al. that were identified through PubMed  (Johns et al., 1989; Mita 
et al., 1989; Larsson and Holme, 1992; Oldfors et al., 1992; Ishikawa et al., 2000; 
Gellerich et al., 2002; Jacobs et al., 2004; Sadikovic et al., 2010).  
All data from the meta-analysis can be found in Appendix XII. All amendments and 
exclusions are listed in Appendix XIII. 
For phenotypic analysis, patients classified by López-Gallardo et al. as “CPEO without 
non-muscular signs” were combined with patients classified “CPEO” or “CPEO + 
myopathy” from the other sources (101 cases in total). This patient group was compared 
to the patients classified as “KSS” from all sources (104 cases in total). For other 
analyses, we used the patients in the meta-analysis that had all the appropriate 
information available. 
5.3.3. Muscle biopsy histochemistry data 
Sequential cytochrome c oxidase (COX)/succinate dehydrogenase (SDH) histochemical 
reactions were performed on SKM sections following standardised protocols (Old and 
Johnson, 1989). The percentage of COX-deficient fibres (measuring the extent of COX 
deficiency) was determined by counting all the fibres in a section (minimum 200). 
Counting was performed by a single researcher to ensure consistency.  
All muscle biopsy histochemistry was conducted by Gavin Falkous. 
5.3.4. Determination of level of mtDNA deletion 
All molecular analyses were performed using total SKM DNA extracted using standard 
protocols. mtDNA deletion levels in muscle homogenates was quantified using a 
validated, multiplex real-time PCR (qPCR) MT-ND1/MT-ND4 assay (He et al., 2002; 
Krishnan et al., 2007).  
All mtDNA deletion level quantification was performed by Georgia Campbell and 
Thiloka Ratnaike. 
5.3.5. Determination of mtDNA deletion size and location 
Long-range PCR was used to amplify ~ 9.5 kb region of the mitochondrial genome 
across the major arc using a single primer set corresponding to nucleotides 6378-15896 
(GenBank Accession number: NC_012920.1). PCR reactions used ~100ng of DNA 
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which was added to PCR mastermix (dH2O, LA Taq buffer (TaKaRa), 10mM dNTPs, 
20mM forward and reverse primers and XX units of LA Taq enzyme (TaKaRa)) to a 
total volume of 50μl and subjected to the following cycling conditions: 94°C for 1 
minute; 35 cycles of 94°C for 30 seconds, 58°C for 30 seconds and 68°C for 11 
minutes; final extension of 72°C for 10 minutes. Amplified products were separated 
through a 0.7% agarose gel, using a 1kb DNA ladder to estimate product size and 
determine mtDNA deletion sizes.  
Long-range PCR products were further assessed by restriction digests to map the 
precise location of the mtDNA deletion breakpoints (Khrapko et al., 1999). PCR 
amplimers (5µl) were digested to a series of DNA fragments of known length and 
position within the mitochondrial genome using restriction enzymes Xho I, BamH I, 
Xcm I and Dra I (New England Biolabs) prior to separation through a 0.7% agarose gel. 
The size of restriction products allows the location of the mtDNA deletion within the 
genome to be estimated, guiding the choice of appropriate sequencing primers 
(Supplementary Table 4) to characterise mtDNA deletion breakpoints by Sanger 
sequencing. (BigDye v3.1 terminator cycle sequencing chemistries using an ABI 3130xl 
Genetic Analyser; Applied Biosystems). 
All mtDNA deletion breakpoint determination was carried out by Georgia Campbell. 
5.3.6. Statistical analyses 
5.3.6.1. Basic statistical modelling 
The general methods for basic statistical analyses are described in section 2.11.1.1. 
5.3.6.2. Longitudinal modelling of disease progression 
Longitudinal modelling is conducted as described in section 2.11.1.2. Appendix XIV 
lists the SAS code to generate the models used in this section. 
5.3.6.3. Data transformation 
As described in section 2.11.1.2, Box-Cox analysis was used to investigate the 
relationship between the NMDAS score and age at assessment. In addition to this, I 
wished to investigate the relationship between the other independent variables 
(heteroplasmy and deletion size) with the scaled NMDAS score. 
This was done in two ways; the first used PROC TRANSREG and Box-Cox analysis, 
but with the QPOINT option to allow examination of quadratic surfaces, i.e. the 
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introduction of simple powers of the dependent variables and cross interactions to see 
the effect on variance stability. 
QPOINT identifies simple powers of independent variables that stabilize the variance of 
the data, but does not explore other transformations such as the log function. It was 
hypothesised that the effect of heteroplasmy may have increased exponentially as 
heteroplasmy approaches 100%. Hence the transformation hetlog=log(1-het) was 
examined to see the effect of this transformation on the fit of the model and variance 
stability. 
5.3.6.4. Individual phenotypic features 
The general methodology for logistic regression is explained in section 2.8.  
I used two approaches to logistic regression. Both used the three predictors of age, 
muscle heteroplasmy, and deletion size. For each NMDAS question, a single summary 
score was determined for each patient by taking the maximum score achieved on each 
question and the age at which that score was first recorded. 
The first approach used binary (dichotomous) logistic regression by identifying the 
optimal cut-off point for each NMDAS question to divide the cohort into two groups. 
To identify the optimal cut-off point the area under the ROC curve (AUC) was 
maximized. This was done separately for each individual predictor, each pair of 
predictors, and the three predictors together in the model, to allow a full understanding 
of the use of each predictor. Only cut-off points that partitioned the data into sets 
containing at least 6 patients (10% of the cohort) in each group were considered to 
avoid small numbers of patients skewing the results.  
The second approach used a proportional odds multiple logistic regression. NMDAS 
scores were re-categorised as asymptomatic (NMDAS = 0), moderate (1-3), and severe 
(4-5); this re-categorisation was necessary for a majority of phenotypic features for 
model to conform to the proportional odds assumption. Pseudo-R
2
 values, as described 
in 2.8.2, were used to compare models. 
In both approaches, standardised parameters for the predictors were calculated. 
5.4. Results 
5.4.1. Patient cohort 
The number of patients used in the various analyses are detailed in Table 5.1. 
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The distributions of age, heteroplasmy, deletion size, and number of NMDAS 
assessments in the Newcastle cohort are shown in Figure 5.1.  
5.4.1.1. Phenotypic spectrum 
The phenotypic profile of patients in the cohort is shown in Figure 5.2. There are 
several features that are absent or rare in the cohort, including seizures, stroke-like 
episodes, diabetes, and both pyramidal and extra-pyramidal features. The majority of 
the other features are present in the cohort at level of at least 50%. CPEO and ptosis are 
100% penetrant, vision is also affected in 80% of people according to the current 
function (section I), whilst visual acuity is impaired in 70% of patients. Exercise 
tolerance is affected in 77% of patients, though 93% of patients are myopathic. 
Cerebellar ataxia is prevalent at 80%, with gait stability affected in 70% of patients.  
 With 
NMDAS 
Without 
NMDAS 
Cohort 
(total) 
Meta-
analysis 
Number of patients with mtDNA deletion 
size and muscle mtDNA heteroplasmy data 
55 32 87 256 
Number of patients with mtDNA 
breakpoints identified 
52 31 83 184 
     
Number of patient with  age at onset data 52 8 60 117 
Number of patients with age at onset data 
and mtDNA breakpoints identified 
49 7 56 83 
      
Number of patients with  COX-deficient 
fibre density data and mtDNA breakpoints 
identified 
49 23 72 40 
     
Number of patients presenting with a 
CPEO, CPEO + Myopathy or KSS 
phenotype 
36 27 63 205 
Number of patients presenting with a 
CPEO, CPEO + Myopathy or KSS 
phenotype and mtDNA breakpoints 
identified 
35 26 61 149 
Table 5.1 Summary of Newcastle patient cohort and available data in literature.  
SKM heteroplasmy and deletion size data was available for all patients. The sub-cohort of patients with 
identified mtDNA breakpoints is used where gene location is under investigation; the larger cohort with 
mtDNA deletion size is used where location is not considered. The small number of patients with 
phenotype data reflects the fact that patients with a multisystem phenotype are excluded from the 
analysis; this number is restricted to patients with CPEO, CPEO + Myopathy, or KSS.  
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Figure 5.1 Age, heteroplasmy, deletion size, and number of assessments in the cohort. 
The patients with heteroplasmy, deletion size, and NMDAS data are considered in this graph (N = 55). 
(A) Age is positively skewed with a median age of 42 year, minimum 18 years and maximum 82 years. 
(B) Muscle heteroplasmy is negatively skewed, with a median of 46.5%. Heteroplasmy ranges from 
undetectable (0%) to 85%, with an interquartile range of 35%. (C) Deletion sizes range from 2.3kB to 
9.1kB, and the distribution is fairly uniform other than the great peak at around 5kB, which are in the 
main common deletion (4,977kB) patients. (D) The median number of assessments is 4.5, with a 
maximum of 12, and an interquartile range of 5. 
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Figure 5.2 Phenotypic profile of the single large-scale deletion cohort. 
All patients with NMDAS data are included (N = 55). Bars show the stacked NMDAS score. All patients suffer from ptosis and CPEO to some extent, and 94% from more 
widespread myopathy. Visual impairment and cerebellar ataxia are the next most common symptoms. General encephalopathy, including stroke and seizure, are almost entirely 
absent from the cohort, as is diabetes mellitus. Pyramidal and extra-pyramidal features are rare. Mild neuropathy is common but more severe neuropathy is very rare. 
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5.4.2. Association of NMDAS score and traditional phenotypic classification 
NMDAS score was shown to correlate with the traditional phenotype classification, as 
shown in Figure 5.3 NMDAS score and classical phenotype are highly significantly 
correlated. 
 
Figure 5.3 NMDAS score and classical phenotype are highly significantly correlated. 
P-values for significant individual comparisons are shown; other comparisons are not significant (P > 
0.05). The three comparisons significant at P < 0.0001 are highlighted in red. Pure CPEO phenotype 
patients have a narrower range of NMDAS scores than the other phenotypes; KSS patients have the 
largest range. KSS patients have the highest NMDAS scores, followed by multisystem, CPEO + 
myopathy, then CPEO patients. NMDAS scores for patients with a purely CPEO phenotype patients are 
highly significantly lower than the other three phenotype groups.  
5.4.3. Data transformation 
Box-Cox identified the fourth root of the NMDAS score (NMDAS
0.25
) as the optimal 
transformation for linear regression with the single independent variable of age, 
hereafter called scaled NMDAS score. 
The QPOINT option of PROC TRANSREG in SAS with heteroplasmy, deletion size 
and age as independent variables found the square of the deletion size (size
2
) to be 
optimal. The transformation hetlog=log(1-het) was also found to stabilise the variance 
and improve the model fit. These transformations were used throughout the disease 
progression modelling.  Only the basic investigations into inter-correlations between the 
predictors used untransformed heteroplasmy and deletion size.  
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5.4.4. Putative predictors of disease burden and progression are inter-correlated 
Before considering the relationship between the putative predictors of disease 
progression and disease progression itself, I chose to look for inter-correlations between 
the various predictors. In the Newcastle patient cohort I observed a strong negative 
linear correlation between the mtDNA heteroplasmy and mtDNA deletion size (N=87, 
r=-0.49, p <0.0001) (Figure 5.4A). This observation was confirmed in the meta-analysis 
(N=256, r =-0.18, p=0.0032).  
mtDNA deletion size and location were also highly significantly correlated in the 
Newcastle cohort (N=83, r=-0.48, p<0.0001) (Figure 5.4B), and again this was 
confirmed by the meta-analysis (N=184, r=-0.29, p<0.0001).  
Highly significant correlations were also found between mtDNA heteroplasmy, mtDNA 
deletion size, and the two proposed genetic loci (MT-CO and MT-CYB genes) that were 
identified as significant in previous literature (Yamashita et al., 2008; López-Gallardo et 
al., 2009) (Table 5.2)  
5.4.5. Clinical phenotype, age at disease onset, and NMDAS progression, are 
correlated with muscle heteroplasmy and mtDNA deletion size  
The square root of age at onset was used in these analyses, which was identified by 
Box-Cox as the optimal transform. For the subjects in the Newcastle cohort with known 
age at onset (N=60), age at onset was significantly correlated with both mtDNA 
deletion size (b=-0.41, p=0.0039) and muscle mtDNA heteroplasmy (b=-0.42, 
p=0.0027) using multiple linear regression (R
2
=0.18) (Figure 5.5A). Similarly, in the 
meta-analysis (N=117), both mtDNA deletion size (b=-0.30, p=0.0008) and muscle 
mtDNA heteroplasmy (b=-0.30, p=0.0010) were significantly correlated with age at 
onset (R
2
=0.15).   
In the phenotypic analysis comparing KSS patients to CPEO patients (excluding 
intermediate phenotypes, as described in the methods), in the Newcastle cohort (N=64) 
I found that both mtDNA heteroplasmy (b=-1.4, p=0.0020) and mtDNA deletion size 
(b=-0.74, p=0.0318) were significantly correlated with phenotype using multiple 
regression. Similarly, in the meta-analysis (N=192), both mtDNA heteroplasmy (b=-
0.56, p<0.0001) and mtDNA deletion size (b=-0.18, p=0.0453) were significantly 
correlated with phenotype. 
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Figure 5.4 Putative predictors of disease progression are inter-correlated.  
Regression lines with 95% confidence intervals are shown in each case. (A) SKM heteroplasmy is negatively correlated with mtDNA deletion size in the Newcastle cohort. N=87, 
r=-0.49, p<0.0001. The dense cluster of points just below 5.0kB represents the cohort of patients with the 4,977bp common mtDNA deletion. (B) mtDNA deletion size is negatively 
correlated with the location of the mtDNA deletion midpoint in the Newcastle cohort. N=83, r=-0.48, p<0.0001. 
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The scaled NMDAS score was divided by the age at assessment to measure NMDAS 
progression. In the Newcastle cohort (N=55), I found that both mtDNA deletion size 
(b=0.49, p<0.0001) and mtDNA heteroplasmy (b=0.70, p<0.0001) were significant 
predictors of NMDAS progression using multiple regression (R
2
=0.49) (Figure 5.5B). 
 mtDNA 
heteroplasmy 
(%) 
mtDNA 
deletion Size 
(kB) 
mtDNA 
deletion 
midpoint kB) 
MT-CO 
gene 
deletion 
MT-CYB 
gene 
deletion 
mtDNA 
heteroplasmy 
(%) 
 <0.0001 
-0.49 
(-9.8, -4.3) 
%/kB 
0.3918 
+0.10 
(-2.6, 6.5) 
%/kB 
0.0423 
-0.22 
(-27,-0.50) 
% 
0.0199 
-0.26 
(-27, -2.4) % 
mtDNA 
deletion Size 
(kB) 
0.0032 
-0.18 
(-4.1, -0.8) 
%/kB 
 <0.0001 
-0.48 
(-0.99,-0.42) 
<0.0001 
+0.54 
(1.6, 3.2) kB 
0.0069 
+0.29 
(0.34, 2.0) 
kB 
mtDNA 
deletion 
midpoint 
(kB) 
0.1260 
+0.11 
(-0.67, 5.4) 
%/kB 
<0.0001 
-0.29 
(-0.62, -0.21) 
 <0.0001 
-0.73 
(-2.7,-1.8) 
kB 
<0.0001 
+0.46 
(0.72, 1.8) 
kB 
MT-CO gene 
deletion 
0.1262 
-0.11 
(-15, 1.9)% 
<0.0001 
+0.47 
(1.42, 2.48) 
kB 
<0.0001 
-0.72 
(-2.3, -1.7) kB 
 0.0180 
-0.28 
N/A 
MT-CYB gene 
deletion 
0.1625 
+0.10 
(-2.1, 13)% 
<0.0001 
+0.39 
(0.93, 1.89) 
kB 
<0.0001 
+0.55 
(1.1, 1.6) kB 
<0.0001 
-0.28 
N/A 
 
Table 5.2 Inter-correlations between putative predictors of disease burden and progression.  
Shaded cells (upper right triangle) show for our cohort p values, correlation coefficients, and 95% 
confidence intervals for linear regression gradient or estimated difference due to specific mtDNA gene 
deletion; unshaded cells (bottom left triangle) show the same for the meta-analysis. Units for 95% 
confidence intervals identify y and x for linear regression, except in the case of mtDNA deletion size (kB) 
vs. mtDNA deletion midpoint (kB). The strongest correlations in each dataset are between mtDNA 
deletion midpoint or size and MT-CO gene deletion; larger mtDNA deletions tend to include MT-CO 
genes. MT-CYB deletion is also associated with larger mtDNA deletion size and mtDNA deletions. The 
same trends are seen in all cases in our cohort and the meta-analysis, excepting that in our cohort MT-
CYB gene deletion is significantly associated with lower mtDNA heteroplasmy, whereas in the meta-
analysis there is a non-significant trend relating MT-CYB gene deletion with higher mtDNA heteroplasmy 
levels. 
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Figure 5.5 Heteroplasmy and deletion size are linearly correlated with age at onset and NMDAS 
score progression.  
For both graphs, mtDNA deletion size is dichotomous for visualization only; regression is performed with 
deletion size as a continuous predictor. (A) Age at onset is predicted by both mtDNA heteroplasmy and 
deletion size.  Y axis shows the square root of age at onset. Data is from the Newcastle cohort. N=60, 
R
2
=0.18. Both mtDNA heteroplasmy (p=0.0027) and deletion size (p=0.0039) are significantly correlated 
with age at onset using multiple regression. (B) NMDAS progression (scaled NMDAS points per year) is 
highly significantly correlated with both mtDNA deletion size (p < 0.0001) and heteroplasmy (p < 
0.0001). N=55, R
2
=0.49. Y axis shows scaled NMDAS score per year.  
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5.4.6. Disease burden and progression of patients with the 4,977bp common mtDNA 
deletion are correlated with heteroplasmy 
I also examined the cohort of patients whose mtDNA disease is associated with a 
common 4,977 bp single, large-scale mtDNA deletion (Schon et al., 1989).  For this 
analysis I combined both the Newcastle cohort and the meta-analysis, as neither cohort 
was large enough in isolation for analysis of the common deletion patients. I observed 
that SKM mtDNA heteroplasmy was a significant predictor of both clinical phenotype 
(N=85, OR for 10% change in heteroplasmy 1.43 95%CI (1.13, 1.81), p=0.0030) and 
also age of disease onset (N=37, r=-0.44, p=0.0063). 
5.4.7. COX deficient fibre density is dependent on muscle heteroplasmy and deletion 
location but not deletion size 
I next studied the relationship between the proportion of COX-deficient muscle fibres in 
patient biopsies, mtDNA heteroplasmy, and MT-CO gene deletion (namely, deletion of 
part or all of at least one of the MT-CO1, MT-CO2 or MT-CO3 genes). The square root 
of COX-deficient fibre density was used in all analyses, which was identified by Box-
Cox as the optimal transform. 
In the Newcastle cohort (N=72) I observed that both SKM mtDNA heteroplasmy 
(b=0.68, p<0.0001) and MT-CO gene deletion (b=0.31, p=0.0018) were significantly 
correlated with COX-deficient fibre density using multiple linear regression (R
2
=0.43) 
(Figure 5.6). Similarly, in the meta-analysis (N=39), both mtDNA heteroplasmy 
(b=0.49, p=0.0012) and MT-CO gene deletion (b=0.34, p=0.0192) were significantly 
correlated with COX-deficient fibre density (R
2
=0.31).  
In both the Newcastle cohort and the meta-analysis the inclusion of MT-CO genes 
within the deleted mtDNA region was significantly correlated with a larger mtDNA 
deletion size, as seen in section 5.4.4. Hence I chose to examine whether there was a 
correlation between mtDNA deletion size and COX-deficient fibre density.  For this I 
used multiple regression with all three predictors. In the Newcastle patient cohort 
(N=72), mtDNA deletion size (b=-0.081, p=0.5104) was not a significant predictor, 
although both mtDNA heteroplasmy (b=0.65, p<0.0001) and MT-CO gene deletion 
(b=0.35, p=0.0028) remained significant even with deletion size in the model (R
2
=0.44). 
Similarly, in the meta-analysis (N=39), mtDNA deletion size (b=-0.00010, p=0.5586) 
was not a significant predictor, however both mtDNA heteroplasmy (b=0.48, p=0.0016) 
and MT-CO gene deletion (b=0.43, p=0.0445) remained significant (R
2
=0.32). 
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Figure 5.6 COX-deficient fibre density is dependent on SKM mtDNA heteroplasmy and 
deletion of MT-CO genes. 
Y axis shows the square root of the COX-deficient fibre density %. Data are from the Newcastle cohort, 
N=72, R
2
=0.43. Heteroplasmy (p<0.0001) and deletion of MT-CO genes (p=0.0018) are both significant 
predictors. Separate regression lines are shown for those that delete or partially delete one or more MT-
CO genes (N=63, 95% confidence interval for regression line shown) and those that do not (N=9, gradient 
of regression line is not significantly non-zero, confidence interval not shown). 
5.4.8. Longitudinal mixed modelling shows that mtDNA heteroplasmy, mtDNA 
deletion size and location are predictors of disease progression 
Using longitudinal mixed modelling I found that muscle mtDNA heteroplasmy 
(p<0.0001) and mtDNA deletion size (p<0.0001) were both highly significantly 
correlated with NMDAS progression in our patient cohort (N=55) (Figure 5.7). The 
interaction between mtDNA deletion size and mtDNA heteroplasmy was also 
significant (p=0.0046), which is exemplified by comparing panels A to B, where 
mtDNA deletion size has a stronger effect at high mtDNA heteroplasmy levels than low 
mtDNA heteroplasmy levels, and C to E, where mtDNA heteroplasmy has a strong 
effect with large mtDNA deletions but negligible effect with small mtDNA deletions.   
The location of the mtDNA deletion within the mitochondrial genome was also shown 
to affect disease progression. With mtDNA heteroplasmy and mtDNA deletion size in 
the model, deletion of the MT-CYB gene is significantly predictive of faster progression 
(p=0.0085, N=52) (Figure 5.74F). 
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Figure 5.7 The effect of mtDNA deletion size and heteroplasmy on NMDAS progression. 
All panels show 95% confidence intervals. (A-B) The effect of mtDNA deletion size at 80% and 40% 
heteroplasmy respectively. Deletion size is shown to have a greater impact at high heteroplasmy than at 
low heteroplasmy. (C-E) The effect of mtDNA heteroplasmy for a 2.0kB, 5.0kB and 8.0kB mtDNA 
deletion respectively. For small deletions the effect of heteroplasmy on NMDAS progression is 
negligible, but for larger deletions the effect is substantial. (F) The effect of deletion location for a 5.0kB 
deletion present at 80% heteroplasmy; progression is faster when MT-CYB is included in the deleted 
region. Panels A-E are generated from a model using time, deletion size and heteroplasmy as predictors. 
The model used for Panel F has an additional deletion location predictor (MT-CYB gene inclusion). 
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5.4.9. Individual patient progression can be modelled longitudinally 
Mixed modelling allows incorporation of random effects to model unknown variance in 
a given system. Hence I was also able to use the clinical and molecular genetic data to 
model the progress of individual patients and predict the expected course of progression 
for their overall disease burden.  Progression graphs were produced for all patients; in 
Figure 5.8 I present the predicted progression for five individual patients. The model 
used to produce these graphs incorporated muscle mtDNA heteroplasmy, mtDNA 
deletion size, and deletion of the MT-CYB gene as predictive factors. Expected 
progression is shown with 95% prediction intervals. Patients 4 and 5 have similar 
heteroplasmy but different deletion sizes, and thus exemplify the effect of deletion size 
on disease progression. Patients 1 and 3, conversely, have similar sizes of deletion 
(6.9kb and 6.5kB respectively) but different heteroplasmy levels. Patient 2 demonstrates 
rapid progression, despite low heteroplasmy, on account of the exceptionally large 
deletion size (9.1kB mtDNA deletion). Patient 1 demonstrates that even a single 
NMDAS score can represent a useful prognostic input. 
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Figure 5.8 Longitudinal 
modelling of five 
individual patients with 
single, large-scale 
mtDNA deletion disease. 
The chosen patients are 
representative of the range 
of rates of disease 
progression found in our 
cohort. Actual NMDAS 
assessment scores are 
depicted as crosses joined 
by solid lines. Each 
patient is shown with their 
predicted progression 
trendline with 95% 
prediction intervals, and is 
labelled with deletion size 
and heteroplasmy. Only 
patient 2 includes part of 
the MT-CYB gene in their 
deletion. 
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5.4.10. Individual phenotypic features 
Using a model with age, muscle heteroplasmy, and deletion size as predictors, the area 
under the ROC (AUC) curve was calculated for each phenotypic feature at each 
dichotomous cut-off point that had at least 6 patients (10% of the cohort) in each group 
(below the cut-off point, and above or including the cut-off point). The AUCs for each 
cut-off point are shown in Figure 5.9. The higher the AUC the better the predictive 
power of the model. Steep gradients or inflections in the graphs indicate instability in 
the predictability of the features, i.e. prediction success is heavily dependent on where 
the cut-off is drawn. Cognitive impairment is notably poor at a cut-off of 2. Hearing is 
highly predictive at high cut-off points but poor at low cut-offs. 
Using the optimal cut-off for each NMDAS feature, models were generated with each 
combination of the three predictors of age, heteroplasmy, and deletion size. The results 
are shown in Figure 5.10. As seen in panel C, the combination of all three predictors 
was the optimal model in almost all cases, other than psychiatric and CPEO, where the 
addition of deletion size (psychiatric) or age (CPEO) into the model reduces the AUC 
slightly. Of the lone predictors, heteroplasmy is generally the most predictive, deletion 
size the least predictive. Age is highly predictive of several features, most noticeably 
neuropathy and migraine, as neither of the other two predictors contribute much to the 
AUC. The most highly predicted features were hearing, exercise tolerance, and ptosis, 
though speech, dressing, and visual acuity also achieved AUCs over 0.8. The lowest 
AUCs were observed in myopathy and psychiatric disturbance, though gait stability, 
cutting food, and handwriting are also noticeably poorly predicted. Migraine and 
psychiatric disturbance are the only features negatively associated with age. 
A second approach used the proportional-odds logistic regression with three levels 
(asymptomatic, mild/moderate, and severe), results are shown in Figure 5.11. Again, 
heteroplasmy appears to be generally the most valuable predictor, out of age, 
heteroplasmy, and deletion size, and is significantly associated with half of the 22 
features. Exercise tolerance is the most predictable feature, and all three predictors are 
statistically significant; the only other features significantly associated with all three 
predictors are ptosis and handwriting, though handwriting has a low pseudo-R
2
. 
Deletion size is a statistically significant predictor for 7 of 22 examined features, most 
notable exercise tolerance and cerebellar ataxia.  Hearing is noticeably poorly predicted 
in this model as compared to the dichotomous model. 
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Figure 5.9 Area under the ROC curve (AUC) for each phenotypic feature and various score cut-off points with all three predictors in the model (age, heteroplasmy, and 
deletion size). 
The cut-off score is used to divide the cohort into two groups; those scoring the cut-off or above versus those scoring below. For each feature, the cut-offs tested were those with a 
minimum of 6 patients (approximately 10% of the cohort) in each group. Exercise tolerance, dressing, hearing, visual acuity, dysphonia/dysarthria, cognition, and ptosis achieve an 
accuracy above 80% using the ROC curve, however most features achieve 70% accuracy for at least one cut-off point. Some features are poorly predicted at any cut-off, for instance 
psychiatric involvement, migraine, and myopathy, and several features from the current function assessment. Hearing is much more accurately predicted at higher levels of 
dysfunction, whilst exercise tolerance is fairly well predicted across the spectrum. 
Chapter 5 Disease progression in single large-scale mtDNA deletions 
165 
 
 
 
Figure 5.10 Standardised parameters and area under ROC curves (AUC) for each phenotypic 
feature from the NMDAS using age, urine heteroplasmy, and deletion size as predictors. 
(A) Optimal cut-off point for each NMDAS feature, by maximizing AUC for the model with all three 
predictors. Cohort is dichotomised into those scoring the cut-off or above against those scoring below the 
cut-off. (B) Standardised parameters with 95% confidence intervals for the binary logistic model using 
the optimal cut-off with all three predictors. Parameters are statistically significant if the confidence 
interval does not cross the line at Y = 1. (C) The AUC using the optimal cut-off for each lone predictor 
and combination of predictors. Nine features achieve an AUC over 0.8, indicating strong predictive 
power. In almost all cases the regression with all three predictors is optimal, though in CPEO and 
cognition age is not predictive. Deletion size is generally the weakest predictor, though age is noticeably 
poorer in predicting gait stability and myopathy. Age is the principal predictor of migraine and 
neuropathy, and noticeable predictive of vision, dressing, hygiene, GI disturbance, ptosis, and ataxia.  
Heteroplasmy is better than the other lone predictors for many features, and significantly predictive for 15 
out of 22 features. Migraine is the only feature that decreases in severity with age.  
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Appendix XV details the parameters required for risk calculation in the proportional-
odds, including intercepts, and Appendix VIII is an explanation of how to calculate the 
risk for a given age and heteroplasmy with these parameters. 
Models were also generated with a further predictor included in addition to age, 
heteroplasmy, and deletion size, indicating the presence or absence of specific genes in 
the deletion. Both MT-CYB and MT-CO genes were tested. Cerebellar ataxia was the 
only feature significantly predicted by MT-CYB gene inclusion (P = 0.0151). No 
features were significantly predicted by MT-CO gene inclusion. 
 
Figure 5.11 Pseudo-R
2
 and standardised parameters for the logistic modelling of individual 
phenotypic features. 
Logistic models include age, heteroplasmy, and deletion size as predictors. Pseudo-R
2
 indicates that 
exercise tolerance and ptosis are the most predictable features using this model. Standardised parameters 
are statistically significant if the 95% confidence interval does not cross zero. Deletion size is only 
statistically significant for exercise tolerance, ataxia, neuropathy, GI disturbance, and cognitive 
impairment. Heteroplasmy is in general the strongest predictor of the three and is significant for 11 of the 
22 features, including almost all of the current function assessment (section I). Cerebellar ataxia is the 
most predictable by age, indicating this is particularly progressive.    
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5.5. Discussion 
Single large-scale mtDNA deletions are a common cause of mitochondrial disease, and 
the challenges in understanding the progression of disease for these patients highlights 
many of the challenges observed with other mtDNA deletions. 
The significant finding of the work presented in this chapter is that SKM mtDNA 
heteroplasmy levels, mtDNA deletion size and mtDNA deletion location are all 
important in understanding the expression and progression of clinical disease in patients 
with single large-scale mtDNA deletions. 
Two major factors have helped to reach this understanding. The first is a validated 
rating scale that covers the major clinical features of mitochondrial disease, the 
NMDAS. This, as a quantitative measure of mitochondrial disease burden, permits the 
study of disease progression in a manner which was previously unfeasible. Though I 
have presented the correlation between traditional phenotypic classification and 
NMDAS scores in the Newcastle cohort, the difficultly in using a discrete phenotype 
classification is clearly apparent. Longitudinal modelling of successive NMDAS 
assessments for patients demonstrates the benefits of a quantitative approach. It also 
highlights the dynamic nature of the patient phenotype. 
The second major factor is the use of statistical techniques, including multiple 
regression analyses that I have applied to both the Newcastle cohort data and those 
previously published in the literature. This includes use of the Box-Cox transformation 
to identify optimal transformations to normality, which allows the use of more powerful 
parametric statistical tests where appropriate. Multiple regression, however, is of high 
valuable in this particular study; where there is inter-correlation between the predictive 
factors, such techniques are required to correctly identify significant findings.  
5.5.1. Predictability of disease progression 
The longitudinal modelling shows that disease burden and progression is predicted by 
muscle mtDNA heteroplasmy level, mtDNA deletion size and the location of the 
mtDNA deletion within the mitochondrial genome. These findings are supported by 
other findings from both the Newcastle cohort and the meta-analysis; both phenotype 
and age at onset are predicted by mtDNA deletion size and mtDNA heteroplasmy, and 
also heteroplasmy is a significant predictor of phenotype in the cohort of patients with 
the common 4,977bp mtDNA deletion. Previous studies have been contradictory 
regarding the utility of these factors as predictors. It has been reported that both 
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phenotype and age at onset were dependent on mtDNA deletion size, but not 
significantly related to mtDNA heteroplasmy (Yamashita et al., 2008), however it has 
also been shown that the clinical phenotype was related to mtDNA heteroplasmy, but 
unrelated to mtDNA deletion size (although age at onset was related to both factors) 
(López-Gallardo et al., 2009). In a study specifically addressing disease progression it 
was reported that SKM mtDNA heteroplasmy and mtDNA deletion size were not of 
utility in disease progression prediction (Auré et al., 2007). More seminal studies also 
reported inconsistently on the utility of these predictors in predicting phenotype or age 
at onset (Holt et al., 1989b; Moraes et al., 1989; Goto et al., 1990a). However, we 
found that multiple regression identifies consistent correlation between disease 
phenotype or progression and both mtDNA heteroplasmy and deletion size. 
Furthermore, multiple regression of previously published data is revealing; for example, 
whilst López-Gallardo and colleagues found that mtDNA deletion size is not predictive 
of phenotype (P = 0.3953), multiple regression with both deletion size and heteroplasmy 
shows that deletion size is indeed a significant predictor of phenotype (P = 0.0330); in 
this case, the negative correlation between heteroplasmy and deletion size leads to the 
masking of the effect of deletion size when simple linear regression is used.  
5.5.2. Inter-correlation of heteroplasmy, deletion size, and location 
The correlations observed between the predictive factors are themselves of interest. 
López-Gallardo and colleagues noted the negative correlation between muscle 
heteroplasmy levels and mtDNA deletion size (López-Gallardo et al., 2009). From this 
they surmised that shorter mtDNA deletions do not have a replicative advantage, since 
one would expect in this case large deletions to be found at higher heteroplasmy levels, 
not lower. However, I would speculate that the observed correlation between muscle 
mtDNA heteroplasmy and mtDNA deletion size is more likely a reflection of the 
spectrum of disease that presents with a clinically-recognisable phenotype within the 
population, and is not an outcome of an intrinsic biochemically driven relationship. This 
speculation is supported by the results presented here on disease progression; small 
mtDNA deletions at low heteroplasmy levels would not be expected to be pathogenic 
and therefore patients with such deletions would not present clinically with symptoms. 
This is also consistent with the observation that potentially pathogenic mtDNA 
mutations are widespread at sub-threshold levels in the non-diseased population (Elliott 
et al., 2008).  
5.5.3. Deletion location and pathogenicity 
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I have shown that deletions including all or part of the MT-CYB gene are associated 
with faster disease progression. This is consistent with the report by López-Gallardo et 
al. that deletion of the MT-CYB gene was linked to a more severe phenotype (López-
Gallardo et al., 2009). The reason for this remains uncertain, but could potentially 
indicate that complex III deficiency has a particularly important role in the disease 
mechanism. 
I also showed that MT-CO gene deletion (that is, deletion of part or all of any of MT-
CO1, MT-CO2 or MT-CO3) is predictive of COX-deficient fibre density. Though 
previous studies reported no such link (Goto et al., 1990a; Oldfors et al., 1992), using 
multiple regression to reanalyse these studies reveals the same trend in all cases, indeed 
at statistical significance when the study is large enough (Goto et al., 1990a).  
It has been widely accepted for some time that the root of the pathogenicity of mtDNA 
deletions is the deletion of mitochondrial tRNA (mt-tRNA) genes (Schon et al., 2012). 
This hypothesis is somewhat challenged by the results presented in this study, 
consequently I will discuss the studies which have contributed to this hypothesis and re-
evaluate them in the light of the current study. 
Mita et al. showed that COX deficiency in SKM fibres was associated with low level 
wild-type mtDNA and high levels deleted mtDNA, which is a non-contentious finding 
(Mita et al., 1989). They also found that the distribution of mRNA demonstrated that 
the deleted mtDNA species was undergoing transcription. However, although COX 
subunit IV (nuclear encoded) was present using immunocytochemistry, COX subunit II 
(mitochondrially encoded) was absent; this was despite the fact that COX subunit II was 
not part of the deleted region. This showed that a deletion could affect mitochondrially 
encoded translation products that were outside the deleted region. However, it should be 
noted that this study was on a single KSS patient. 
A study published the following year showed that deletion of a single tRNA gene could 
compromise mitochondrial protein translation (Nakase et al., 1990). Using cloned 
fibroblasts from two KSS patients with different deletions they showed that the mutant 
DNA was transcriptionally active and produced RNA species, though the fusion mRNA 
spanning the deleted region in each case was not translated. Their conclusion was that 
the biochemical defects were due to lack of translation of the mtDNA encoded proteins 
in mitochondria harbouring mutant mtDNA, most likely due to tRNA insufficiency. 
They concluded that the mutant DNA species must be segregated from the wild-type for 
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lack of complementation to occur (i.e. tRNA from the wild-type mtDNA supplementing 
the lack of tRNA from the deleted mtDNA species). 
Hayashi et al. (Hayashi et al., 1991) introduced deletions into HeLa cells, and found 
that below 60% heteroplasmy there was normal translation of proteins in mitochondria, 
but above this level mRNA levels mismatched protein levels and thus showed that 
translation was impaired. An interesting conclusion that can be drawn from this study is 
that there is functional complementation of mutant mtDNA by wild-type in the same 
mitochondrion, which contrasted with the conclusion of Nakase et al.; however, this 
complementation breaks down above approximately 60% heteroplasmy and overall 
translation is impaired. They suggested that the lack of complementation cited by 
Nakase et al. was most likely due to exceeding the threshold for normal translation, and 
competition for tRNA interfering with translation throughout the mitochondrion. This 
work was consistent with an earlier study by Shoubridge et al. that showed that deleted 
mtDNA species are functionally dominant over wild-type, since they accumulate in 
ragged red fibres and impair biochemical activity despite normal wild-type levels of 
mtDNA in these cells (Shoubridge et al., 1990).  
More recently this functional complementation has been confirmed by a study in which 
two cell lines, each with distinct and non-overlapping mtDNA deletions, were fused, 
and restoration of mitochondrial protein translation was demonstrated, despite the two 
mtDNA species existing in discrete nucleoids within the same mitochondrion 
(Gilkerson et al., 2008).   
In summary, the conclusion that pathogenicity is based on tRNA insufficiency is 
predicated on a lack of correlation between the quality (size and location) of the deletion 
and the resulting biochemical defect and clinical phenotype. However, in this study I 
have demonstrated that both the biochemical defect (COX deficiency) and the clinical 
phenotype (disease burden) are correlated with both deletion size and location, which is 
evidence that tRNA insufficiency is not entirely responsible for the pathogenicity of 
deletions. However, a more comprehensive data set would be required to elucidate the 
relative importance of mt-tRNA genes, specific oxidative phosphorylation protein 
genes, and other potential pathogenic mechanisms as regards biochemical defects and 
the resulting clinical phenotype.  
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5.5.4. Pathogenic threshold level 
An important implication of this study regards is that threshold level for pathogenicity 
of a mtDNA deletion (Rossignol et al., 2003). Since the biochemical defect and the 
resulting clinical phenotype are dependent on the deletion size and location, the 
threshold for phenotypic expression at the cellular level would be expected to be 
dependent on the location and size of the deletion.  
5.5.5. Specific phenotypic features 
It has been shown that many individual phenotypic features are predictable by either 
age, heteroplasmy, or deletion size, or some combination of these factors. Exercise 
tolerance and ptosis are notably predictable, and this is not unexpected since 
neuromuscular features are prominent in disease associated with single large-scale 
mtDNA deletions. There are several other features that are strongly predictable, for 
instance dysphonia/dysarthria, which is a noted feature of single deletion disease (Auré 
et al., 2007), cerebellar ataxia, and cognitive impairment.  
Though most features demonstrated similar outcomes in the two approaches to logistic 
modelling (binary and multi-level proportional odds), hearing is noticeably different in 
the two, predicted by the dichotomous model but not by the multi-level model. 
However, as was noted in Figure 5.9, hearing is not predicted well when looking at low 
cut-off points in the NMDAS score, and significant effects of the predictors may only 
be apparent at higher levels of impairment.    
Hearing is also interesting from another perspective, in that the improvement seen in 
moving from a single- or two-predictor model to a model with all three predictors is 
very large; in particular, adding age into the model with heteroplasmy and deletion size 
improves the AUC from 0.7 to over 0.85. This is a strong reinforcement of the necessity 
for multiple regression techniques.  
CPEO is a second feature that was not well predicted by the multi-level model but that 
is reasonably predicted by the dichotomous model; the reason for this is found in the 
optimal cut-off score for CPEO of 5, which is more or less the only level between which 
prediction can be made for CPEO. However, both 4 and 5 scores are grouped together 
in the multi-level model. This emphasises the importance of thorough analysis of data 
from a number of perspectives, and also highlights the importance of optimising the 
analysis on question by question basis. CPEO is also curious in that heteroplasmy alone 
is almost entirely responsible for the prediction of this feature; age and deletion size are 
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not contributory. In this CPEO stands out from the other features. This is surprising, 
since the very nature of CPEO is progressive, and thus association with age should be 
expected. However, this finding may be related to the rating scale itself; CPEO is a 
ubiquitous feature of single large-scale mtDNA deletions, and over 50% of the cohort 
score maximally on this feature, suggesting that if CPEO continues to be progressive for 
these patients the severity range is inadequate for this group. 
Age appears to be almost the sole contributor to vision decline (from the current 
function part of the NMDAS), psychiatric disturbance, and migraine, suggesting that 
these features may be more related to general ageing than factors due to mtDNA 
deletion. Indeed all of these features are indeed common in the general population and 
associated with ageing. Interestingly migraine is the only NDMAS feature to 
significantly decrease with age, and this reflects the reported pattern in the general 
population (Dahlof et al., 2009). Psychiatric disturbance is the only other feature to be 
negatively associated with age; again, this is the reported trend in the population (Jorm, 
2000). 
Heteroplasmy and age are shown to be reasonably consistent predictors of most 
phenotypic features, however deletion size is generally less effective and less consistent. 
This has already been seen in the longitudinal modelling, but it is assuring to see the 
same pattern at the level of the individual phenotypic features. That deletion size is 
predictive but secondary to heteroplasmy and age for many phenotypic features does 
suggest that the pathogenic nature of the deletions may be to a large extent deletion-size 
independent, and may be due the effect of tRNA gene deletion. However, the growing 
understanding of the role of supercomplexes (Vartak et al., 2013) suggests a second 
pathway by which a deletion of any of the OXPHOS genes may affect the structural 
integrity and function of other complexes further up or down the respiratory chain. 
The location of the deletion did not prove to be a significant predictor of any phenotypic 
features excepting cerebellar ataxia. Interpretation of this finding as statistically 
significant would be naïve, and no firm conclusions can be drawn from this. However, 
the lack of significant association is not of great concern; the dataset used for these 
analyses is summary, containing only a single predictive point per patient; with 
heteroplasmy, age, and deletion size in the model already it is no great surprise that the 
model lacks statistical power to expose any significant relationships between deleted 
genes and phenotypic features. This is an important area for future research with a 
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larger dataset however; though the study on total disease burden is informative 
regarding the pathology of the mtDNA deletions, characterising and understanding 
association between specific phenotypic features and the properties of the deletion 
would be fascinating indeed. 
Though I have not displayed any graphical risk profiles of the individual feature 
modelling, the purpose of this section has not been to present the model outputs but to 
discuss the utility of the various predictors for understanding phenotypic feature 
development. However, the modelling of m.3243A>G did present models for several 
features, and the model outputs for this section would be similar in form. All models 
from this section of work will be available at https://research.ncl.ac.uk/mitoresearch as 
an aid to understanding the outcomes of this work.  
5.5.6. Limitations and future work 
Although this study provide new insights into disease progression in patients with 
single, large-scale mtDNA deletions, much further work is still required.  
Firstly, both mtDNA deletion size and the location parameter used in the longitudinal 
modelling (MT-CYB gene deletion) are perhaps merely proxies for the underlying 
pathogenic nature of the mtDNA deletion. A more nuanced characterization of these 
mtDNA deletions may better predict pathogenesis and mitochondrial disease 
progression. It is unclear, for instance, why MT-CO gene deletion is associated with 
more severe COX deficiency in cells but it does not have a clear modulatory effect on 
overall disease progression. However, expanding the model to characterise the deletions 
more fully would potentially involve a large number of parameters, in which case a 
larger dataset would be required to achieve reasonable statistical power.   
Secondly, it is notable that we do not have any predictor that encapsulates the 
sometimes multi-system nature of disease. In this regard, Auré et al. found that the 
presence of the mutation in blood was predictive of a neurological phenotype (Auré et 
al., 2007), and a similar trend in urine, a result confirmed by Blackwood et al. with 
regard to severe early-onset disease as compared to milder phenotypic presentation 
(Blackwood et al., 2010). These reports suggest that blood or urine mtDNA 
heteroplasmy levels, in tandem with SKM mtDNA heteroplasmy, may lead to an 
improved prediction of disease prognosis. For this to be included in the model blood or 
urine samples will need to be collected for the patients included in the model, but these 
are not available for the Newcastle patient cohort at the current time.  
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Thirdly, the impact of other mitochondrial DNA rearrangements has not been 
considered in this study, for instance duplications (Poulton et al., 1989). However, it is 
not generally thought that duplications have a pathogenic effect. 
Fourthly, though most of the findings from our cohort are corroborated by the meta-
analysis, there are differences in the datasets, and in particular the correlations between 
predictors are on the whole stronger in the Newcastle cohort than in the meta-analysis. 
These differences may arise in part from the fact that the data from the Newcastle 
cohort are more homogeneous, but also because the makeup of this cohort is somewhat 
different; there are relatively few patients with the KSS phenotype as compared to the 
meta-analysis.  
Finally, though I do not use Bonferroni adjustment in the analyses for reasons well 
documented in the literature (particularly where a priori hypotheses are under test) 
(Thomas, 1998), the large number of statistical tests employed do open up the potential 
for more frequent type I statistical errors. However, consistent findings in both the 
Newcastle cohort and the meta-analysis provide support for firm conclusions to be 
drawn. Multiple testing is particularly relevant in the section on the prediction of 
specific phenotypic features. However, though caution must be taken in interpretation of 
statistical significance, the analytical techniques employed remain valid. 
5.5.7. Web tool 
The finding that deletion size, heteroplasmy, and deletion location are predictors of 
disease progression is important for all clinicians looking after patients with single, 
large-scale mtDNA deletions. A web based tool is therefore under development 
(https://research.ncl.ac.uk/mitoresearch) to support clinicians in their management of 
these patients. This tool currently uses the predictive longitudinal model detailed in this 
chapter to provide progression graphs, but is intended to also provide individual 
phenotypic feature risk profiles. 
5.5.8. Conclusion 
I have demonstrated that muscle heteroplasmy, deletion size and deletion location are 
predictive of disease severity and progression in single large-scale mtDNA deletions. 
Using these predictors together with the NMDAS, a quantitative measure of total 
disease burden, longitudinal modelling of disease progression can be performed both at 
a population level and for individual patients, as well as calculation of risk of 
developing specific phenotypic features. The end result is that advice and care plans for 
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patients can be given on an individual basis, and discussions about the expected course 
of their disease burden can be provided.  
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 Discussion Chapter 6.
The principal aim of these studies has been to further understanding of the nature and 
progression of mtDNA disease. Despite the fact that the first mtDNA mutations were 
described over twenty five years ago (Holt et al., 1988), this remains challenging.   
There are several areas in which these studies have presented novel data and 
significantly progressed knowledge of disease progression in mtDNA disease. The 
study on m.3243A>G has expanded the current understanding regarding the predictive 
nature of disease associated with the mutation, both in terms of overall disease burden 
and also specific phenotypic features; it has provided new understanding of the dynamic 
(or not so dynamic) nature of heteroplasmy in various tissues of patients with the 
m.3243A>G mutation; it has generated several observations on sex differences in 
disease phenotype and heteroplasmy; it has presented novel data on the altered live-birth 
sex ratio; and it has shown that blood may be a more appropriate source of 
heteroplasmy than urine for use as a prognostic measure, in contradiction to long 
standing belief. Regarding single large-scale mtDNA deletions, there are several novel 
observations on stronger than previously understood connections between the genetic, 
biochemical, and clinical phenotype that shed new light on the pathology of large scale 
mtDNA deletions; and, as for m.3243A>G, the disease modelling provide useful 
prognostic data for clinicians in the care and management of patients. 
These studies have convincingly demonstrated the importance of simultaneous 
consideration of multiple factors when trying to understand the link between genotype 
and phenotype in mitochondrial disease, due to population level inter-correlation of all 
the predictive factors including age, heteroplasmy, and in the single large-scale 
deletions, deletion size and location. Without proper consideration of these relationships 
either true relationships between putative predictive factors and disease burden and 
progression are obscured, or false causal relationships are suggested. 
They have also clearly demonstrated the utility of the NMDAS as a tool for recording 
and understanding disease burden and progression in mitochondrial disease. This 
clinical tool has enabled the development of the prognostic models for overall disease 
burden and individual phenotypic feature progression, which are valuable tools for 
clinicians in the care and management of patients. 
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There are numerous avenues to explore in progressing the work begun in this thesis. 
Both in m.3243A>G and single large-scale mtDNA deletions factors to improve the 
prediction models have been identified, whether mtDNA copy number, alternative 
sources of heteroplasmy data, or investigations into the wider genetics and biochemical 
activity of the cells in mtDNA disease patients, for instance the role of tRNA 
synthetases. In particular, the limitations of heteroplasmy as a predictor of disease 
burden and progression in m.3243A>G have been clearly demonstrated, and improving 
on this prognostic ability is a critically important area for future research. The 
limitations of urine heteroplasmy in particular as a prognostic device have been clearly 
demonstrated, and the analysis strongly suggests that though urine has good properties 
for diagnostic identification of the presence of the m.3243A>G mutation, it performs 
poorly as an indicator of average heteroplasmy for a patient, and the existing 
recommendations for its use in this manner should be reviewed. The dynamism of 
heteroplasmy, particularly in patients with the m.3243A>G mutation, is also a rich area 
for exploration. 
The scope for further research is much wider however. This study has considered only 
two of the most common of the large number of mtDNA mutations, and the scope of 
mitochondrial disease is far wider indeed than even these, encompassing a huge number 
of nDNA mutations. Extending the techniques and understanding gained in these 
mutations to a wider array of genetic defects will be important future work.  
The models developed here are open for a great deal of further development. For 
instance, the logistic regression models presented are only analyses of the prevalence of 
each feature within the population of patients with the respective mutations; though this 
is an important characterisation of the phenotypic presentation of m.3243A>G and 
single large-scale mtDNA deletion disease, from the perspective of clinical care it is 
imperative to develop models to predict their expected progression of specific 
phenotypic features for individual patients, in a similar manner to the models provided 
for overall disease burden, by incorporating random effects and repeated measures 
analysis. This is important future work to be conducted on these cohorts of patients.  
A final important consequence of this modelling is that it has a very practical use as a 
baseline from which to measure the effectiveness of any future treatments for 
mitochondrial disease. Without a thorough understanding of the expected progression of 
disease then interventions cannot be confidently assesses for efficacy. 
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In conclusion, much progress has been made in understanding disease progression in 
patients with the m.3243A>G mutation and single large-scale mtDNA deletions, but 
much progress remains to be made, not only in these particular mutations, but in 
mitochondrial disease in general. 
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Appendix I The NMDAS Assessment. 
 
THE NEWCASTLE 
MITOCHONDRIAL DISEASE ADULT SCALE 
(NMDAS) 
Name: ________________ 
Date of birth: ________________ 
Date of assessment: ________________ 
Height: ____________ 
FVC - 1st attempt ____________ 
FVC - 2nd attempt ____________ 
FVC - 3rd attempt ____________ 
 
Section I- Current Function 
 
Rate function over the preceding 4 week period, according to patient and/or 
caregiver interview only. The clinician’s subjective judgement of functional ability 
should not be taken into account. 
 
1. Vision with usual glasses or contact lenses 
0. Normal. 
1. No functional impairment but aware of worsened acuities. 
2. Mild - difficulty with small print or text on television. 
3. Moderate - difficulty outside the home (eg bus numbers, road signs or shopping). 
4. Severe - difficulty recognising faces. 
5. Unable to navigate without help (eg carer, dog, cane). 
 
2. Hearing with or without hearing aid 
0. Normal. 
1. No communication problems but aware of tinnitus or deterioration from prior 
‘normal’ hearing. 
2. Mild deafness (eg missing words in presence of background noise). Fully corrected 
with hearing aid. 
3. Moderate deafness (eg regularly requiring repetition). Not fully corrected with 
hearing aid. 
4. Severe deafness - poor hearing even with aid (see 3 above). 
5. End stage - virtually no hearing despite aid. Relies heavily on non-verbal 
communication (eg lip reading) or has cochlear implant. 
 
3. Speech 
0. Normal. 
1. Communication unaffected but patient or others aware of changes in speech patterns 
or quality. 
2. Mild difficulties - usually understood and rarely asked to repeat things. 
3. Moderate difficulties - poorly understood by strangers and frequently asked to repeat 
things. 
4. Severe difficulties - poorly understood by family or friends. 
5. Not understood by family or friends. Requires communication aid. 
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4. Swallowing 
0. Normal. 
1. Mild - sensation of solids ‘sticking’ (occasional). 
2. Sensation of solids ‘sticking’ (most meals) or need to modify diet (eg avoidance of 
steak/salad). 
3. Difficulty swallowing solids - affecting meal size or duration. Coughing, choking or 
nasal regurgitation infrequent (1 to 4 times per month) but more than peers. 
4. Requires adapted diet - regular coughing, choking, or nasal regurgitation (more than 
once per week). 
5. Requiring enteral feeding (eg PEG). 
 
5. Handwriting 
0. Normal. 
1. Writing speed unaffected but aware of increasing untidiness. 
2. Mild – Has to write slower to maintain tidiness/legibility. 
3. Moderate – Handwriting takes at least twice as long or resorts to printing (must 
previously have used joined writing). 
4. Severe – Handwriting mostly illegible. Printing very slow and untidy (eg ‘THE 
BLACK CAT’ takes in excess of 30 seconds). 
5. Unable to write. No legible words. 
 
6. Cutting food and handling utensils (irrespective of contributory factors – eg 
weakness, coordination, cognitive function etc. This is also true for questions 7-10) 
0. Normal. 
1. Slightly slow and/or clumsy but minimal effect on meal duration. 
2. Slow and/or clumsy with extended meal duration, but no help required. 
3. Difficulty cutting up food and inaccuracy of transfer pronounced. Can manage alone 
but avoids problem foods (eg peas) or carer typically offers minor assistance (eg cutting 
up steak). 
4. Unable to cut up food. Can pass food to mouth with great effort or inaccuracy. 
Resultant intake minimal. Requires major assistance. 
5. Needs to be fed. 
 
7. Dressing 
0. Normal. 
1. Occasional difficulties (eg shoe laces, buttons etc) but no real impact on time or effort 
taken to dress. 
2. Mild – Dressing takes longer and requires more effort than expected at the patient’s 
age. No help required. 
3. Moderate - Can dress unaided but takes at least twice as long and is a major effort. 
Carer typically helps with difficult tasks such as shoe laces or buttons. 
4. Severe – Unable to dress without help but some tasks completed unaided. 
5. Needs to be dressed. 
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8. Hygiene 
0. Normal. 
1. Occasional difficulties only but no real impact on time or effort required. 
2. Mild – hygienic care takes longer but quality unaffected. 
3. Moderate - bathes and showers alone with difficulty or needs bath chair / 
modifications. Dextrous tasks (eg brushing teeth, combing hair) performed poorly. 
4. Severe - unable to bathe or shower without help. Major difficulty using toilet alone. 
Dextrous tasks require help. 
5. Dependent upon carers to wash, bathe, and toilet. 
 
9. Exercise Tolerance 
0. Normal. 
1. Unlimited on flat - symptomatic on inclines or stairs. 
2. Able to walk < 1000m on the flat. Restricted on inclines or stairs - rest needed after 1 
flight (12 steps). 
3. Able to walk < 500m on the flat. Rest needed after 8 steps on stairs. 
4. Able to walk < 100m on the flat. Rest needed after 4 steps on stairs. 
5. Able to walk < 25m on the flat. Unable to do stairs alone. 
 
10. Gait stability 
0. Normal. 
1. Normal gait - occasional difficulties on turns, uneven ground, or if required to 
balance on narrow base. 
2. Gait reasonably steady. Aware of impaired balance. Occasionally off balance when 
walking. 
3. Unsteady gait. Always off balance when walking. Occasional falls. Gait steady with 
support of stick or person. 
4. Gait grossly unsteady without support. High likelihood of falls. Can only walk short 
distances (< 10m) without support. 
5. Unable to walk without support. Falls on standing. 
 
Section II – System Specific Involvement 
 
Rate function according to patient and/or caregiver interview and consultation with the 
medical notes. Each inquiry should take into account the situation for the preceding 12 
month period only, unless otherwise stated in the question. 
 
1. Psychiatric 
0. None. 
1. Mild & transient (eg reactive depression) - lasting less than 3 months. 
2. Mild & persistent (lasting more than 3 months) or recurrent. Patient has consulted 
GP. 
3. Moderate & warranting specialist treatment (e.g. from a psychiatrist) - eg. bipolar 
disorder or depression with vegetative symptoms (insomnia, anorexia, abulia etc). 
4. Severe (eg self harm - psychosis etc). 
5. Institutionalised or suicide attempt. 
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2. Migraine Headaches During the last 3 months, how many days have headaches 
prevented the patient from functioning normally at school, work, or in the home? 
0. No past history. 
1. Asymptomatic but past history of migraines. 
2. One day per month. 
3. Two days per month. 
4. Three days per month. 
5. Four days per month or more. 
 
3. Seizures 
0. No past history. 
1. Asymptomatic but past history of epilepsy. 
2. Myoclonic or simple partial seizures only. 
3. Multiple absence, complex partial, or myoclonic seizures affecting function or single 
generalised seizure. 
4. Multiple generalised seizures. 
5. Status epilepticus. 
 
4. Stroke-like episodes (exclude focal deficits felt to be of vascular aetiology) 
0. None. 
1. Transient focal sensory symptoms only (less than 24 hours). 
2. Transient focal motor symptoms only (less than 24 hours). 
3. Single stroke-like episode affecting one hemisphere (more than 24 hours). 
4. Single stroke-like episode affecting both hemispheres (more than 24 hours). 
5. Multiple stroke-like episodes (more than 24 hours each). 
 
5. Encephalopathic Episodes 
0. No past history. 
1. Asymptomatic but past history of encephalopathy. 
2. Mild - single episode of personality or behavioural change but retaining orientation in 
time/place/person. 
3. Moderate - single episode of confusion or disorientation in time, place or person. 
4. Severe – multiple moderate episodes (as above) or emergency hospital admission due 
to encephalopathy without associated seizures or stroke-like episodes. 
5. Very severe - in association with seizures, strokes or gross lactic acidaemia. 
 
6. Gastro-intestinal symptoms 
0. None. 
1. Mild constipation only or past history of bowel resection for dysmotility. 
2. Occasional symptoms of ‘irritable bowel’ (pain, bloating or diarrhoea) with long 
spells of normality. 
3. Frequent symptoms (as above) most weeks or severe constipation with bowels open 
less than once/week or need for daily medications. 
4. Dysmotility requiring admission or persistent and/or recurrent 
anorexia/vomiting/weight loss. 
5. Surgical procedures or resections for gastrointestinal dysmotility. 
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7. Diabetes mellitus 
0. None. 
1. Past history of gestational diabetes or transient glucose intolerance related to 
intercurrent illness. 
2. Impaired glucose tolerance (in absence of intercurrent illness). 
3. NIDDM (diet). 
4. NIDDM (tablets). 
5. DM requiring insulin (irrespective of treatment at onset). 
 
8. Respiratory muscle weakness 
0. FVC normal (≥ 85% predicted). 
1. FVC < 85% predicted. 
2. FVC < 75% predicted. 
3. FVC < 65% predicted. 
4. FVC < 55% predicted. 
5. FVC < 45% predicted or ventilatory support for over 6 hours per 24 hr period (not 
for OSA alone). 
 
9. Cardiovascular system 
0. None. 
1. Asymptomatic ECG change. 
2. Asymptomatic LVH on echo or non-sustained brady/tachyarrhythmia on ECG. 
3. Sustained or symptomatic arrhythmia, LVH or cardiomyopathy. Dilated chambers 
or reduced function on echo. Mobitz II AV block or greater. 
4. Requires pacemaker, defibrillator, arrhythmia ablation, or LVEF < 35% on 
echocardiogram. 
5. Symptoms of left ventricular failure with clinical and/or x-ray evidence of pulmonary 
oedema or LVEF < 30% on echocardiogram. 
 
Section III – Current Clinical Assessment 
 
Rate current status according to examination performed at the time of assessment 
 
1. Visual acuity with usual glasses, contact lenses or pinhole. 
0. CSD ≤ 12 (ie normal vision - 6/6, 6/6 or better). 
1. CSD ≤ 18 (eg 6/9, 6/9). 
2. CSD ≤ 36 (eg 6/12, 6/24). 
3. CSD ≤ 60 (eg 6/24, 6/36). 
4. CSD ≤ 96 (eg 6/60, 6/36). 
5. CSD ≥ 120 (eg 6/60, 6/60 or worse). 
 
2. Ptosis 
0. None. 
1. Mild ptosis - not obscuring either pupil. 
2. Unilateral ptosis obscuring < 1/3 of pupil. 
3. Bilateral ptosis obscuring < 1/3 or unilateral ptosis obscuring > 1/3 of pupil or prior 
unilateral surgery. 
4. Bilateral ptosis obscuring > 1/3 of pupils or prior bilateral surgery. 
5. Bilateral ptosis obscuring >2/3 of pupils or >1/3 of pupils despite prior bilateral 
surgery. 
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3. Chronic Progressive External Ophthalmoplegia 
0. None. 
1. Some restriction of eye movement (any direction). Abduction complete. 
2. Abduction of worst eye incomplete. 
3. Abduction of worst eye below 60% of normal. 
4. Abduction of worst eye below 30% of normal. 
5. Abduction of worst eye minimal (flicker). 
 
4. Dysphonia/Dysarthria 
0. None. 
1. Minimal - noted on examination only. 
2. Mild – clear impairment but easily understood. 
3. Moderate – some words poorly understood and infrequent repetition needed. 
4. Severe – many words poorly understood and frequent repetition needed. 
5. Not understood. Requires communication aid. 
 
5. Myopathy 
0. Normal. 
1. Minimal reduction in hip flexion and/or shoulder abduction only (eg MRC 4+/5). 
2. Mild but clear proximal weakness in hip flexion and shoulder abduction (MRC 4/5). 
Minimal weakness in elbow flexion and knee extension (MRC 4+/5 - both examined 
with joint at 90 degrees). 
3. Moderate proximal weakness including elbow flexion & knee extension (MRC 4/5 or 
4 -/5) or difficulty rising from a 90 degree squat. 
4. Waddling gait. Unable to rise from a 90 degree squat (=a chair) unaided. 
5. Wheelchair dependent primarily due to proximal weakness. 
 
6. Cerebellar ataxia 
0. None. 
1. Normal gait but hesitant heel-toe. 
2. Gait reasonably steady. Unable to maintain heel-toe walking or mild UL dysmetria. 
3. Ataxic gait (but walks unaided) or UL intention tremor & past-pointing. Unable to 
walk heel-toe – falls immediately. 
4. Severe - gait grossly unsteady without support or UL ataxia sufficient to affect 
feeding. 
5. Wheelchair dependent primarily due to ataxia or UL ataxia prevents feeding. 
 
7. Neuropathy 
0. None. 
1. Subtle sensory symptoms or areflexia. 
2. Sensory impairment only (eg glove & stocking sensory loss). 
3. Motor impairment (distal weakness) or sensory ataxia. 
4. Sensory ataxia or motor effects severely limit ambulation. 
5. Wheelchair bound primarily due to sensory ataxia or neurogenic weakness. 
 
8. Pyramidal Involvement 
0. None. 
1. Focal or generalised increase in tone or reflexes only. 
2. Mild focal weakness, sensory loss or fine motor impairment (eg cortical hand). 
3. Moderate hemiplegia allowing unaided ambulation or dense UL monoplegia. 
4. Severe hemiplegia allowing ambulation with aids or moderate tetraplegia (ambulant). 
5. Wheelchair dependant primarily due to hemiplegia or tetraplegia. 
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9. Extrapyramidal 
0. Normal. 
1. Mild and unilateral. Not disabling (H&Y stage 1). 
2. Mild and bilateral. Minimal disability. Gait affected (H&Y stage 2). 
3. Moderate. Significant slowing of body movements (H&Y stage 3) 
4. Severe. Rigidity and bradykinesia. Unable to live alone. Can walk to limited extent 
(H&Y stage 4). 
5. Cannot walk or stand unaided. Requires constant nursing care (H&Y stage 5). 
 
10. Cognition 
Patients undergo testing using WTAR, Symbol Search and Speed of Comprehension 
Test. 
0. Combined centiles 100 or more. 
1. Combined centiles 60 - 99 
2. Combined centiles 30 - 59 
3. Combined centiles 15 - 29 
4. Combined centiles 5 - 14 
5. Combined centiles 4 or below. 
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Appendix II Matlab resampling code. 
function [ stats answers] = Do_Resample( no_resamples, data, 
nColsToUse, nRepsToUse, dopower, drawfigs, remove_outliers, 
ratio_check) 
%work out dimensions. each column is a single GROUP containing 
replicates 
nCols = size(data,2); 
nReps = size(data,1); 
nSets = size(data,3); 
%Don't use remove outliers anymore! Remove them before calling. 
removed = 0; 
ratio = 0; 
n = 0; 
if remove_outliers == 1, 
%Work out the acceptable limits for the data. The output of this 
is the limits variable 
  
std_dev_before = 0; 
std_dev_after = 0; 
[data removed ratio] = remove_outliers_using_iqr_1(data); 
end 
     
number_of_vals = sum(isnan(data(:))); 
fprintf('%d of %d reps, %d of %d groups, %d points total, %d outliers 
removed\n', nRepsToUse, nReps, nColsToUse, nCols, 
nColsToUse*nRepsToUse, removed); 
stats = []; %3 rows, for each of the above estimate 
samples = zeros(2,no_resamples);%we just record the differences 
  
if drawfigs==1, 
       figure; 
       hist(data(:,:,1)); 
end 
     
%Note - this actual answer is calculated from the values we supply, 
but really we should be using the answer calculated from ALL the 
values. So be careful about requesting ratio_check. 
actual_answer =  nanmean(nanmean(data(:,:,1))); 
answers = zeros(1,no_resamples); 
for rs = 1:no_resamples; 
        actualSet = randi(nSets, 1, 1); 
        %Do it col by col, so that we can remove  
        actualCols = randi(nCols,1,nColsToUse); %Multiple columns for 
the group dist 
        actualReps = randi(nReps,1,nRepsToUse); %Some of the summaries 
use the actual reps 
        vals = data(actualReps,actualCols,actualSet); %Both cols 
        if ratio_check==1, 
           vals = vals - actual_answer; %subtract the true ratio, so 
that we are comparing relatively  
        end 
         
        switch dopower, 
            case 1, 
            vals = 10.^vals; 
            case 2, 
            vals = 1-10.^vals; 
            case 3, 
            vals = 10.^(vals+2); %This is for the B2M MT-ND1 assay 
that is 100 fold different. 
            case 4, 
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            vals = vals+2; %This is for the B2M MT-ND1 assay that is 
100 fold different, looking at logs. 
        end 
         
%The groups are arranged in cols, so we need to take the mean of each 
col and then look at std. 
        samples(1,rs) = nanstd(nanmean(vals,1)); %rawgroup 
        samples(2,rs) = nanmean(nanstd(vals)); %rep 
        samples(4,rs) = nanmean(nanmean(vals,2)); %actual value. 
        answers(rs) = samples(4,rs); 
    end 
    
%For the overall variance, this is tricky... Samples4 contains the 
actual values we come out with each time. 
%We need to look at the variance within this. So we actually need to 
resample the resamples.... to get a variance for these 
    x = samples(4,:); 
    no_x = size(x,2); 
    %just do 1000 for this 
    overall_std = zeros(1,1000); 
    for i = 1:1000, 
        overall_std(1,i) = nanstd(x(randi(no_x,1,no_x))); 
    end 
     
    if no_resamples == 1, 
%If we are just doing one resample, we pass back all the values as the 
answer 
        answers = vals'; 
    else 
samples(3,:) = abs(sqrt(samples(1,:).^2 - 
samples(2,:).^2/nRepsToUse)); %this is the adjusted VARIANCE, which 
measures the GROUP. We need to take the square root to get the final 
answer. 
        stats(1,1:4) = calculate_rep_group_stats(samples(2,:), 
nRepsToUse); %rep variance 
        stats(1,5:8) = calculate_rep_group_stats(samples(3,:), 
nColsToUse); %group variance 
        stats(1,9:12) = calculate_rep_group_stats(samples(4,:), 0); 
%actual values 
        stats(1,13:16) = calculate_rep_group_stats(overall_std, 0); 
%overall variance 
        stats(1,17) = removed; 
        stats(1,18) = ratio(1,:); %Note - this takes the ratio of the 
front page of data. The second should be zeros anyway... 
        stats(1,19) = nReps - number_of_vals; %This will give is 
number of rows minus any NaNs that we have removed, so how many good 
vals we have. 
    end 
function output = remove_outliers_using_iqr(data) 
%Removes outliers using a threshold level that detects changes to the 
%standard deviation above and beyond acceptable limits 
sz = size(data,1); 
mul = 2; 
prcs = prctile(data, [25 75]); 
iqr = prcs(2) - prcs(1); 
lims = [(prcs(1) - iqr*mul) (prcs(2) + iqr*mul)]; 
sum(data < lims(1) | data > lims(2)) 
data(data < lims(1) | data > lims(2)) = NaN; 
output = data; 
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Appendix III m.3243A>G Heteroplasmy data, with sequential measurements. 
For each patient, the table lists the heteroplasmy data available and the age at sample. The age column 
records the age of the first sample, and age diff records the time in years between two samples(where two 
samples are available). A blank age diff implies only one sample is available; 0 implies repeated samples 
taken very close together in time. The number of NMDAS assessments for each patient is also shown. 
 Urine Heteroplasmy Blood Heteroplasmy Muscle Heteroplasmy  
ID Age Age 
Diff 
Het 
First 
Het 
Last 
Age Age 
Diff 
Het 
First 
Het 
Last 
Age Age 
Diff 
Het 
First 
Het 
Last 
No. 
NMDAS 
1 34.8 10.8 35 32 34.8 9.8 6 7 45.6   52   11 
2 46.2 10.5 93 66 52.9 3.8 20 19         6 
3 37.8 10.1 29 15 37.1 10.8 18.5 13         3 
4 62.9 9.4 49 49 72.3  10      12 
5 29.5 9 80 88 36.9   26   34.1 4.1 67 91 7 
6 50.7 8.8 74 67     54.9 0.2 62 64 14 
7 47.1 8.8 54 48 55.9  5  47.1  53  9 
8 44.4 8.4 8 11 44.4 10.3 2 2 44.4   11   10 
9 17.8 8.4 65 32 17.8 8.4 8 13     2 
10 51.3 8.1 42 59 50.4 6.3 8 6         12 
11 30.7 7.9 62 89 30.7 7.7 15 19 30.5   67   5 
12 37.1 7.9 72 60 37.1   14   41.9   69   3 
13 52.5 7.9 52 44 60  13      11 
14 50.8 7.8 20 33 50.8   9   54.7 4 60 62 3 
15 41 7.6 82 56                 9 
16 21.2 7.5 77 68 21.2 7.5 64 53     13 
17 42.4 7.5 82 87 42.4  28  46.2  26  7 
18 16 7 73 73 16 7 48 48     5 
19 40.1 6.9 75 79 46.1 3.3 12 11 40.3   57   6 
20 39.2 6.9 50 61 46.2  13      9 
21 46.8 6.7 23 22 44.3 8.8 9 11         4 
22 65.3 6.6 6 11 65.3 6.6 3 4     1 
23 28.7 6.5 4 3 35.1   1           4 
24 25.6 5.3 57 53 25.6 5.3 38 38         2 
25 41.2 5.2 87 86 41.2 5.2 37 25     8 
26 43.7 5 83 74 43.7  16  43.7  53  3 
27 23.7 4.9 98 93 23.8 4.9 48 41     8 
28 30.3 4.9 44 44 30.3 4.9 7 7 30.7   24   7 
29 44 4.4 38 52 44 4.4 27 12 48.4  73  6 
30 20.4 4.4 82 72 20.4  46      7 
31 15.6 4.2 64 55 15.6 4.2 41 40     1 
32 43.3 4.2 48 51 43.3  5  43.3  46  6 
33 40.3 4 43 72 40.3 4 21 19 41 2.5 73 78 8 
34 15.7 4 85 72 15.7 4 45 42 19.8   72   6 
35 43.9 3.9 72 63 43.9   16           10 
36 43.3 3.7 52 57 43.3   8   43.3   50   2 
37 52.9 3.6 39 59 52.9 3.6 16 16 52.9  78  2 
Appendices 
191 
 
 Urine Heteroplasmy Blood Heteroplasmy Muscle Heteroplasmy  
ID Age Age 
Diff 
Het 
First 
Het 
Last 
Age Age 
Diff 
Het 
First 
Het 
Last 
Age Age 
Diff 
Het 
First 
Het 
Last 
No. 
NMDAS 
38 19.5 3.5 73 81 19.5 3.5 50 45         5 
39 45.7 3.1 80 89 45.5   23           10 
40 43.5 3 6 6 43.5 
  
0.1 
  -
60.5 
0 2 2 
4 
41 60.4 3 29 29 59.4  2  60.4  27  9 
42 41.1 2.7 88 86 41.1   24           4 
43 57.2 2.7 27 33 57.2   18           4 
44 49.3 2.6 46 40 49.3   21           2 
45 30.2 2.4 77 94 30.2 2.4 47 43     2 
46 35.4 2.3 80 92 35.4 2.3 34 31         7 
47 36.3 1.9 42 44 35.8 0.4 32 26         3 
48 44.5 1.7 14 12 44.5   4           2 
49 20.3 1.5 91 87 20.3 1.5 48 51     3 
50 40.3 1.5 40 45 40.3 1.5 19 24         2 
51 59.1 1.5 71 62 59.1  14      2 
52 56.7 1.4 50 34 51.8 6.3 15 18     3 
53 54.5 1.4 46 53 54.3 1.5 22 20 54.4  66  7 
54 5.4 1.4 92 91 5.5   68            
55 49.9 1.4 19 24 49.9   13           1 
56 31.7 1.2 71 64 32.7 0.1 12 11     1 
57 46 1 76 85 46 1 25 27     4 
58 26.9 0.9 93 92 26.9 0.9 39 39         1 
59 41.1 0.9 74 71 41.1   23           3 
60 57.9 0.7 22 35 56.3   7           3 
61 43.7 0.6 56 78 43.7 0.6 27 27 44.2   89   2 
62 22 0.6 89 91 21.5 0.5 33 34     2 
63 24.6 0.6 92 96 24.6   44           5 
64 23.4 0.6 54 60 23.4  34      7 
65 38 0.6 64 53 38  12      2 
66 39.4 0.6 64 47         4 
67 49.3 0.5 60 66 49.3   13           1 
68 32.8 0.5 57 65 32.8  30      4 
69 53.1 0.5 72 60 53.1   9           2 
70 34.9 0.4 78 71 34.9 0.4 28 28     4 
71 47.2 0.4 73 77 47.6  29      3 
72 24.9 0.2 87 57 24.9 0.2 40 29     1 
73 37.7 0.2 87 85 37.7   30           3 
74 37.4 0.2 47 56 37.6   10            
75 31.6 0.1 99.9 99 31.6 0 38 40     3 
76 56.8 0.1 41 49 56.8 0 8 7         8 
77 20.5 0.1 27 50 20.5   10           1 
78 51.9 0.1 20 29 51.9  2       
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 Urine Heteroplasmy Blood Heteroplasmy Muscle Heteroplasmy  
ID Age Age 
Diff 
Het 
First 
Het 
Last 
Age Age 
Diff 
Het 
First 
Het 
Last 
Age Age 
Diff 
Het 
First 
Het 
Last 
No. 
NMDAS 
79 36.2   37   36.2 6 0.1 0.1 41.2   41   2 
80 13  93  19.7 2.8 62 54     3 
81 22.5   71   21.8 0.7 35 31         1 
82 39.3   63   38.8 0.6 23 21         2 
83 45.7  88  45.5 0.5 24 24     2 
84 19  82  18.5 0.5 57 60     1 
85 24.7  92  24.7 0.2 54 48     15 
86 64.7   54           73.5 0.2 12 66 11 
87 7.1  99      6.9  94  7 
88 14.1  96  13.8  47      12 
89 8.4  96          2 
90 10.3   96                   5 
91 9.7   93   9.7   66            
92 12   91   12   62           1 
93 22   91   22   38            
94 46.3  91          1 
95 43.3   88   41.3   46           2 
96 17.1   86   16.7   53           1 
97 26.2  86  26.2  44  26.7  86  1 
98 23.2  85  23.2  41      1 
99 26.3   82   26.3   49           5 
100 8.7  82  8.7  46      1 
101 54.3   79   54.3   27           6 
102 25  78  25  31      10 
103 4.4  78          5 
104 25.9   77   25.9   23           10 
105 38.2  76  38.2  25      3 
106 45.2   76   44.9   23   44.9   78   1 
107 55.1  76          3 
108 37   75   37   22           3 
109 59.8  74  57.1  16      8 
110 9.7   72   9.7   44           8 
111 31.6  72  31.6  16      4 
112 31.2  71  31.2  48      4 
113 14.6  71  14.6  40       
114 35.4   70   35.4   25           2 
115 0   69   0   68           1 
116 55.2  68           
117 19   67   19   44            
118 27.5   62   27.5   27           3 
119 37.8  61          4 
120 60  60  61  17  64.2  62  3 
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 Urine Heteroplasmy Blood Heteroplasmy Muscle Heteroplasmy  
ID Age Age 
Diff 
Het 
First 
Het 
Last 
Age Age 
Diff 
Het 
First 
Het 
Last 
Age Age 
Diff 
Het 
First 
Het 
Last 
No. 
NMDAS 
121 23.2   59   23.2   18           2 
122 32.2  57  39.2  23  31  66  2 
123 44.9  57  44.9  9      2 
124 29.3   56   29.3   33           1 
125 55.1   56   55.1   18   54.8   70   1 
126 45.8   56   45.8   14   41.9   52   2 
127 70.6  56  70.5  3      2 
128 38.2   55   45.2   13           1 
129 25.1  55  22.3  12      1 
130 55.1  55  55.6  6  55.1  39   
131 18.2  54  18.2  19       
132 52.8   54                    
133 39.8   53   39.8   25            
134 26.5  52  26.5  29  26.7  63  2 
135 37.2  51  37.2  17      3 
136 14.1  50  14.1  43       
137 25   47           24.6   77   1 
138 23.5  44  23.5  23  23.5  64   
139 25.8   42   25.8   18            
140 46.2  40  46.2  22      1 
141 49.7   40   49.7   20           1 
142 23.2  40  23.2  8      1 
143 26.2  39  26.2  15      2 
144 32.5   38   32.5   13           1 
145 27.7   35   27.7   7   27.7   17   1 
146 20.5   34   20.5   48           1 
147 55  34  55  16      1 
148 51.7   34                   1 
149 19.3   32   19.3   16           1 
150 59.1  32  59.1  7      2 
151 49.5   31   49.5   13           2 
152 43.4  31  43.4  8       
153 60  26  51.3  1.6      1 
154 69.4   26   68.8   0.001   68.8   58   1 
155 29.1   23   29.1   14           1 
156 35.4   23   35.9   8   35.3   47   1 
157 42.9   22   42.9   10           1 
158 49.8  22  49.4  6      1 
159 62.5   22                   1 
160 27.3  18  27.3  1  27.5  41  5 
161 20.8  15.5  20.8  0.1       
162 36.9  14  36.9  0.1      12 
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 Urine Heteroplasmy Blood Heteroplasmy Muscle Heteroplasmy  
ID Age Age 
Diff 
Het 
First 
Het 
Last 
Age Age 
Diff 
Het 
First 
Het 
Last 
Age Age 
Diff 
Het 
First 
Het 
Last 
No. 
NMDAS 
163 59.9   12   59.9   0.1           3 
164 37.1  11          7 
165 67.4  10  67.4  0.1      3 
166 26.7   7   26.7   1           2 
167 45.3  6  45.3  0.1       
168 78   5   78   3           5 
169 61.7   3   61.7   1           2 
170 19.7  2  19.7  2       
171 29.6  1  29.6  1       
172 43.7  0.1  43.7  0.1       
173         41   30            
174         41.7   28           1 
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Appendix IV m.3243A>G Longitudinal Model SAS code. 
 
Create table sasuser.n3243 as  
Select patient_id, family_id, sex, aao, avg_age, no_ass,  
het_wt_muscle*100 as hm, het_wt_urine*100 as hu, het_wt_blood*100 as 
hb, (dt_nm - dt_birth)/365.0 as time, scaled_score, log_score, 
max_response from connection to odbc  
(Select dd.*, ddd.avg_age, stroke_seizure from data_sum_with_pd_ct dd 
inner join patient_sum_ct ddd on dd.patient_id = ddd.patient_id  
left join patient_melas_phenotype mel on dd.patient_id = 
mel.patient_id) where genetics = 14 and exclude_flags is null  and 
institution = 1 and max_response >= 130 
 order by patient_id asc, time asc  ;  
 
data n1; 
set sasuser.n3243; 
dv = scaled_score**0.25; 
time_scaled = time*1000; 
if family_id = 99999 then family_group = 'other'; else family_group = 
'individual'; 
het = hu; 
if not missing(hu); if not missing(hb); 
run;quit; 
 
proc sql; 
create table p_fam_temp as select family_id, patient_id, count(*) from 
n1 group by family_id, patient_id; 
 
create table p_fam as select family_id, count(*) from p_fam_temp group 
by family_id having count(*) < 2; 
update n1 set family_id = 99999 where family_id in (select family_id 
from p_fam); 
create table p_fam_uniq as  select family_id, count(*) from n1 where 
family_id < 99999 group by family_id ; 
run; 
 
proc sql; 
create table young  as select patient_id, count(*) from n1 where time 
< 25 and scaled_score > 3 group by patient_id; 
create table n1 as select n1.*, case when young.patient_id is not null 
then 1 else 0 end as young  from n1 left join young on n1.patient_id = 
young.patient_id ; 
create table n1 as select n1.*, case when melas.patient_id is not null 
then 1 else 0 end as melas from n1 left join melas on n1.patient_id = 
melas.patient_id ; 
select young, count(distinct patient_id) from n1 group by young; 
run; 
 
proc mixed data=n1 method=ml plots=all; 
class patient_id young; 
    model dv =  time time*time time*time*time time*hu time*young /s 
noint outp=PredR outpm = PredF residual; 
 repeated /type=sp(pow)(time_scaled ) subject=patient_id 
group=young ; 
random time /subject=patient_id; 
run;
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Appendix V Binomial logistic regression SAS code. 
 
data q; 
set sasuser.allq; 
t = age_at_ass/10; 
h  = hu; 
run; 
 
data stuff; do max=1 to 5 by 1; output; end; 
data q_id;  do q_id=1 to 29 by 1; output; end; 
data q_id_filtered; set q_id;  
if  q_id ne 18 ;  
run; 
 
proc sql; 
create table q1 as select max, case when q_max >= max then 1 else 0 
end as qval,q.* from stuff cross join q order by q.q_id, q.q_text, 
max; 
create table qs as select qif.q_id, q1.max, sum(case when qval = 1 
then 1 else 0 end) as yes,  sum(case when qval = 1 then 0 else 1 end) 
as no from q_id_filtered qif inner join q1 on qif.q_id = q1.q_id group 
by qif.q_id, q1.max; 
create table qs1 as select *, yes+no as total from qs where yes >= 10 
and no >= 10; 
create table qdata as select q1.* from q1 inner join qs1 on q1.q_id = 
qs1.q_id and q1.max = qs1.max; 
drop table qs; drop table q1; drop table qs1; 
run; 
 
proc sort data=q; by q_id; run; 
 
*Find the optimal cutoff point; 
ods html close;  
proc logistic data = qdata plots = none; by q_id q_text max; 
model qval =  h  /stb rsq CLPARM=PL; 
ods output Association=Assoc1; 
run; 
ods html; 
 
*Create the data sets using the optimal cutoff point; 
proc sql; 
create table out as select q_id, q_text, max, 
round(sum(nValue2),.0001) as c from Assoc1 where label2 = 'c' group by 
q_id, q_text, max; 
create table best_cutoff as select t.q_id, t.max as max, t.c from out 
t inner join (select q_id, max(c) as c from out group by q_id) a2 on 
t.q_id = a2.q_id and t.c = a2.c; 
create table qbestcutoff as select q.*, max as cutoff, case when 
q.q_max >= qbest.max then 1 else 0 end as score from q inner join 
best_cutoff qbest on q.q_id = qbest.q_id order by q_id, q_text; 
drop table out; drop table Assoc1;  
run; 
 
proc logistic data = qbestcutoff plots = none; 
by q_id q_text ; 
model score =  h  /stb rsq CLPARM=PL; 
ods output ParameterEstimates=ParsBest ClparmPL=ParsCLBest 
Association=AssocBEST  FitStatistics = Fit2;; 
output out = PredR p=Pred stdxbeta=StdErrPred lower=Lower upper=Upper 
PREDPROBS=(I); 
run;  
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Appendix VI Multilevel ordered logistic regression SAS code. 
data q; 
set sasuser.allq; 
decade = age_at_ass/10; 
het_10 = hu/10; 
 
if q_max > 3 then q_hml = 2; else if q_max > 1 then q_hml =1 ; else 
q_hml = 0; 
 
het_10  = hu/10; 
het_10  = hb/10; 
if not missing(hu); 
*if not missing(hb); 
run; 
 
 
proc sql; 
create table young as select patient_id, count(*) from n1 where time < 
25 and scaled_score > 3 group by patient_id; 
 
create table q1 as select q.*, case when young.patient_id is not null 
then 1 else 0 end as young  from q left join young on q.patient_id = 
young.patient_id ; 
run; 
 
*this is to do analysis of frequencies; 
proc sql; 
create table q_summary as select q_text,  
sum(case when q_max = 0 then 1 else 0 end)/count(*) as q_0, 
sum(case when q_max = 1 then 1 else 0 end)/count(*) as q_1, 
sum(case when q_max = 2 then 1 else 0 end)/count(*) as q_2, 
sum(case when q_max = 3 then 1 else 0 end)/count(*) as q_3, 
sum(case when q_max = 4 then 1 else 0 end)/count(*) as q_4, 
sum(case when q_max = 5 then 1 else 0 end)/count(*) as q_5, 
count(*) as n from q group by q_text; 
run; 
 
proc sort data = q; by q_text; run; 
 
proc logistic data = q plots=EFFECT(X=decade at(het_10 = 0.5 4 6.5)) 
plots=EFFECT(X=het_10  at(decade = 2 4 6)); 
by q_text; 
model q_hml =  decade het_10   /stb rsq CLPARM=PL; 
ods output OddsRatios=OddsDia ParameterEstimates=ParsDia 
CumulativeModelTest=TestDia FitStatistics=FitDia RSquare=R2Dia 
ClparmPL=ParsCL; 
output out = PredR p=Pred stdxbeta=StdErrPred lower=Lower upper=Upper 
PREDPROBS=(I); 
run; 
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Appendix VII. Parameters for calculation of risk profiles for m.3243A>G multilevel ordinal logistic model. 
Each parameter is shown with its standard error. The het parameter is for urine heteroplasmy decades, age is for age decades. Standardised parameters are also shown in the final two 
columns. 
Item Int 0 S.E P Int 1 S.E P Het S.E P Age S.E P Het STD Age STD 
Cardiovascular 3.612 0.976 0.0002 7.251 1.195 1E-09 -0.253 0.089 0.0044 -0.478 0.152 0.0017 -0.347 -0.371 
Cerebellar ataxia 4.660 0.939 7E-07 8.767 1.184 1E-13 -0.313 0.083 0.0002 -0.928 0.161 8E-09 -0.436 -0.742 
CPEO 5.011 1.094 5E-06 7.134 1.185 2E-09 -0.324 0.095 0.0007 -0.547 0.156 0.0004 -0.452 -0.428 
Cognition 2.002 0.748 0.0074 3.785 0.795 2E-06 -0.259 0.072 0.0003 -0.236 0.121 0.0511 -0.361 -0.185 
Cutting food 4.106 0.991 3E-05 7.023 1.143 8E-10 -0.247 0.088 0.0051 -0.460 0.145 0.0015 -0.345 -0.369 
Diabetes mellitus 5.384 1.025 2E-07 5.857 1.044 2E-08 -0.276 0.086 0.0014 -0.873 0.161 5E-08 -0.386 -0.685 
Dressing 3.829 0.912 3E-05 6.353 1.015 4E-10 -0.258 0.081 0.0015 -0.482 0.137 0.0004 -0.361 -0.383 
Dysphonia/dysarthria 3.820 0.975 9E-05 6.984 1.131 7E-10 -0.336 0.090 0.0002 -0.324 0.142 0.0228 -0.469 -0.254 
Encephalopathy 4.252 1.137 0.0002 5.451 1.176 4E-06 -0.335 0.104 0.0012 -0.260 0.162 0.1078 -0.469 -0.203 
Exercise Tolerance 1.699 0.730 0.0199 3.984 0.797 6E-07 -0.173 0.068 0.0111 -0.428 0.122 0.0004 -0.242 -0.341 
Extrapyramidal 7.713 2.411 0.0014 10.151 2.616 0.0001 -0.564 0.224 0.0118 -0.352 0.285 0.2171 -0.787 -0.276 
Gait stability 2.529 0.785 0.0013 5.719 0.913 4E-10 -0.188 0.073 0.0097 -0.539 0.131 4E-05 -0.263 -0.436 
Gastro-intestinal -0.174 0.757 0.8178 3.083 0.815 0.0002 -0.039 0.071 0.5865 -0.145 0.126 0.2472 -0.054 -0.116 
Handwriting 3.429 0.876 9E-05 5.841 0.970 2E-09 -0.222 0.079 0.0047 -0.442 0.134 0.0009 -0.311 -0.352 
Hearing  4.438 0.874 4E-07 7.664 1.050 3E-13 -0.460 0.083 3E-08 -0.873 0.148 4E-09 -0.644 -0.695 
Hygiene 4.442 0.970 5E-06 6.340 1.043 1E-09 -0.308 0.086 0.0003 -0.538 0.142 0.0002 -0.431 -0.425 
Migraine Headaches 0.308 0.717 0.6673 2.134 0.739 0.0039 -0.167 0.067 0.013 0.011 0.117 0.9229 -0.234 0.009 
Myopathy 3.583 0.881 5E-05 7.376 1.065 4E-12 -0.275 0.080 0.0005 -0.652 0.145 7E-06 -0.383 -0.514 
Neuropathy 4.706 0.971 1E-06 8.345 1.170 1E-12 -0.216 0.083 0.0093 -0.821 0.155 1E-07 -0.301 -0.657 
Psychiatric 0.991 0.755 0.1895 4.149 0.841 8E-07 -0.161 0.071 0.0229 -0.209 0.125 0.0961 -0.226 -0.164 
Ptosis 2.191 0.796 0.0059 4.792 0.886 6E-08 -0.132 0.073 0.0711 -0.313 0.126 0.0131 -0.184 -0.250 
Pyramidal 5.855 1.594 0.0002 8.221 1.751 3E-06 -0.350 0.140 0.0125 -0.431 0.214 0.0438 -0.488 -0.337 
Seizures 3.108 1.005 0.002 4.489 1.045 2E-05 -0.289 0.094 0.0021 -0.093 0.150 0.5361 -0.404 -0.073 
Speech 3.853 0.942 4E-05 7.171 1.111 1E-10 -0.306 0.085 0.0003 -0.409 0.140 0.0034 -0.429 -0.324 
Stroke-like episodes 5.085 1.361 0.0002 5.658 1.380 4E-05 -0.368 0.124 0.003 -0.299 0.186 0.107 -0.514 -0.234 
Swallowing 3.972 0.938 2E-05 6.307 1.033 1E-09 -0.258 0.084 0.0021 -0.473 0.138 0.0006 -0.360 -0.381 
Vision with glasses 2.536 0.827 0.0022 7.816 1.336 5E-09 -0.186 0.075 0.0139 -0.406 0.134 0.0024 -0.260 -0.321 
Visual acuity 2.704 0.840 0.0013 7.053 1.148 8E-10 -0.128 0.076 0.0929 -0.472 0.136 0.0005 -0.179 -0.378 
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Appendix VIII Calculation of odds ratio and probability. 
The tables in the following appendices contains the parameters for calculating individual features of m.3243A>G and single-large scale mtDNA 
deletions in model with age, heteroplasmy, and deletion size (for single deletionos)  as predictors.  
Int 0 is the intercept for calculating the probability of being asymptomatic.  
Int 1 is used to calculate the probability of being asymptomatic or moderate (it is cumulative).  
To calculate the probability of being moderately affected, subtract the probability of being asymptomatic (calculated using Int 0) from the probability 
of being asymptomatic or moderate (calculated using Int 1). To calculate the probability of being severely affected subtract the probability of being 
asymptomatic or moderate from 100%. 
The formula is 
                                                           
e.g. For m.3243A>G and cerebellar ataxia, the log odds of being asymptomatic at age 20 and heteroplasmy level 80% is                     
     . 
To convert a log odds to a probability, 
             
         
            
 
Thus in this case Probability = 3/(1 + 0.3) = 23.1%. 
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Appendix IX Proportion of female offspring in pedigrees from the Newcastle cohort. 
The proportions are calculated from the total of live-born offspring for each generation below that of the 
first mother known or suspected to carry the m.3243A>G mutation.  
No Female Male Female 
Proportion 
1 1 4 20% 
2 1 4 20% 
3 1 2 33% 
4 2 0 100% 
5 2 0 100% 
6 1 2 33% 
7 1 3 25% 
8 0 2 0% 
9 13 6 68% 
10 1 1 50% 
11 1 2 33% 
12 1 2 33% 
13 1 3 25% 
14 3 0 100% 
15 4 3 57% 
16 4 3 57% 
17 12 14 46% 
18 1 1 50% 
19 2 0 100% 
20 7 0 100% 
21 8 5 62% 
22 2 2 50% 
23 12 8 60% 
24 1 1 50% 
25 8 10 44% 
26 10 7 59% 
27 13 5 72% 
28 1 2 33% 
29 1 2 33% 
30 2 1 67% 
31 2 1 67% 
32 1 1 50% 
33 3 5 38% 
34 2 0 100% 
35 2 0 100% 
36 3 3 50% 
37 5 2 71% 
38 6 4 60% 
39 3 0 100% 
40 0 1 0% 
41 2 0 100% 
42 4 2 67% 
43 1 0 100% 
44 2 0 100% 
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Appendix X Proportion of female offspring in pedigrees from the meta-analysis. 
The proportions are calculated from the total of live-born offspring for each generation below that of the 
first mother known or suspected to carry the m.3243A>G mutation. Some studies contain multiple 
pedigrees; multiple values are included for each study in this case. 
Source Female Male Female 
Proportion 
(Chen et al., 2012) 2 2 50% 
(Conway et al., 2011) 5 5 50% 
(de Wit et al., 2012) 3 2 60% 
(Doleris et al., 2000) 5 3 63% 
(Doleris et al., 2000) 3 0 100% 
(Dougherty et al., 1994) 8 7 53% 
(Gilchrist et al., 1996) 1 4 20% 
(Hammans et al., 1995) 4 2 67% 
(Hammans et al., 1995) 7 2 78% 
(Hammans et al., 1995) 4 2 67% 
(Hammans et al., 1995)) 4 2 67% 
(Hammans et al., 1995) 8 3 73% 
(Hammans et al., 1995) 13 9 59% 
(Hammans et al., 1995) 2 3 40% 
(Hotta et al., 2001) 1 3 25% 
(Hotta et al., 2001) 5 0 100% 
(Hotta et al., 2001) 2 1 67% 
(Iwasaki et al., 2001) 2 3 40% 
(Iwasaki et al., 2001) 5 2 71% 
(Iwasaki et al., 2001) 1 1 50% 
(Iwasaki et al., 2001) 1 0 100% 
(Iwasaki et al., 2001) 0 3 0% 
(Iwasaki et al., 2001) 1 1 50% 
(Kobayashi et al., 1992) 1 1 50% 
(Kobayashi et al., 1992) 1 1 50% 
(Koga et al., 2000) 5 1 83% 
(Koga et al., 2000) 2 0 100% 
(Koga et al., 2000) 1 1 50% 
(Koga et al., 2000) 4 2 67% 
(Li et al., 2008) 3 2 60% 
(Massin et al., 1999) 4 1 80% 
(Salsano et al., 2011) 5 0 100% 
(Shanske et al., 2004) 1 2 33% 
(Sue et al., 1998a) 8 7 53% 
(Sue et al., 1998a) 15 22 41% 
(Sue et al., 1998a) 1 1 50% 
(Tay et al., 2008) 7 1 88% 
(Walter, 2009) 16 6 73% 
(Zhang et al., 2009) 4 0 100% 
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Appendix XI Single large-scale mtDNA deletion Newcastle cohort data. 
No Phenotype Age at 
Onset 
Age at 
Biopsy 
COX 
% 
Deletion 
Size 
Break 
point 5’ 
Break 
Point 3' 
NMDAS 
Assessments 
Het 
% 
1 KSS 11 27 10 9120 6468 15588 7 37% 
2 Multisystem 6 46 15 8704 7175 15879 4 13% 
3 CPEO  57 4 8560 5942 14502  6% 
4 CPEO 30 34 40 8039 7637 15676 3 36% 
5 CPEO  65 25 7977 6537 14514  45% 
6 CPEO 38   7958 6033 13991 1 32% 
7 CPEO+MM 15 25 25 7768 6352 14120 7 44% 
8 Multisystem 14 59 10 7676 6323 13999 5 39% 
9 Multisystem 55 85 12 7671 6741 14412  23% 
10 Multisystem 5 28 22 7648 6341 13989 4 33% 
11 CPEO 20 38 0.5 7595 7845 15440 4 6% 
12 CPEO 39 72 5 7500    10% 
13 CPEO 30  15 7498 7130 14628 2 28% 
14   113  7451 8287 15738  5% 
15 CPEO+MM  60 3 7355 7168 14523  24% 
16 CPEO+MM  59 20 7284 6774 14058  51% 
17 CPEO 18 30 15 7144 5772 12916 4 37% 
18 CPEO 16 16 20 7129 8543 15672  7% 
19 CPEO+MM  68  6978 7821 14799  56% 
20 CPEO 27 63 13 6864 7128 13992 3 35% 
21 KSS 11 23 50 6864 7128 13992 1 90% 
22 CPEO+MM 22 36 20 6549 6006 12555 6 40% 
23 KSS 10 24 30 6472 7540 14012 8 73% 
24 Multisystem 15 41 45 6058 8838 14896 2 50% 
25 CPEO+MM   15 5958 6002 11960  45% 
26 CPEO  41  5906 8324 14230  20% 
27 CPEO 15 40 12 5899 9523 15422 7 35% 
28 CPEO 16 33 20 5813 9754 15567 1 25% 
29 CPEO+MM 15 34 35 5470 6603 12073 7 71% 
30 Multisystem 9 31 25 5340 6714 12054 5 45% 
31 Multisystem 18 49 20 5160 9258 14418 11 53% 
32 Multisystem 12 32 49 5000   4 79% 
33 Multisystem 11 56 16 5000   1 42% 
34 Multisystem 12 20 20 4999 6625 11624  75% 
35 CPEO 23 51 32 4977 8470 13447 8 58% 
36 Multisystem 28 40 20 4977 8470 13447 7 75% 
37 CPEO+MM 14 31 10 4977 8470 13447 6 62% 
38 Multisystem 16 37 43 4977 8470 13447 6 67% 
39 Multisystem 10 34 30 4977 8470 13447 5 61% 
40 CPEO+MM 27 55 14 4977 8470 13447 5 34% 
41 Multisystem 28 41 80 4977 8470 13447 5 78% 
42 CPEO 20 28  4977 8470 13447 3 54% 
43 KSS 12 15 30 4977 8470 13447 2 76% 
44 KSS 15 33 35 4977 8470 13447 1 78% 
45 CPEO+MM 19 43 60 4977 8470 13447 1 81% 
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No Phenotype Age at 
Onset 
Age at 
Biopsy 
COX 
% 
Deletion 
Size 
Break 
point 5’ 
Break 
Point 3' 
NMDAS 
Assessments 
Het 
% 
46 CPEO+MM 33 41 70 4977 8470 13447 1 78% 
47 CPEO  35 8 4977 8470 13447 1 26% 
48 CPEO+MM  43 30 4977 8470 13447 1 56% 
49 CPEO+MM 18 57 40 4977 8470 13447  57% 
50 CPEO 45  16 4977 8470 13447  30% 
51 CPEO  18 6 4977 8470 13447  48% 
52 CPEO+MM  25  4977 8470 13447  71% 
53   37 14 4977 8470 13447  42% 
54 CPEO  39 60 4977 8470 13447  65% 
55 CPEO+MM  40 20 4977 8470 13447  63% 
56 CPEO  46  4977 8470 13447  13% 
57 CPEO+MM 15   4963 10105 15068 1 23% 
58 KSS  16  4959 8474 13433  88% 
59 CPEO 39 61 7 4909 8814 13723 4 1% 
60 CPEO 37  28 4885 7205 12090 1 34% 
61 CPEO  27  4851 10747 15598  65% 
62 CPEO 23 63 15 4770 9349 14119 1 35% 
63 CPEO+MM   60 4770 9349 14119  56% 
64 CPEO 15 40 12 4752 8289 13041 9 50% 
65 Multisystem 15 26 26 4641 10946 15587 3 83% 
66 CPEO+MM 34 38 34 4604 9057 13661 5 65% 
67 KSS  17 17 4599 9752 14351  60% 
68 CPEO  41 15 4596 9528 14124  35% 
69 KSS 15 29 50 4500   9 85% 
70 Multisystem 27 58 30 4392 8576 12968 4 22% 
71 CPEO+MM 21 32 45 4382 8586 12968 6 69% 
72 CPEO 21 25 40 4372 8929 13301  53% 
73 Multisystem 30 45 25 4241 9498 13739 8 39% 
74 Multisystem 25 40 48 4237 9486 13723 6 81% 
75 CPEO 47 60 13 4237 9486 13723 6 46% 
76 CPEO  70 22 4223 9500 13723  76% 
77 CPEO+MM 16 32 20 4113 11262 15375 9 72% 
78 KSS 15   3979 11657 15636  50% 
79 Multisystem 24 44 10 3693 9756 13449 7 47% 
80 CPEO  63 50 3527 7729 11256  55% 
81   105 11 3039 10950 13989  55% 
82 Multisystem 36 50 5 2803 11637 14440 11 72% 
83 CPEO+MM  40 30 2308 12113 14421  87% 
84 CPEO 35 50 20 2300 12112 14412 9 55% 
85 Multisystem 48 72 17 2300 12112 14412 9 41% 
86 CPEO   18 2300 12112 14412 1 76% 
87 CPEO  56 25 2297 12115 14412  55% 
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Appendix XII Single large-scale mtDNA deletion meta-analysis data. 
 
No Original 
Study 
Phenotype Age at 
Onset 
Age at 
Biopsy 
COX 
% 
Del 
Size 
Break 
point 5’ 
Break 
point 3’ 
Het% In López-
Gallardo et al. 
1 López-Gallardo et al., 2009 KSS    11041 4166 15207 84% Yes 
2 Marin-Garcia et al., 2002 KSS 3 15  11000 4500 15500 20% Yes 
3 Kornblum et al., 2005b CPEO 55 59  10900   23% Yes 
4 Kornblum et al., 2005b CPEO 56 60  10900   49% Yes 
5 De Coo et al., 1997     10000   1% No 
6 Solano et al., 2003 KSS 8 17  9438 6003 15441 87% Yes 
7 Gellerich 2002   0 27 9000 6000 15000 69% No 
8 Fromenty et al., 1996 CPEO 3 18  8800   32% Yes 
9 Ishikawa 2000     8731 6903 15634 55% No 
10 Emma et al., 2006 KSS 1 14  8661 7836 16497 60% Yes 
11 López-Gallardo et al., 2009 KSS 6   8477 6123 14600 82% Yes 
12 Solano et al., 2003 KSS 9 20  8431 7515 15946 86% Yes 
13 Degoul et al., 1991 CPEO 28 45  8137 5786 13923 25% Yes 
14 Simaan et al., 1999 KSS 3 13  8000   18% Yes 
15 De Coo et al., 1997 KSS    8000   60% Yes 
16 Blok et al., 1995 KSS 10 14  7865 6238 14103 25% Yes 
17 Heddi et al., 1994 KSS    7768 7669 15437 74% Yes 
18 Goto et al., 1990 CPEO 7 15 14.5 7700 6000 13700 20% Yes 
19 Matsuoka et al., 1992 CPEO Multi  15  7700   20% Yes 
20 Matsuoka et al., 1992 KSS  21  7700   20% Yes 
21 Goto et al., 1990 CPEO Multi 7 7 15.3 7700 6000 13700 30% Yes 
22 Goto et al., 1990 CPEO 9 16 27.2 7700 6000 13700 40% Yes 
23 Matsuoka et al., 1992 CPEO  16  7700   40% Yes 
24 Sadikovic 2010 Multisystem   40  7673 6331 14004 24% No 
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No Original 
Study 
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Onset 
Age at 
Biopsy 
COX 
% 
Del 
Size 
Break 
point 5’ 
Break 
point 3’ 
Het% In López-
Gallardo et al. 
25 Solano et al., 2003 KSS    7663 6331 13994 64% Yes 
26 Johns et al., 1989 CPEO    7650 6250 13900 25% Yes 
27 Montiel-Sosa, 2013   10  7628 7437 15065 85% No 
28 Sadikovic 2010 CPEO  59  7603 8469 16072 22% No 
29 Kiyomoto et al., 1997 CPEO Multi 6 12 15 7565 7827 15392 66% Yes 
30 Sadikovic 2010 CPEO + MM  48  7544 7865 15409 14% No 
31 Oldfors 1992   56 9 7534 8366 15900 52% No 
32 Oldfors 1992   5 30 7534 8366 15900 73% No 
33 Odoardi et al., 2003 KSS 7 21  7521 7983 15504 38% No 
34 Schroder et al., 2000 CPEO  30  7500   15% Yes 
35 Kornblum et al., 2005a CPEO Multi 10 34  7500   16% Yes 
36 Barrientos et al., 1995 CPEO Multi 10 47  7500   23% Yes 
37 Kornblum et al., 2005a CPEO Multi 14 42  7500   26% Yes 
38 Schroder et al., 2000 CPEO  34  7500   26% Yes 
39 Schroder et al., 2000 CPEO  26  7500   27% Yes 
40 Barrientos et al., 1995 KSS 12 20  7500   40% Yes 
41 Odoardi et al., 2003 CPEO + MM 8 18  7500   42% No 
42 Barrientos et al., 1995 CPEO Multi 3 12  7500   50% Yes 
43 Kornblum et al., 2005a CPEO Multi 10 38  7500   58% Yes 
44 Sadikovic 2010 Multisystem   18  7436 8637 16073 45% No 
45 Goto et al., 1990 CPEO 13 31 17.2 7300 6000 13300 40% Yes 
46 Oldfors 1992   13 5 7300 8600 15900 43% No 
47 Sadikovic 2010 Multisystem   46  7213 8427 15640 47% No 
48 Sadikovic 2010 KSS   31  7213 8427 15640 82% No 
49 Matsuoka et al., 1992 CPEO  16  7200   5% Yes 
50 Moraes et al., 1992 KSS    7100   70% Yes 
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No Original 
Study 
Phenotype Age at 
Onset 
Age at 
Biopsy 
COX 
% 
Del 
Size 
Break 
point 5’ 
Break 
point 3’ 
Het% In López-
Gallardo et al. 
51 Sadikovic 2010 Multisystem  6  7039 8623 15662 70% No 
52 Zeviani et al., 1988 KSS 8 15  7025 5275 12300 45% Yes 
53 Schroder et al., 2000 KSS  19  7000   20% Yes 
54 Kornblum et al., 2005a KSS 12 31  7000   66% Yes 
55 Goto et al., 1990 CPEO 22 49 11.6 6800 8600 15400 30% Yes 
56 López-Gallardo et al., 2009 CPEO 31   6798 6024 12822 30% Yes 
57 Barrientos et al., 1995 KSS 14 24  6500   56% Yes 
58 Kornblum et al., 2005b CPEO 25 51  6500   58% Yes 
59 Schroder et al., 2000 CPEO  50  6500   60% Yes 
60 Schroder et al., 2000 KSS  21  6500   66% Yes 
61 Fromenty et al., 1996 KSS 8 22  6495 7836 14331 31% Yes 
62 Solano et al., 2003 KSS 12 13  6366 7949 14315 69% Yes 
63 López-Gallardo et al., 2009 CPEO    6279 7409 13688 21% Yes 
64 Solano et al., 2003 CPEO    6213 7407 13620 7% Yes 
65 Sadikovic 2010 CPEO + MM  26  6119 9516 15635 32% No 
66 Larsson and Holme, 1992 KSS 7 16 5 6100 8800 14900 59% No 
67 Kornblum et al., 2005a CPEO Multi 8 61  6000   46% Yes 
68 Schroder et al., 2000 CPEO  49  6000   46% Yes 
69 De Coo et al., 1997 CPEO    6000 9500 15500 70% Yes 
70 De Coo et al., 1997     6000   82% No 
71 Zeviani et al., 1988 KSS 4 7  5980 9020 15000 66% Yes 
72 Solano et al., 2003 CPEO    5928 9816 15744 29% Yes 
73 Sadikovic 2010 KSS  42  5905 8467 14372 70% No 
74 Marie et al., 1999 KSS 1 5  5900   30% Yes 
75 Sadikovic 2010 KSS  11  5867 8558 14425 65% No 
76 Okulla et al., 2005 CPEO 12 13  5800   32% Yes 
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No Original 
Study 
Phenotype Age at 
Onset 
Age at 
Biopsy 
COX 
% 
Del 
Size 
Break 
point 5’ 
Break 
point 3’ 
Het% In López-
Gallardo et al. 
77 Sadikovic 2010 CPEO + MM  38  5630 8429 14059 33% No 
78 Kornblum et al., 2005a CPEO Multi 28 52  5600   85% Yes 
79 Sudoyo et al., 1993 CPEO 12 34  5500 8000 13500 39% Yes 
80 Kornblum et al., 2005b KSS 16 47  5500   58% Yes 
81 Schroder et al., 2000 KSS  40  5500   58% Yes 
82 Goto et al., 1990 KSS 11 12  5500 7500 13000 80% Yes 
83 Zeviani et al., 1988 KSS 3 12  5448 10600 16048 57% Yes 
84 Sadikovic 2010 MM  26  5438 8140 13578 11% No 
85 Goto et al., 1990 KSS 2 13 23.9 5400 7000 12400 60% Yes 
86 Shanske et al., 2002 CPEO    5355 10004 15359 40% No 
87 López-Gallardo et al., 2009 KSS    5311 7450 12761 73% Yes 
88 Sadikovic 2010 CPEO + MM  57  5225 6076 11301 13% No 
89 Goto et al., 1990 KSS 4 14 40.6 5200 8500 13700 90% Yes 
90 López-Gallardo et al., 2009 CPEO    5113 8477 13590 80% Yes 
91 Sadikovic 2010 Multisystem   34  5112 8468 13580 50% No 
92 Goto et al., 1990 KSS 12 30 14 5100 10059 15159 70% Yes 
93 Carta et al., 2000 CPEO  28  5049 9570 14619 55% Yes 
94 Vazquez-Acevedo et al., 1995 KSS 4 17  5026 10050 15076 86% Yes 
95 Johns and Hurko, 1989 KSS 13 43  5014 8708 13722 65% Yes 
96 Kornblum et al., 2005a CPEO Multi 55 61  5000   5% Yes 
97 Schroder et al., 2000 CPEO  39  5000   26% Yes 
98 Moraes et al., 1992 KSS    5000   36% Yes 
99 Barrientos et al., 1995 CPEO Multi 8 16  5000   42% Yes 
100 Kornblum et al., 2005a CPEO Multi 12 50  5000   53% Yes 
101 Tanaka et al., 1989 CPEO 14 32  5000 8600 13600 53% Yes 
102 Schroder et al., 2000 CPEO  38  5000   53% Yes 
Appendices 
208 
 
No Original 
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Phenotype Age at 
Onset 
Age at 
Biopsy 
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% 
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point 5’ 
Break 
point 3’ 
Het% In López-
Gallardo et al. 
103 Schroder et al., 2000 KSS  18  5000   54% Yes 
104 Moraes et al., 1992 CPEO    5000   55% Yes 
105 Schroder et al., 2000 CPEO  30  5000   55% Yes 
106 Schroder et al., 2000 KSS  19  5000   58% Yes 
107 Vielhaber et al., 2002 CPEO  44  5000   58% Yes 
108 Vielhaber et al., 2002 CPEO  29  5000   68% Yes 
109 Matsuoka et al., 1992 CPEO  14  5000   70% Yes 
110 Kornblum et al., 2005b CPEO 30 48  5000   72% Yes 
111 Schroder et al., 2000 CPEO  42  5000   72% Yes 
112 Vielhaber et al., 2002 CPEO  47  5000   72% Yes 
113 Kornblum et al., 2005a CPEO Multi 16 57  5000   74% Yes 
114 Vielhaber et al., 2002 KSS  13  5000   74% Yes 
115 Moraes et al., 1992 KSS    5000   76% Yes 
116 Kornblum et al., 2005a KSS 9 39  5000   78% Yes 
117 Schroder et al., 2000 KSS  29  5000   78% Yes 
118 Sadikovic 2010 PEO  24  4995 5835 10830 58% No 
119 López-Gallardo et al., 2009 CPEO    4978 8482 13460 6% Yes 
120 Wong, 2001 KSS  26  4978 8482 13460 10% Yes 
121 Odoardi et al., 2003 CPEO 39 43  4978 8482 13460 12% Yes 
122 Bernes et al., 1993 CPEO 16 24  4978 8482 13460 15% Yes 
123 Pineda et al., 2004 CPEO    4978 8482 13460 15% Yes 
124 López-Gallardo et al., 2009 CPEO    4978 8482 13460 16% Yes 
125 Goto et al., 1990 CPEO 20 53 5 4978 8482 13460 20% Yes 
126 Odoardi et al., 2003 CPEO 12 14  4978 8482 13460 26% Yes 
127 Odoardi et al., 2003 CPEO 35 45  4978 8482 13460 31% Yes 
128 Odoardi et al., 2003 CPEO 15 36  4978 8482 13460 33% Yes 
Appendices 
209 
 
No Original 
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Gallardo et al. 
129 Wong, 2001 KSS  28  4978 8482 13460 33% Yes 
130 Degoul et al., 1991 CPEO Multi 4 31  4978 8482 13460 34% Yes 
131 Gellerich 2002     4978 8482 13460 39% No 
132 Poulton et al., 1991 KSS 14 14 3 4978 8482 13460 40% Yes 
133 Goto et al., 1990 CPEO 14 32 12.8 4978 8482 13460 40% Yes 
134 López-Gallardo et al., 2009 CPEO 20   4978 8482 13460 40% Yes 
135 Chen et al., 1998 CPEO    4978 8482 13460 44% Yes 
136 López-Gallardo et al., 2009 CPEO    4978 8482 13460 45% Yes 
137 Wong, 2001 KSS  20  4978 8482 13460 45% Yes 
138 Wong, 2001 CPEO  60  4978 8482 13460 45% Yes 
139 Goto et al., 1990 CPEO 12 15 18.5 4978 8482 13460 50% Yes 
140 Shoffner et al., 1989 CPEO Multi 20 61  4978 8482 13460 50% Yes 
141 López-Gallardo et al., 2009 CPEO 48   4978 8482 13460 50% Yes 
142 Wong, 2001 KSS  34  4978 8482 13460 51% Yes 
143 López-Gallardo et al., 2009 CPEO    4978 8482 13460 54% Yes 
144 Gellerich 2002     4978 8482 13460 61% No 
145 López-Gallardo et al., 2009 KSS 4   4978 8482 13460 62% Yes 
146 López-Gallardo et al., 2009 KSS    4978 8482 13460 62% Yes 
147 Obermaier-Kusser et al., 1990 KSS 11 26  4978 8482 13460 63% Yes 
148 Wong, 2001 KSS  16  4978 8482 13460 63% Yes 
149 Wong, 2001 KSS  36  4978 8482 13460 64% Yes 
150 Boles et al., 1998 KSS 1 5  4978 8482 13460 65% Yes 
151 Wong, 2001 KSS  6  4978 8482 13460 65% Yes 
152 Gellerich 2002    48 4978 8482 13460 66% No 
153 Degoul et al., 1991 KSS 7 27  4978 8482 13460 68% Yes 
154 López-Gallardo et al., 2009 CPEO    4978 8482 13460 68% Yes 
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155 Odoardi et al., 2003 KSS 6 17  4978 8482 13460 69% Yes 
156 Goto et al., 1990 KSS 10 14 41.4 4978 8482 13460 70% Yes 
157 Wong, 2001 KSS  44  4978 8482 13460 70% Yes 
158 López-Gallardo et al., 2009 KSS 12   4978 8482 13460 72% Yes 
159 Ponzetto et al., 1990 KSS    4978 8482 13460 72% Yes 
160 López-Gallardo et al., 2009 KSS    4978 8482 13460 72% Yes 
161 Consalvo et al., 1997 KSS 9 19  4978 8482 13460 80% Yes 
162 Degoul et al., 1991 KSS 10 31  4978 8482 13460 80% Yes 
163 Goto et al., 1990 CPEO 22 26 40.2 4978 8482 13460 80% Yes 
164 López-Gallardo et al., 2009 KSS    4978 8482 13460 80% Yes 
165 Johns et al., 1989 KSS    4978 8482 13460 83% Yes 
166 Odoardi et al., 2003 KSS 6 10  4978 8482 13460 85% Yes 
167 Johns et al., 1989     4978 8482 13460 86% No 
168 Sadikovic 2010 CPEO + MM  60  4977 8470 13447 6% No 
169 Sadikovic 2010 KSS  26  4977 8470 13447 10% No 
170 Kiyomoto et al., 1997 CPEO 30 44 1 4977 8483 13460 14% Yes 
171 Sadikovic 2010 Multisystem   24  4977 8470 13447 24% No 
172 Sadikovic 2010 Multisystem   14  4977 8470 13447 27% No 
173 Sadikovic 2010 CPEO + MM  78  4977 8470 13447 27% No 
174 Sadikovic 2010 KSS  28  4977 8470 13447 33% No 
175 Sciacco et al., 1994 KSS  35  4977 8470 13447 36% Yes 
176 Sadikovic 2010 CPEO + MM  39  4977 8470 13447 42% No 
177 Sadikovic 2010 KSS  20  4977 8470 13447 45% No 
178 Sadikovic 2010 CPEO + MM  60  4977 8470 13447 45% No 
179 Sadikovic 2010 Multisystem   45  4977 8470 13447 49% No 
180 Sciacco et al., 1994 CPEO 61 66  4977 8470 13447 50% Yes 
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181 Shanske et al., 1990 KSS    4977 8470 13447 50% Yes 
182 Kiyomoto et al., 1997 CPEO 15 33 8.5 4977 8483 13460 54% Yes 
183 Sciacco et al., 1994 KSS 11 13  4977 8470 13447 55% Yes 
184 Sadikovic 2010 CPEO + MM  56  4977 8470 13447 55% No 
185 Sadikovic 2010 CPEO  39  4977 8470 13447 60% No 
186 Sadikovic 2010 KSS  13  4977 8470 13447 61% No 
187 Sadikovic 2010 KSS   16  4977 8470 13447 62% No 
188 Sudoyo et al., 1993 CPEO 4 41  4977 8470 13447 64% Yes 
189 Sadikovic 2010 MM  36  4977 8470 13447 64% No 
190 Sadikovic 2010 Multisystem   6  4977 8470 13447 65% No 
191 Sadikovic 2010 Renal tubular 
acidosis 
 8  4977 8470 13447 67% No 
192 Sadikovic 2010 CPEO + MM  9  4977 8470 13447 67% No 
193 Sadikovic 2010 CPEO + MM  36  4977 8470 13447 70% No 
194 Sadikovic 2010 KSS  44  4977 8470 13447 70% No 
195 Sciacco et al., 1994 KSS  28  4977 8470 13447 75% Yes 
196 Kiyomoto et al., 1997 CPEO Multi 12 14 18 4977 8483 13460 77% Yes 
197 Mita 1989 KSS  30 51 4977 8483 13460 80% No 
198 Sadikovic 2010 CPEO + MM  27  4977 8470 13447 85% No 
199 Sadikovic 2010 PEO  20  4977 8470 13447 88% No 
200 Solano et al., 2003 CPEO    4958 8380 13338 30% Yes 
201 Pistilli et al., 2003 KSS 10 36  4949 8631 13580 60% Yes 
202 Oldfors 1992   27 20 4914 7586 12500 79% No 
203 Barrientos et al., 1995 KSS 3 28  4800   38% Yes 
204 Larsson and Holme, 1992 KSS 5 12  4800 10800 15600 87% No 
205 López-Gallardo et al., 2009 KSS    4754 11292 16046 45% Yes 
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206 Oldfors 1992   11 1 4700 10500 15200 87% No 
207 Degoul et al., 1991 KSS 18 25  4500 11300 15800 30% Yes 
208 Johns et al., 1989 CPEO    4500 9300 13800 55% Yes 
209 Zeviani et al., 1988 KSS 14 26  4500 9000 13500 62% Yes 
210 Zeviani et al., 1988 KSS 14 28  4500 9000 13500 75% Yes 
211 Solano et al., 2003 KSS 7 18  4421 10951 15372 80% Yes 
212 Kiyomoto et al., 1997 KSS 4 15 3.5 4420 10952 15372 20% Yes 
213 Sadikovic 2010 Multisystem   8  4420 10560 14980 55% No 
214 Wong, 2001 KSS  8  4420 10560 14980 55% Yes 
215 Sadikovic 2010 Multisystem   48  4369 9256 13625 38% No 
216 Carod-Artal et al., 2003 CPEO 19 26  4238 9500 13738 55% Yes 
217 Solano et al., 2003  CPEO    4238 9485 13723 55% No 
218 Goto et al., 1990 CPEO 40 52 19 4200 5850 10050 30% Yes 
219 Zeviani et al., 1988 KSS 17 27  4200 9000 13200 66% Yes 
220 Pineda et al., 2006 KSS 7 8  4124 11033 15157 72% Yes 
221 Blakely et al., 2004 CPEO   20 4115 11262 15375 66% Yes 
222 Gellerich 2002     4093 10057 14150 62% No 
223 De Coo et al., 1997 KSS    4000   60% Yes 
224 Kiyomoto et al., 2006 CPEO 60 62 14 3800   4% Yes 
225 Vielhaber et al., 2002 CPEO  48  3800   10% Yes 
226 Kornblum et al., 2004 CPEO 28 35  3800   45% Yes 
227 Solano et al., 2003 KSS 14 31  3720 11727 15447 50% Yes 
228 Kiyomoto et al., 1997 CPEO 27 43 8 3716 10845 14561 44% Yes 
229 Kiyomoto et al., 2006 CPEO 18 28 12 3700   65% Yes 
230 Degoul et al., 1991 CPEO 31 51  3513 7483 10996 40% Yes 
231 Wong, 2001     3500   16% No 
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232 Gellerich 2002     3500 11300 14800 58% No 
233 Kornblum et al., 2005a KSS 20 37  3500   62% Yes 
234 Schroder et al., 2000 KSS  30  3500   62% Yes 
235 Schroder et al., 2000 CPEO  29  3500   65% Yes 
236 Lertrit et al., 1999 KSS 35 37  3485 10280 13765 37% Yes 
237 Barbiroli et al., 1995 CPEO 22 30  3300   20% Yes 
238 Wong et al., 2003 KSS 29 36  3079 8419 11498 92% Yes 
239 Sadikovic 2010 Multisystem   25  3030 10958 13988 47% No 
240 Sadikovic 2010 KSS  41  2976 8388 11364 92% No 
241 Goto et al., 1990 CPEO 35 45 16.6 2800 11500 14300 50% Yes 
242 Kornblum et al., 2005a CPEO Multi 44 49  2700   32% Yes 
243 Gellerich 2002    22 2600 11000 13600 62% No 
244 Kornblum et al., 2005b CPEO 48 48  2500   39% Yes 
245 Ohno et al., 1996 KSS 26 27  2500   88% Yes 
246 Solano et al., 2003 KSS    2434 10620 13054 77% Yes 
247 Solano et al., 2003 KSS    2310 12112 14422 70% Yes 
248 Kiyomoto et al., 1997 CPEO 20 47 20 2309 12113 14422 59% Yes 
249 Kiyomoto et al., 1997 CPEO 21 31 4 2309 12113 14422 89% Yes 
250 Goto et al., 1990 CPEO 39 70 10.7 2300 11000 13300 50% Yes 
251 Moraes et al., 1992 CPEO    2300   80% Yes 
252 Goto et al., 1990 CPEO 34 37 7.2 2200 12000 14200 50% Yes 
253 Goto et al., 1990 CPEO 52 55 19.3 2200 12000 14200 60% Yes 
254 Zeviani et al., 1988 KSS 24 33  2060 7440 9500 60% Yes 
255 Schroder et al., 2000 CPEO  45  2000   32% Yes 
256 Goto et al., 1990 KSS 35 36 12.6 1800 13000 14800 50% Yes 
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Appendix XIII Single large-scale mtDNA deletion meta-analysis exclusions. 
Details of the excluded case and reasons for exclusion are noted.  
Study Pheno- 
type 
AAO Age at 
Biopsy 
COX 
% 
Deletion 
Size 
Break 
point 3’ 
Break 
point 5’ 
Het% Notes In 
López-
Gallardo  
Mori et al., 1991 KSS 2 6  6596 6383 12979 60% Deletion size does not match original publication yes 
Larsson et al., 1992 KSS 16 26  4667 7697 12364 70% Deletion size does not original publication yes 
Goto et al., 1990 CPEO 13 31 50% 5300 9206 14506 90% Deletion size is inconsistent with reported breakpoints yes 
Schaefer et al., 2005 CPEO 15 24  7400   8% In our cohort  yes 
Zoccolella et al., 2006  6 32  1813 3505 5318 70% Location is unlike any other deletion in the study yes 
Reynier et al., 1994 CPEO  41      50% Other mutations; also contains a point mutation yes 
Odoardi et al., 2003 KSS 20 27  4978 8482 13460 51% Other mutations; Dimers yes 
Odoardi et al., 2003 CPEO 30 40  7000   51% Other mutations; Dimers yes 
Brockington et al., 
1995 
KSS 12 19  8562 7354 15916 27% Other mutations; Dimers and duplications yes 
Brockington et al., 
1995 
KSS 4 22  4978 8482 13460 89% Other mutations; Dimers and duplications yes 
Jacobs et al., 2004 PS/KSS 0 3  8034 7934 15968  Other mutations; Dimers and duplications no 
Jacobs et al., 2004 PS 0 1.5  3444 6097 9541 64% Other mutations; Dimers and duplications no 
Tengan et al., 1998 KSS 5 12  9660 5784 15444 65% Other mutations; Duplications yes 
Vazquez-Acevedo et 
al., 2002 
KSS 8 23  4978 8482 13460 75% Other mutations; multiple deletions yes 
Tanaka et al., 1989 CPEO 39 70  2100   36% Uncertain breakpoints yes 
Oldfors 1992   52 10% 3940 10060 14000 76% Uncertain breakpoints no 
Kunz et al., 1997 CPEO  34  3200   53% Uncertain breakpoints yes 
Kunz et al., 1997 CPEO  55  4700   67% Uncertain breakpoints yes 
Kunz et al., 1997 CPEO  32  2600   84% Uncertain breakpoints yes 
Marzuki et al., 1997 CPEO 20 59  5020 9780 14800 16% Uncertain breakpoints and multiple deletions yes 
Sudoyo et al., 1993 CPEO 25 60  2664 12336 15000 55% Uncertain breakpoints and multiple deletions yes 
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Appendix XIV Single large-scale mtDNA deletion longitudinal model SAS code. 
 
data n1; 
set sasuser.n3243; 
if scaled_score = 0 then scaled_score = 0.1; 
dv = scaled_score**0.25; 
time_scaled = time*1000; 
if missing(family_id) then family_id = 99999; 
if family_id = 99999 then family_group = 'other'; 
else family_group = 'individual'; 
het = hu; 
if not missing(hu); 
if not missing(hb); 
run;quit; 
 
 
proc sql; 
create table p_fam_temp as select family_id, patient_id, count(*) from 
n1 group by family_id, patient_id; 
create table p_fam as select family_id, count(*) from p_fam_temp group 
by family_id having count(*) < 2; 
update n1 set family_id = 99999 where family_id in (select family_id 
from p_fam); 
create table p_fam_uniq as  select family_id, count(*) from n1 where 
family_id < 99999 group by family_id ; 
run; 
 
proc sql; 
create table young  as select patient_id, count(*) from n1 where time 
< 25 and scaled_score > 3 group by patient_id; 
create table n1 as select n1.*, case when young.patient_id is not null 
then 1 else 0 end as young, from n1 left join young on n1.patient_id = 
young.patient_id ; 
run; 
 
proc mixed data=n1 method=ml plots=none RATIO COVTEST ; 
 class patient_id young family_group family_id; 
       model dv =  time time*time time*time*time time*hu time*young  
/s noint outp=PredR outpm = PredF residual; 
  repeated /type=sp(pow)(time_scaled ) 
subject=patient_id(family_id) group=young*family_group ; 
 random time /subject=patient_id(family_id) ; 
  random time /subject=family_id ; 
 ods output FitStatistics=fm SolutionF=SFfm; 
run; 
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Appendix XV. Parameters for calculation of risk profiles for single large-scale mtDNA deletion multilevel ordinal logistic model. 
Each parameter is shown with its standard error. The parameters are age in decades (Decade), the square of the deletion size in kB (Size
2
), and the natural log of (100%-
heteroplasmy) (ln(1-h)). 
Item Int 0 Std P Int 1 Std P Decade Std P ln(1-h)  Std P Size
2
 Std P 
Vision 3.451 1.989 0.083 6.614 2.166 0.002 -0.559 0.263 0.033 1.523 0.689 0.027 -0.008 0.019 0.657 
Hearing 5.241 2.297 0.023 6.616 2.371 0.005 -0.324 0.290 0.265 1.819 0.755 0.016 -0.041 0.021 0.054 
Speech 7.904 2.583 0.002 10.941 2.846 0.000 -0.811 0.325 0.013 2.689 0.842 0.001 -0.037 0.022 0.096 
Swallowing 5.748 2.096 0.006 7.705 2.219 0.001 -0.641 0.273 0.019 1.980 0.695 0.004 -0.044 0.019 0.021 
Handwriting 6.313 2.388 0.008 9.606 2.674 0.000 -0.641 0.300 0.032 1.661 0.767 0.030 -0.031 0.021 0.148 
Cutting food 5.819 2.454 0.018 
   
-0.428 0.300 0.154 1.575 0.806 0.051 -0.043 0.023 0.058 
Dressing 5.134 2.253 0.023 8.345 2.520 0.001 -0.488 0.285 0.088 1.006 0.728 0.167 -0.035 0.021 0.089 
Hygiene 7.247 2.301 0.002 10.130 2.528 <.0001 -0.900 0.298 0.003 1.953 0.733 0.008 -0.034 0.020 0.086 
Exercise tolerance 6.710 2.163 0.002 8.718 2.410 0.000 -0.733 0.271 0.007 2.858 0.789 0.000 -0.048 0.020 0.015 
Gait stability 5.047 2.133 0.018 
   
-0.584 0.282 0.039 1.821 0.726 0.012 -0.045 0.021 0.030 
Psychiatric disturbance 0.123 1.959 0.950 
   
0.176 0.270 0.514 0.225 0.654 0.730 -0.010 0.019 0.590 
Migraine headaches -1.430 1.986 0.472 -0.457 1.981 0.818 0.469 0.283 0.097 0.232 0.642 0.717 0.002 0.019 0.933 
Seizures 13.613 8.089 0.092 
   
-0.778 0.955 0.415 2.729 1.999 0.172 -0.106 0.057 0.064 
Encephalopic episodes 18.914 17.916 0.291 8.421 2.283 0.000 0.507 1.811 0.780 8.162 7.682 0.288 -0.192 0.170 0.259 
GI disturbance 4.653 2.097 0.027 8.028 2.379 0.001 -0.642 0.278 0.021 0.029 0.672 0.966 -0.055 0.021 0.010 
Diabetes mellitus 9.718 4.806 0.043 
   
-1.093 0.589 0.064 0.031 1.860 0.987 -0.046 0.035 0.180 
Cardiovascular  7.145 2.620 0.006 8.958 2.742 0.001 -0.631 0.325 0.053 1.930 0.817 0.018 -0.051 0.022 0.021 
Visual acuity 1.708 1.916 0.373 4.930 2.071 0.017 -0.297 0.255 0.243 0.649 0.645 0.314 0.011 0.019 0.562 
Ptosis 3.190 2.284 0.162 5.473 2.345 0.020 -0.690 0.312 0.027 2.736 0.960 0.004 -0.036 0.022 0.108 
CPEO 
   
1.373 2.702 0.611 -0.254 0.369 0.491 1.758 1.119 0.116 -0.022 0.027 0.419 
Dysphonia/dysarthia 9.760 2.984 0.001 12.907 3.293 <.0001 -0.942 0.356 0.008 3.492 0.986 0.000 -0.046 0.024 0.055 
Myopathy 1.165 1.997 0.560 4.737 2.131 0.026 -0.266 0.274 0.332 0.965 0.693 0.164 -0.002 0.019 0.912 
Cerebellar ataxia 8.338 2.484 0.001 11.819 2.814 <.0001 -1.048 0.321 0.001 2.327 0.799 0.004 -0.052 0.022 0.017 
Extrapyramidal 18.161 7.621 0.017 
   
-1.584 0.797 0.047 5.118 2.278 0.025 -0.088 0.052 0.092 
Neuropathy 47.364 102.800 0.645 
   
-0.838 10.196 0.935 -7.010 59.590 0.906 -0.647 0.996 0.516 
Cognitive impairment 2.698 2.119 0.203 3.816 2.154 0.076 -0.038 0.278 0.890 0.959 0.765 0.210 -0.034 0.020 0.093 
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